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Abstract 
 
Dietary fat has been correlated with obesity since it induces the proliferation 
and differentiation of pre-adipocytes. However it has become clear that the 
effect of fat on human health depends on the composition and the nature of 
fatty acids. Arachidonic acid (AA) is a major omega-6 polyunsaturated fatty 
acid. Its role in adipocyte differentiation is controversial as published data 
have shown opposing roles of AA in pre-adipocyte differentiation. 
 
We investigated the effect of a brief exposure of AA on pre-adipocyte 
differentiation. After a 24h of AA treatment during pre-adipocyte 
differentiation, the expression of aP2, a differentiation marker, and Fra-1, an 
AP-1 transcription factor, was induced. We showed that this effect was 
PPARγ-dependent since AA treatment was unable to up-regulate aP2 and 
Fra-1 in PPARγ knockdown cells. Furthermore, we identified that both of 
these genes were regulated by the AA metabolite, PGF2α, through binding to 
its cognate GPCR, the FP receptor, initiating a cascade of signalling pathways 
involving PKC and ERK activation.  
 
We also showed that short-term treatment of pre-adipocytes with AA at the 
beginning of differentiation induced events with a long-lasting inhibitory effect 
on adipogenesis. Treatment of pre-adipocytes with AA for only 24h, blocked 
adipogenesis as revealed by significantly reduced expression of adipocyte 
markers and lipid accumulation after 10 days of differentiation. We 
demonstrated that Fra-1 mediated the inhibitory effect of AA, as Fra-1 
depletion rescued the inhibition of differentiation by AA. 
 
We suggest that short-term exposure of pre-adipocytes to AA at the early 
stages of differentiation has a dual effect. In the early stages, the presence of 
AA causes a rapid up-regulation in two target genes, the aP2 and Fra-1, in a 
PPARγ-dependent way. In the later stages of differentiation, when AA is 
withdrawn, the early up-regulation of Fra-1 results in inhibition of the 
differentiation program. 
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1.1. Obesity  
 
Obesity has been described as the new epidemic as by 2008, 1.46 billion 
adults worldwide were overweight (body-mass index [BMI] >25 kg/m²) and 
502 million adults were obese (BMI >30 kg/m²) (Swinburn et al., 2011). In 
western countries the prevalence of obesity is dramatically high e.g. in 2009-
2010, in USA the incidence of obesity was 35.5% among adult men and 
35.8% among adult women (Flegal et al., 2012). In Great Britain the 
equivalent was 23% and 25% for adult males and females, respectively in 
2002 (Rennie and Jebb, 2005).  
 
Obesity is associated with a series of disorders, such as type 2 diabetes, 
dyslipidaemia, fatty liver disease hypertension, atherosclerosis, gallbladder 
disease, degenerative disorders including dementia and some forms of 
cancer (Bray and Bellange, 2006; Hotamisligil, 2006). Obesity together with 
insulin resistance, dyslipidaemia and hypertension are the four aspects of the 
metabolic syndrome which is described as a pre-diabetic state (Grundy, 
2012). Even though obesity by itself is unlikely to be the driving factor to 
metabolic syndrome since lean individuals can become insulin resistant 
whereas some very obese individuals do not, obesity is still an important risk 
factor (Virtue and Vidal-Puig, 2010). 
 
Obesity has also programming effects as pregnant women being obese 
before and during pregnancy, or gaining weight in pregnancy have a higher 
risk of delivering overweight babies (Desai and Ross, 2011). In the USA 25% 
of children are now overweight or obese and obesity in childhood or 
adolescence makes an individual more susceptible to being overweight or 
obese at 35 years of age with a higher risk of developing diabetes (Guo et al, 
2002).  
 
Obesity has been classically termed as the result of an imbalance in energy 
homeostasis where the energy intake exceeds the energy expenditure. Today 
this idea is considered to be oversimplistic since obesity is a multi-factorial 
and complex condition involving the interplay between nutritional, hormonal, 
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neuronal and psychological factors on a variable genetic background (Sabin 
et al., 2011; Rosen and Spiegelman, 2006). 
 
Different genes have been associated with the regulation of body weight. 
Monogenetic mutations such as in leptin and leptin receptor, melanocortin 4 
receptor or the FTO gene have been correlated with the onset of obesity 
(Sabin et al., 2011). Although the genetic background defines the individual‘s 
predisposition to obesity, the genotype is susceptible to social trends. 
Nowadays there is a more ‗‘obesogenic‘‘ environment characterised by 
decreased physical activity and increased intake of high caloric food and drink 
but also other factors such as the ingestion of novel medications, the 
presence of pollutants, the reduction of the variability in seasonal temperature 
due to the presence of almost ubiquitous air conditioning (Tam and Ravussin, 
2012).  
 
To develop new therapies for the current obesity epidemic, it is essential to 
elucidate the cellular and molecular mechanisms underlying the regulation of 
energy balance. Adipose tissue (AT) is a central player of energy metabolism 
and knowledge of adipose biology is crucial to understand the mechanism by 
which environmental factors (e.g. diet) affect obesity (Flier, 2004; Ailhaud et 
al., 2006; Rosen and Spiegelman, 2006). 
 
1.2 Adipose tissue (AT) 
 
AT is a complex organ that plays a central role in energy and metabolic 
homeostasis. It is composed of different cell types: adipocytes, pre-
adipocytes, macrophages, stromal cells, fibroblasts and monocytes. (Frigolet 
Vazquez-Vela et al., 2008). There are two different types of adipose tissue: 
the white adipose tissue (WAT) and the brown adipose tissue (BAT).  
 
1.2.1. White Adipose Tissue (WAT) 
 
Most mammals have distinct WAT depots. Some depots have a structural role 
such as the fat pads of the heels, fingers and toes, and the eye orbital fat. The 
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two WAT depots that have a role in metabolism are the subcutaneous fat 
which is associated with the skin and the visceral fat found in the abdominal 
cavity and is further subdivided into the perigonadal (epididymal in males and 
periovarian in females), the perirenal, the omental, and the mesenteric fat. 
The subcutaneous and the visceral fat depots display different patterns of 
gene expression (including developmental genes), different rates of 
lipogenesis and lipolysis and different abilities of the pre-adipocytes to 
differentiate into mature adipocytes in vitro (Gesta et al., 2006). Thus, these 
fat depots are intrinsically different showing distinct developmental 
characteristics and responses to hormones indicating that these depots are 
composed of different types of white adipocytes. Fat distribution has a strong 
hereditary component e.g. Hottentot women have excessive fat accumulation 
in the buttocks, a condition known as steatopygia (Gesta et al., 2006). 
Individuals with increased visceral fat are at high risk of type 2 diabetes and 
cardiovascular disease, whereas body mass index-matched individuals with 
increased subcutaneous fat are at little or no risk of metabolic disease since it 
is thought to offer glucose tolerance (Ibrahim, 2010; Yamamoto et al, 2010; 
Rosen and Spiegelman, 2006)  
 
WAT is the primary site of free-fatty acid (FFAs) or non-esterified fatty acids 
(NEFAs) storage in the form of triglycerides (TAGs) during energy 
consumption and the release of FFAs during energy expenditure. White 
adipocytes also release a repertoire of secreted proteins involved in glucose 
metabolism (e.g. adiponectin), inflammation (e.g. adipsin), blood pressure 
(e.g. angiotensinogen) and feeding behaviour (e.g. leptin). Therefore, WAT is 
not only a storage tissue but also a central regulator of the metabolic program 
regulating diverse activities, such as insulin sensitivity and lipid metabolism 
(Hajer et al., 2008). Morphologically, white adipocytes are characterised by a 
large lipid droplet (LD) (unilocular) occupying 90% of the cell volume. The rest 
of the cytoplasm contains the nucleus, an under-developed Golgi apparatus, 
an endoplasmic reticulum (ER), few lysosomes, and few elongated 
mitochondria with short, randomly arranged cristae (Cinti, 2011).  
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In rodents, WAT develops mainly after birth, first in the peri-gonadal and 
subcutaneous depots and only later in the omental depot. The WAT grows in 
the young animals as a result of both increased adipocyte number 
(hyperplasia) and adipocyte size (hyperotrophy). However, by the 15th week 
of life the WAT size is increased solely by an increase in the size of the 
adipocytes rather than in the cell number (Hirsch and Han, 1969; Billon et al, 
2007). In humans, WAT develops from the second trimester, more extensively 
the third trimester and early in postnatal life. It expands very rapidly after birth 
as a result of increased cell size but also of increased cell number (Gregoire 
et al., 1998; Ailhaud et al., 2006). The proliferation and differentiation ability of 
adipocytes and precursor cells decrease with age. Hence, it was believed that 
hypertrophy rather than hyperplasia was the main reason for the expansion of 
the WAT in adults. However, there is now evidence supporting a 10% 
turnover rate of adipocytes every year in all adult ages confirming that 
adipogenesis remains active to maintain the adipose compartment (Spalding 
et al., 2008). Therefore, there must be a pool of precursor cells that are able 
to differentiate in the adults since mature adipocytes are post-mitotic.  
 
Disrupting the formation of WAT might sound as a quite efficient way to 
manage obesity but this would result to the storage of lipids in ectopic tissues 
such as liver and muscle and lead to a syndrome called lipodystrophy. 
Lipodystrophies are characterised by general (e.g. congenital generalised 
lipodystrophy) or partial (e.g. familial partial lipodystrophy) absence of the 
WAT and the symptoms are insulin resistance, fatty liver and dyslipidaemia 
which are very similar to obesity-associated disorders (Huang-Doran et al., 
2010). 
 
1.2.2. Brown Adipose Tissue (BAT) 
 
BAT is found in the interscapular region in rodents whereas in humans it is 
present in fetuses and newborns in axillary, cervical, perirenal, and 
periadrenal regions (Cannon and Nedergaard, 2004). Although it was thought 
to disappear rapidly postnatally, positron emission tomography (PET) using 
radiotracers such as [18F]-2-fluoro-D-2-deoxy-D-glucose (18F-FDG) revealed 
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that adults have active brown depots in the neck and chest region, as well as 
in the kidney area (Nedergaard et al 2007; Nedergaard et al, 2010). 
Dedicated studies revealed that 30%-100% of adults have BAT, depending on 
the cohort, with no difference between the genders (Nedergaard et al, 2011). 
 
The main role of the brown adipocytes is the dissipation of energy through the 
process of adaptive thermogenesis. They express the uncoupling protein 1 
(UCP1) which is localised in the inner mitochondrial membrane and its role is 
to uncouple Adenosine-5'-triphosphate (ATP) from the classical electron 
transport chain to produce heat (Hansen and Kristiansen, 2006). Other 
molecular markers of BAT are high-levels of expression of type 2 
iodothyronine deiodinase (DIO2), the transcription coregulators PR domain 
containing 16 (PRDM16), peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α), and the regulator of lipolysis Cidea (Cypess 
and Kahn, 2010). Morphologically, brown adipocytes have multiple small LDs 
(multilocular) and numerous spherical mitochondria rich in laminar cristae. 
They are much smaller in diameter, 15–60mm, than white adipocytes which 
are 25–200 mm in diameter (they are able to increase their size several 
times). BAT is highly vascularised and innervated by the sympathetic nervous 
system (SNS) (Cinti, 2011). When there is a need for release of stored energy 
or for producing heat, then a signal is transmitted from the SNS to individual 
brown adipocytes. The neurotransmitter norepinephrine via β3-adrenergic 
receptors initiate a cascade of events involving the rise of the intracellular 
cyclic 3‘5‘ Adenosine Monophosphate (cAMP) levels and protein kinase A 
(PKA) activation that lead to the release of FFA activating UCP1 (Cannon and 
Nedergaard, 2004).  
 
The human adult BAT is less than 100g and expresses all the BAT gene 
markers (e.g UCP1, PGC-1α). If BAT is activated then humans are able to 
develop non-shivering thermogenesis i.e. the ability to produce heat without 
shivering (which is the acute and immediate heat-producing mechanism) that 
has the capacity to burn an amount of energy equivalent to approximately 4kg 
of WAT in a year, making BAT a significant target tissue for medical 
intervention to manage obesity (Virtanen et al., 2009).  
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In conclusion, BAT and WAT are anatomically, morphologically and 
functionally distinct. The different colour between the BAT and the WAT is due 
to the different number of mitochondria and the difference in the 
vascularisation (Hansen and Kristiansen, 2006). BAT is mainly a thermogenic 
tissue whereas WAT is a storing tissue. WAT does not express UCP1 and 
BAT does not produce leptin. However, under certain conditions e.g. cold 
temperature, exposure to β3-adrenergic agonists or exercise, brown-like 
adipocytes can be found in WAT depots expressing UCP1 representing a 
different adipocyte type called brite or beige (Cinti, 2011; Bostrom et al, 2011). 
Beige adipocytes are shown to have a different lineage origin from brown 
adipocytes (they do not express Myf5, see below) and have a distinct gene 
expression pattern from either white or brown fat (Wu et al., 2012). There is a 
debate as to whether these cells are the result of a direct transdifferentiation 
of mature white adipocytes to brown or they come from totally distinct 
progenitors.  
 
 
 
 
 
 
 
 
White Adipocyte                           Brown Adipocyte 
 
Figure 1.1: Differences between white and brown adipocytes. White adipocytes 
are characterised by a large LD (yellow) and a few mitochondria. They are 
specialised to store energy, and they express low levels of UCP1. In contrast, brown 
adipocytes have many smaller LDs and numerous mitochondria whereas they are 
specialised to catabolise energy, and they express high levels of UCP1. LD: lipid 
droplet, UCP1: uncoupling protein 1. 
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1.3. Adipocyte differentiation (Adipogenesis) 
 
Little is known about the identity, localisation and the biological characteristics 
of the adipocyte progenitors or pre-adipocytes in vivo. The stromal vascular 
fraction (SVF) of the adipose tissue contains adipose precursor cells which 
are morphologically identical to other non-adipogenic fibroblast cells making 
their identification difficult. However, recently, Tang et al (2008) identified a 
population of adipocyte progenitor cells residing in the mural cell compartment 
of the adipose vasculature that show specific molecular markers. These cells 
are found attached to the walls of blood vessels and are often bigger than the 
endothelial cells with a characteristic basal membrane and glycogen granules. 
As the pre-adipocytes develop they detach from the capillaries and 
progressively lose the glycogen vacuoles and accumulate lipid. Thus, the 
vasculature seems to provide the right local microenvironment for the 
development of adipocytes (Tang et al, 2008; Cinti, 2011). Brown pre-
adipocytes have been also found in the proximity of vessels in the BAT and 
they have the characteristic basal membrane and glycogen vesicles as the 
white adipocytes but they also have pretypical mitochondria contrary to the 
white (Cinti, 2011). 
 
Friedman and colleagues identified a cell population in the adult WAT SVF 
expressing specific cell-surface markers (Lin-:CD29+:CD34+: Sca-1+:CD24+) 
that was able to differentiate to mature adipocytes in vitro. Furthermore, when 
transplanted into a lipodystrophic mouse models the cells were able to 
reconstitute a normal size fat pad and correct the diabetic phenotype of these 
mice (Rodeheffer et al., 2008). 
 
Despite the limited information about adipogenesis in vivo, adipocyte 
differentiation is well characterised, mainly from studies using in vitro models. 
To some extent, pre-adipocyte primary culture has been used. However, the 
use of primary culture has a number of disadvantages. During the isolation 
procedure, large amounts of fat tissue are required since pre-adipocytes 
comprise only a small part of the total fat tissue, but also the result is a 
heterogeneous population since pre-adipocytes cannot be distinguished from 
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other ﬁbroblast-like cells. Finally, primary cultures have a limited life span in 
culture (Ntambi and Young-Cheul, 2000). Thus, adipogenesis has been 
studied primarily using in vitro cell lines. There are two main advantages using 
these models, the first one that they are clonal populations and hence 
homogeneous synchronized cells being all at the same stage of differentiation 
and the second is that they can be kept in culture indefinitely (Ntambi 
and Young-Cheul, 2000). 
 
From the study of these cell lines and for practical reasons adipogenesis is 
considered to be a two–phased procedure. The first phase is known as 
determination. During this phase mesenchymal stem cells (MSCs) become 
committed to the adipocyte lineage losing their ability to differentiate into other 
lineages such as osteoblasts, chondrocytes, myoblasts and connective tissue, 
and essentially becoming pre-adipocytes. In this stage pre-adipocytes have a 
fibroblast-like morphology and are undistinguishable from their precursors. In 
the second phase, which is known as terminal differentiation, pre-adipocytes 
develop into mature adipocytes, acquiring LDs, the ability to respond to insulin 
and secrete adipocyte specific proteins such as adiponectin (Figure 1.2) 
(Gesta et al., 2007). The transcriptional regulation of the terminal 
differentiation phase has been well characterised using in vitro pre-adipocyte 
cell lines that have passed through the commitment step and when 
appropriately induced, differentiate into cells having the biochemical and 
morphological phenotype of adipocytes. The most extensively characterised 
preadipocyte cell lines are the 3T3-L1, 3T3-F442A, and Obl771 lines. The 
3T3-L1 and 3T3-F442A cell lines were derived from disaggregated mouse 
embryo cells and were selected for their ability to accumulate TAGs (Green 
and Kehinde, 1975; Green and Kehinde, 1976). When injected into mice, 3T3-
L1 pre-adipocytes differentiate and form fat pads that are indistinguishable 
from normal AT (Green and Kehinde, 1979). Ob17 cells were derived from the 
stroma of epididymal fat pads from adult ob/ob genetically obese mice, and 
several sublines, notably the Ob1771 line, were selected (MacDougald and 
Lane, 1995). The factors that have been identified over the years from the 
study of these immortalised cell lines have proved to be crucial for 
adipogenesis in vivo either in mouse models or even humans (Gupta et al., 
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2012). Based on these in vitro models the terminal differentiation can be 
divided into four stages: growth arrest, clonal expansion, early differentiation 
and late differentiation (Gesta et al., 2007). First, following confluence, the 
cells enter growth arrest due to cell-cell contact inhibition. After the exposure 
of confluent cells to insulin, dexamethasone (DEX) and 
isobutylmethylxanthine (IBMX) in the presence of fetal bovine serum (FBS), 
they re-enter the cell cycle for one or two divisions (clonal expansion). 
However, the clonal expansion step in other cell systems is not always 
required (e.g. human pre-adipocytes). During the early terminal differentiation, 
the cells express a cascade of transcription factors including a rapid induction 
of CCAAT/enhancer binding protein (C/EBPβ) β and C/EBPδ. These 
transcription factors promote the expression of the two most important 
regulators of terminal differentiation peroxisome proliferator-activated receptor 
γ (PPARγ) and C/EBPα leading to a second but permanent growth arrest and 
the induction of many target genes involved in lipogenesis and adipogenesis 
(see Section 1.3.2) (Farmer, 2005; Farmer, 2006). 
 
Brown and white adipocytes share many common features in their 
differentiation despite their functional, morphological and locational 
differences. However, lineage-tracing studies revealed that brown adipocytes 
are developmentally closer to skeletal muscle cells than white adipocytes. 
Both muscle and brown adipocyte progenitors express the muscle marker 
myogenic factor 5 (Myf5) whereas white adipocytes do not (Seale et al., 
2008). Furthermore, knockdown of PRDM16 (a transcriptional co-regulator) in 
brown preadipocytes leads to a more myogenic phenotype whereas 
overexpression of PRDM16 in myoblasts leads their differentiation to a brown 
adipocyte phenotype (Seale et al., 2008). 
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Figure 1.2: Adipocyte differentiation (adipogenesis). Adipocytes arise from 
multipotent MSCs which become pre-adipocytes when they lose their ability to 
differentiate into other mesenchymal lineages and become ‗committed‘ to the 
adipocyte lineage (commitment). During terminal differentiation pre-adipocytes take 
on the characteristics of mature adipocytes, acquiring LDs and the ability to respond 
to hormones such as insulin. Terminal differentiation consists of a cascade of 
transcriptional events. The first wave involves the induction of C/EBPβ and C/EBPδ, 
which, in turn, directly induces expression of C/EBPα and PPARγ. C/EBPα and 
PPARγ subsequently feed back to induce their own expression, in addition to 
activation of many downstream target genes whose expression defines the 
adipocyte. MSCs: mesenchymal stem cells, LD: lipid droplet, C/EBPβ-δ 
CCAAT/enhancer binding protein β-δ, PPARγ: peroxisome proliferator-activated 
receptor γ (modified from Christodoulides et al., 2009). 
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1.3.1 Determination 
 
The full repertoire of factors that cause the conversion of an MSC into an 
adipocyte is largely unknown. Some knowledge about MSC fate decisions has 
been derived from studies using the immortalised mouse stromal cell line, 
C3H10T1/2, or mesenchymal precursor populations isolated from adult or 
fetal tissues (e.g. bone marrow) and embryonic stem cells (ESCs) that have 
been successfully differentiated to adipocytes in vitro (Dani et al, 1997; Billon 
et al., 2008). In contrast to terminal differentiation the transcriptional regulation 
of the determination step is not well defined. However, recently Gupta et al., 
identified Zfp423 transcription factor which is expressed in adipose 
precursors, as sufficient and necessary for adipogenesis (Gupta et al., 2010). 
Isolation of GFP+ cells from the SVFs of Zfp423GFP transgenic mice 
differentiated more efficiently in culture compared to their GFP- counterparts 
proving that Zfp423 expressing cells are bona fide committed pre-adipocytes 
(Gupta et al, 2012). Moreover, Christancho et al., showed that TCF7-like1 
(TDF7L1) transcription factor is essential for the pre-adipocyte as it represses 
cell structure-related genes highlighting the importance of cell structure 
organisation to the differentiation of pre-adipocytes (Christancho and Lazar, 
2011). 
 
A number of factors have been identified that function as molecular switches 
in controlling the fate of the progenitors. These factors could drive the MSC 
differentiation into alternative cell fates and have to be inhibited from pro-
adipogenic factors for the adipogenesis to proceed.  
 
Two Wnt signaling pathways - the canonical Wnt–β catenin pathway and the 
non-canonical Wnt pathway - are described to favour the conversion of the 
MSCs towards the osteoblastic lineage. Wnt10b and Wnt5a are the two main 
canonical and non-canonical Wnt ligands respectively that are expressed in 
pre-adipocytes and inhibit adipogenesis by negatively regulating the 
expression of the two main adipogenic proteins PPARγ and C/EBPα 
(Christodoulides et .al, 2009; Takada et al, 2009). However, adipogenesis has 
been found to proceed by the inhibition of Wnt ligand expression in pre-
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adipocytes by cAMP signalling which is essential for the first steps of 
adipogenesis (Fox et al., 2008). 
 
Transforming growth factor-β (TGFβ) superfamily members such as TGFβ, 
bone morphogenetic proteins (BMPs) and myostatin have all been described 
to have roles in adipogenesis. TGFβ has been shown to have contradictory 
effects in vivo and in vitro promoting and inhibiting adipogenesis, respectively. 
BMP4 is shown to promote the differentiation of C3H10T1/2 cells to white 
adipocytes, whereas BMP7 induces brown adipogenesis. Finally ablation of 
the myostatin gene in mice results in a decrease in AT and an increase in 
muscle tissue (Zamani and Brown, 2011).  
 
There are also many factors that are specifically expressed in committed pre-
adipocytes and their down-regulation sets the stage for terminal 
differentiation. One of these factors is the preadipocyte factor -1 (Pref-1 or 
DLK-1: Drosophila Homolog-like 1) which is widely accepted as a pre-
adipocyte marker. Pref-1 is synthesised as a transmembrane protein and its 
extracellular domain is cleaved generating the active 50kDa soluble form that 
inhibits adipocyte differentiation (Wang et al, 2006). It is highly expressed in 
pre-adipocyte cell lines (e.g. 3T3-L1 cells) but its expression decreases upon 
differentiation (Wang et al, 2006). Overexpression of Pref-1 in pre-adipocytes 
decreases their differentiation to mature adipocytes whereas depleting Pref-1 
increases the ability of the cells to undergo differentiation (Wang et al, 2006). 
Pref-1-/- animals show increased adiposity (Moon et al., 2002) whereas 
transgenic animals show decreased fat mass, reduced expression of 
adipocyte markers and lower levels of adipocyte secreted factors (Lee et al., 
2003). 
 
Finally, transcription factors such as GATA-binding protein 2 (GATA 2) and 3, 
members of the Krüppel-like factor (KLF) family and CHOP (a dominant 
negative partner of C/EBPβ) act as inhibitors of differentiation that eventually 
lead to the repression of PPARγ expression (Tang and Lane, 2000; Tong et 
al., 2000; Banerjee et al., 2003). 
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1.3.2 Terminal Differentiation 
 
As referred to Section 1.3, a number of transcription factors are involved in 
terminal differentiation. This stage is further divided into the early and late 
terminal differentiation.  
 
1.3.2.1 Fos-related antigen 1 or Fra-1 
 
Fra-1 or Fos-related antigen 1 is a member of the transcription factor activator 
protein 1 (AP-1) family. This family consists of the Jun, Fos and activating 
transcription factor protein families. Fra-1 is one of the Fos proteins together 
with c-Fos, FosB and Fra-2 and can only heterodimerise with members of the 
Jun family, whereas the Jun family members (Jun, JunB and JunD) form 
homodimers and heterodimers with Fos members (Zenz et al., 2008). The 
different dimer combinations recognise a common AP-1 binding site 
(TGACTCA) in the promoters and enhancers of target genes. Fra-1 ablation is 
embryonic lethal around embryonic day 10 due to placental defects. However, 
specific deletion of Fra-1 only in the mouse, resulted in viable and fertile Fra-
1-/- mice which developed osteopenia, indicating a role of Fra-1 on the 
regulation of bone mass (Eferl et al, 2004). 
 
A role for AP-1 factors in adipogenesis has been implicated and one of the 
earliest reports in this area identified the binding of c-Fos to the aP2 promoter 
(Distel et al, 1987). In vivo data indicate that AP-1 factors are important in 
adipogenesis. Transgenic mice expressing a dominant-negative protein 
preventing the DNA binding of both the C/EBP and Jun families specifically in 
AT were generated. These mice had no WAT throughout life (Moitra et al, 
1998). In 3T3-L1 cells, c-Jun, c-Fos, Jun-B, JunD, Fos-B, Fra-1 and Fra-2 
were found to be induced immediately after the induction of adipocyte 
differentiation (Stephens et al, 1992). Finally, the recently generated Fra-1 
transgenic mice present with severe lipodystrophy. Futhermore, Fra-1 is found 
to suppress adipogenesis by inhibiting C/EBPα expression (Luther et al., 
2011). 
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1.3.2.2 C/EBPs 
 
C/EBPs are members of a family of highly conserved basic-leucine zipper 
transcription factors (bZip) comprised of six members. All members have a C-
terminal leucine zipper domain for dimerisation and a basic domain for DNA 
binding. These proteins can both homodimerise and heterodimerise with each 
other and bind to the same C/EBP consensus sequences. Three of the C/EBP 
family members (C/EBPα, -β and –δ) play an important role in adipogenesis. 
In 3T3-L1 cells, C/EBPβ and C/EBPδ mRNA and protein levels rise very early 
(2-3h) after the induction of differentiation; they remain constant for the next 
36h and then begin to decline (Tang et al., 2004). It has been shown that 
IBMX (included in the differentiation cocktail), a phosphodiesterase inhibitor 
causes the increase of cAMP which in turn increases C/EBPβ mRNA levels 
(Cao etal., 1991). Consequently, cAMP response element-binding protein 
(CREB) binds to the dual CRE-like elements in C/EBPβ promoter inducing its 
expression immediately after the induction of differentiation in 3T3-L1 cells 
(Zhang et al., 2004). In addition, induction of C/EBPδ is facilitated by C/EBPβ 
and also glucocorticoids which are also included in the differentiation cocktail 
(Cao et al, 1991). C/EBPβ and C/EBPδ single knockouts show a minor 
decrease in adipose mass whereas in double knockouts the size of the AT is 
substantially reduced (Tanaka et al, 1997). These data indicate that there is a 
degree of redundancy between these two transcription factors.  
 
After their induction early in differentiation C/EBPβ and C/EBPδ bind directly 
to C/EBP binding sites on both PPARγ and C/EBPα promoters but also on 
promoters of several genes expressed later in the differentiation process such 
as phosphoenolpyruvate carboxykinase (PEPCK), fatty acid binding protein 4 
(FABP4) and glucose transporter type 4 (Glut4) (Wu et al, 1999; Salma et al, 
2006; Tang et al., 2004). C/EBPβ ectopic expression in NIH-3T3 fibroblasts 
alone or in combination with C/EBPδ induces PPARγ expression and 
adipogenesis, whereas C/EBPδ possesses minimal adipogenic activity (Wu et 
al., 1995; Farmer, 2006).  
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C/EBPα is expressed later in the differentiation program and is considered to 
be an important regulator of white adipocyte differentiation since C/EBPα-/- 
mice lack WAT but they show normal BAT (Linhart et al., 2001). C/EBPα 
replaces C/EBPβ and C/EBPδ binding to each of the various C/EBP binding 
sites at the promoters of adipogenic genes (Christy et al., 1989; Salma et al, 
2006). Overexpression of C/EBPα in 3T3-L1 cells induces their differentiation 
into mature adipocytes (Lin and Lane, 1994), whereas constitutive expression 
of an anti-sense C/EBPα RNA in the same cell model, blocks the expression 
of adipocyte specific genes and triglyceride accumulation (Lin and Lane, 
1992). Moreover, C/EBPα-/- fibroblasts have reduced adipogenic potential, but 
their capacity to accumulate lipids and activate markers of adipogenesis is 
restored when PPARγ is exogenously expressed. It seems that C/EBPα 
maintains PPARγ levels as it was found that C/EBPα binds directly to the 
PPARγ promoter (Elberg et al, 2000). Finally, C/EBPα is important for 
establishing insulin sensitivity since it was found to bind and regulate the 
expression of many genes involved in the insulin signalling such as the insulin 
receptor and insulin receptor substrate (IRS-1) (Wu et al. 1999).  
 
Despite the important role of C/EBPs in adipogenesis the presence of PPARγ 
is pivotal for the function of these transcription factors. For example, C/EBPβ 
cannot induce expression of C/EBPα in the absence of PPARγ (Zuo et al, 
2006) and the ectopic expression of C/EBPα cannot rescue adipogenesis in 
PPARγ –/– fibroblasts (Rosen et al., 2002). 
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1.3.2.3 PPARγ 
 
PPARγ together with PPARα and PPARβ constitute a subfamily of the nuclear 
receptor superfamily which includes receptors for steroids, thyroid hormone, 
vitamin D, and retinoic acid (Mangelsdorf et al, 1995). All the receptors of this 
subfamily form obligate heterodimers with another family of nuclear receptors 
the retinoid X receptors (RXRs). The heterodimers bind to DNA response 
elements called PPAR response elements (PPREs), the consensus being 
repeats of the sequence AGGTCA separated by one or two nucleotides 
(known as DR-1 or DR-2 response elements, respectively). PPARs bind to the 
5‘ repeat unit of PPRE and RXR binds to the 3‘ repeat (Daynes and Jones, 
2002). Using chromatin immunoprecipitation sequencing (ChIP-seq) the 
genome-wide binding profile of PPARγ and RXR confirmed the high degree of 
overlap between the binding sites of the two factors, indicating that PPARγ 
and RXR dimerisation is obligatory for DNA binding. This study also revealed 
that the majority of PPARγ:RXR binding sites are located far away from the 
transcription start sites suggesting that looping between enhancers and 
promoters is a common mechanism for PPARγ to regulate its target genes 
(Lefterova et al., 2008; Nielsen et al., 2008). 
 
In humans, the PPARγ gene has nine exons and exists in four mRNA 
subtypes (-γ1, -γ2, -γ3, and -γ4) whereas in mice there are two mRNA 
subtypes (PPAR-γ1 and -γ2) resulting from alternative promoter usage and 
alternative splicing at the 5‘ end of the gene. Despite the different mRNA 
subtypes, PPAR-γ exists in two protein isoforms PPAR-γ1 and -γ2 in both 
humans and mice. hPPAR-γ1, -γ3, and -γ4 mRNAs and mPPAR-γ1 mRNA, 
give rise to the protein product, PPAR-γ1 (477 amino acids (aa) for hPPAR-γ1 
and 475 aa for mPPAR-γ1). hPPAR-γ2 and mPPAR-γ2 mRNA encodes for 
the PPAR-γ2 protein with 28 and 30 extra N-terminal aa (505 aa) for human 
and mouse respectively, encoded by the B exon (Figure 1.3) (Zhu et al, 1995; 
Fajas et al., 1997; Fajas et al., 1998; Sundvold and Lien, 2001). AT, large 
intestine and haematopoietic cells express high levels of PPARγ, kidney, liver 
and small intestine express intermediate levels whereas muscle barely 
express PPARγ. The expression levels of PPARγ2 are low in all tissues 
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compared to PPARγ1 with the only exception AT where PPARγ2 is expressed 
in more pronounced amounts (Auwerx, 1999). 
 
PPARγ protein has the same structure found in most nuclear receptors 
characterised by 6 regions (A-F). The C-terminal E domain is the ligand- 
binding domain (LBD). This region is comprised of 12 alpha helices (H1-H12) 
and it also contains the ligand-dependent activation domain (AF-2) which 
depends on the highly conserved helix 12 in the C-terminal end of the LBD. In 
the unliganded state, the PPARγ LBD creates a hydrophobic pocket buried 
among the α-helices. In this state PPARγ is able to bind DNA and associates 
with co-repressors such as the silencing mediator for retinoid or thyroid-
hormone receptors (SMRT) and the nuclear receptor co-repressor (NCoR) 
which are part of multiprotein complexes containing histone deacetylase 
(HDAC) activity that repress target gene transcription. Upon ligand binding, 
co-repressor proteins are dissociated from PPARγ and its helix 12 changes 
conformation creating the appropriate interface for the recruitment of co-
activators such as the steroid receptor coactivator (SRC) and p300/CREB-
binding protein (CBP). These co-activators have either intrinsic chromatin 
remodelling activities (such as histone acetyl transferase activity) or recruit 
other complexes that decondense the chromatin making a transcriptionally 
permissive environment at the promoter or enhancer (Zieleniak et al., 2008).  
 
Polyunsaturated fatty acids (PUFAs) (such as linoleic acid and arachidonic 
acid) and their derivatives such as prostaglandins (e.g. 15d-PGJ2) and 
oxidized FAs [e.g. 9-hydroxyoctadecadienoic (9-HODE) and 13- 
hydroxyoctadecadienoic (13-HODE)] have been identified to be the 
endogenous low affinity ligands for PPARγ binding the receptor at micromolar 
levels (Forman et al., 1995; Kliewer et al., 1995; Nagy et al., 1998). It has 
been demonstrated that endogenous PPARγ ligands are produced during the 
early stages of adipogenesis in response to cAMP (Tzameli et al., 2004). 
There are also synthetic, highly specific, ligands for PPARγ called 
thiazolidinediones (TZDs). TZDs exhibit high affinities for the receptor and 
they are used clinically as anti-diabetic agents enhancing insulin sensitivity. 
However, TZDs have several side effects including osteoporosis, increased 
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adiposity, fluid retention and heart failure presumably due to the activation of 
PPARγ in osteoclasts, collecting duct cells and cardiomyocytes (Sugii and 
Evans, 2011). However, how TZDs function as potent insulin sensitizers is still 
unclear since there is not a known PPARγ deficiency in obesity or insulin 
resistance cases (Choi et al., 2010). Hence, it is puzzling how activation of 
this receptor is an efficient anti-diabetic strategy as PPARγ selective 
activation in adipocytes in insulin resistant states leads to whole body insulin 
sensitisation (Sugii et al., 2009) 
 
The N-terminal A/B region is non-conserved between nuclear receptors and it 
contains another transcription/activation domain the AF-1 which acts in a 
ligand-independent manner. In PPARγ2, residue S112 in the AF-1 domain is 
subjected to phosphorylation by the mitogen activated protein kinase (MAPK) 
pathway. This phosphorylation event can disrupt the interdomain interaction 
between the LBD and the AF-1 domain reducing the ligand binding affinity 
resulting in negative regulation of the transcriptional and biological functions 
of PPARγ (Shao et al., 1998). Furthermore, cyclin-dependent kinase 5 (Cdk5) 
is activated in obesity and phosphorylates PPARγ at the S273 residue without 
affecting its transcriptional activity but it causes dysregulation of its target 
genes such as adiponectin and adipsin (Choi et al., 2010). Weak PPARγ 
agonists (e.g. MRL24) have been shown to inhibit this Cdk5-phosphorylation 
event making possible the development of improved anti-diabetic medication 
avoiding the side effects of the full agonists such as TZDs (Choi et al., 2010). 
The C domain is the DNA binding domain (DBD) and it is the most conserved 
among nuclear receptors. It contains two zinc-finger-like motifs that mediate 
DNA binding but it also takes part in the dimerisation with RXR (Zieleniak et 
al., 2008). The adipogenic activity of PPARγ requires a functional DNA-
binding domain, as DBD mutants were not able to activate target genes 
(Tontonoz et al., 1994).  
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Figure 1.3: Gene and protein organization of the mouse and human PPARγ. A) 
PPARγ gene structure. The genes are shown in 5‘ to 3‘ orientation. Exons are 
denoted by rectangles and introns by a solid line. γ1, γ2, γ3, and γ4 represent the 
promoters of PPAR-γ1, -γ2 -γ3, and -γ4 mRNA, respectively. The location of the ATG 
start codon is indicated. The asterisk indicates the different ATG used in mPPARγ1 
A 
B 
C 
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(hPPARγ1 contains two additional aa relative to mPPARγ1). B) PPARγ protein 
structure. The hPPARγ2 protein contains an additional 28aa at the N terminus 
compared to hPPARγ1, whereas the mPPARγ2 30aa. Position of the S112 
phosphorylation site, DNA-binding domain (DBD), hinge domain, ligand-binding 
domain (LBD), and activation function 2 (AF2) are shown. Numbers correspond to aa 
position. C) The human four subtypes of mRNA give rise to two different PPARγ 
proteins. Transcription on the promoters γ1, γ3, and γ4 results in the same protein 
hPPARγ1 477 aa and transcription on the promoter γ1 results in mPPARγ1 475aa. 
The hPPARγ2 and mPPARγ2 protein of 505aa is produced by transcription from the 
promoter γ2. Abbreviations: γ1 (PPARγ1) and γ2 (PPARγ2); P, phosphorylation site; 
(adapted from Fajas et al., 1997; Zieleniak et al., 2008; Tontonoz and Spiegelman, 
2008). 
 
The D domain is called the hinge domain that can act as a docking site for co-
activators. It also contains a nuclear localisation signal which allows the 
translocation of the nuclear receptor into the nucleus. Finally, it can affect the 
activities of nearby domains such as the DBD (Zieleniak et al., 2008).  
 
In elucidate PPARγ transcriptional regulation, DNase I hypersensitivity site 
analysis combined with deep sequencing was performed. This analysis 
revealed changes in chromatin structure near the promoter and distal sites of 
the PPARγ locus within a few hours after the induction of adipocyte 
differentiation. At the same time a set of early transcription factors (including 
C/EBPβ, C/EBPδ, STAT5A, GR and RXR) bind in a cooperative manner early 
in the differentiation program forming transcriptional ‗hotspots‘. These 
hotspots are regions of active chromatin remodelling and are found near 
different PPARγ target genes but also at the PPARγ locus itself (Siersbæk et 
al., 2011). Together with the chromatin remodelling, the PPARγ locus 
displayed increased levels for H3 Lys 4 trimethylation (H3K4me3) and 
dimethylation (H3K4me2) and H3K9 acetylation (H3K9ac). High levels of 
H3K4me3 are correlated with transcription start sites whereas high levels of 
H3K4me2 and H3K9ac are correlated with the presence of enhancers. Pparγ2 
transcription start site contains a peak for H3K4me3 on day 1 after the 
induction of differentiation and is strongly marked by day 10. This is consistent 
with the fact that PPARγ2 is induced 24h after the initiation of differentiation, 
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and significantly up-regulated in mature adipocytes. A notable area -10kb 
upstream Pparγ2 locus is rich in H3K4me2 and H3K9ac levels that increase 
from day 0 to day 1 and then fall back to day 0 levels at day 10. Finally, this 
region was found to bind glucocorticoid receptor (GR) and C/EBPβ indicating 
that enhancer regions can regulate the transition from a pre-adipocyte to a 
mature adipocyte (Steger et al., 2010). 
 
PPARγ is highly expressed in both WAT and BAT tissue and is considered to 
be the ‗master regulator‘ of adipogenesis since it is both necessary (Rosen et 
al., 2002) and sufficient for adipogenesis (Tontonoz et al., 1994). However, 
PPARγ not only stimulate differentiation to adipocytes of resident AT pre-
adipocytes but also promotes the mobilisation of bone marrow-derived 
circulating progenitor cells to WAT and their subsequent differentiation into 
adipocytes (Crossno et al., 2006).  
 
In humans, when PPARγ function is reduced, they become lipodystrophic and 
insulin resistant (Barosso et al., 1999). Homozygous PPARγ-/- mice are not 
viable due to the role that PPARγ plays in trophoblast formation (Kubota et al, 
1999). However, different strategies have been employed to achieve adipose-
specific PPARγ knockdown that establish PPARγ essential for adipogenesis 
(Barak et al., 1999; Rosen et al, 1999; Koutnikova et al. 2003). For example, 
tetraploid rescue of PPARγ null mutants and chimeric mice made from 
PPARγ−/−and PPARγ+/+ blastocysts show that no adipocytes develop from 
PPARγ null cells (Barak et al., 1999). On the other hand, in humans, one 
gain-of-function mutation of PPARγ has been identified (PPARγP115Q). This 
mutation prevents the adjacent residue being phosphorylated (S114) and 
PPARγ activity is increased. All patients carrying this mutation were severely 
obese, supporting the idea of positive correlation between PPARγ activity and 
adiposity (Hamer et al., 2002). Moreover, gain–of–function experiments have 
demonstrated that PPARγ alone is sufficient to initiate the entire adipogenic 
program in non-adipogenic mouse fibroblasts (Tontonoz et al., 1994). PPARγ 
can induce differentiation in C/EBPα-/- MEFs demonstrating that even though 
C/EBPα is important for adipogenesis, PPARγ is the dominant factor (Wu et 
al., 1999). Furthermore, PPARγ-/- cells express reduced levels of C/EBPα 
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(Rosen et al., 1999) and C/EBPα-/- cells express only low amounts of PPARγ 
(Wu et al., 1999). Hence it seems that there is a positive feedback loop 
between C/EBPα and PPARγ expression at the final stage of adipogenesis, 
which ensures the maintenance of the phenotype of mature adipocytes (Wu et 
al., 1999). 
 
Genome-wide studies have revealed that 91% of the genomic regions to 
which PPARγ is bound contain at least one C/EBP motif (Lefterova et al., 
2008). C/EBPα binds nearby to >60% of the locations bound by PPARγ and 
also >60% of the up-regulated genes bound both PPARγ and C/EBPα while 
only 3% of the genes were bound by PPARγ alone (Lefterova et al., 2008). 
Moreover, when PPARγ, C/EBPα and C/EBPβ are all simultaneously 
depleted the expression of many classical adipogenic genes is remarkably 
downregulated, suggesting that these factors have synergistic roles in 
activating transcription (Lefterova et al., 2008).  
 
Finally, besides the role of PPARγ in adipogenesis, it is also a very important 
factor for the survival of the mature adipocytes, since selective PPARγ 
knockdown in white and brown mature adipocytes leads to the death of these 
cells (Imai et al., 2004).  
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1.3.2.4 Adipocyte Fatty acid Binding Protein (or FABP4 or aP2) 
 
As FAs are hydrophobic molecules, they have to bind to albumin, lipocalins 
and fatty acid-binding proteins (FABPs) to increase their aqueous solubility 
and facilitate their transport. FABPs comprise a family of intracellular lipid 
chaperons that consist of nine members having molecular masses around 14-
16kDa. FABPs are highly conserved among all species, from Drosophila 
melanogaster and Caenorhabditis elegans to mice and humans. In mammals, 
they are expressed in almost all tissues and they were named after the tissue 
they were first discovered. The family contains liver (L-FABP/FABP1), 
intestinal (I-FABP/FABP2), heart (H-FABP/FABP3), adipocyte (A-
FABP/FABP4/aP2), epidermal (E-FABP/FABP5/mal1), ileal (Il-FABP/FABP6), 
brain (B-FABP/FABP7), myelin (M-FABP/FABP8), and testis (T-
FABP/FABP9) isoforms. However, this is quite misleading since more than 
one form is expressed in one tissue (Furuhashi and Hotamisligil, 2008).  
 
The FABP members show a moderate amino acid sequence homology 
varying from 20-70%. However, crystallography and nuclear magnetic 
resonance (NMR) analyses revealed that all FABPs share a common tertiary 
structure with 10 anti-parallel β strands folding as an elliptical β barrel, which 
is capped by two short α-helices arranged as a helix-turn-helix segment. The 
binding pocket is located inside the β-barrel whereas the helix-turn-helix motif 
is thought to act as a portal that regulates FA entry and exit from the internal 
binding cavity (Furuhashi and Hotamisligil 2008; Storch and Corsiso, 2008).  
 
The β barrel cavity is two to three times larger than the volume of the FA and 
the structures reveal that on one side of the cavity there are ordered water 
molecules hydrogen bonded to internal polar residues, whereas a single FA 
with the carboxylate group oriented inward is on the other side. Most of the 
FABPs bind a single FA, with the exception of liver-FABP (or FABP1) which 
has a considerably larger binding pocket allowing the binding of two FAs 
(Furuhashi and Hotamisligil 2008; Storch and Corsiso, 2008). 
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All FABPs bind saturated and unsaturated long-chain (≥14-C) FAs (LCFAs) 
without showing any particular selectivity. Affinities tend to increase with 
increasing ligand hydrophobicity. Most of the FABPs examined (e.g. intestinal 
type, adipose-type, heart-type, keratinocyte-type, and myelin-type FABPs) 
collect and deliver their ligands by contact with a membrane. From there 
FABPs as lipid chaperones may facilitate the transport of lipids to specific 
compartments of the cell, such as to the LD for storage; to the ER for 
signalling, trafficking and membrane synthesis; to the mitochondria or 
peroxisome for oxidation; to cytosolic or other enzymes to regulate their 
activity; to the nucleus for lipid-mediated transcriptional regulation; or even 
outside the cell to signal in an autocrine or paracrine manner (Figure 1.4) 
(Furuhashi and Hotamisligil, 2008).  
 
PPARγ and C/EBPα at the final stage of adipogenesis regulate the expression 
of a large group of genes, including adipocyte FABP, which is highly 
expressed in mature adipocytes and is considered to be one of the classical 
adipocyte differentiation markers. Adipocyte FABP (AFABP) is also referred 
to as aP2, due to its sequence similarity to the so-called myelin P2 protein, 
and as ALBP, adipocyte lipid-binding protein. aP2, as all FABPs, reversibly 
binds hydrophobic ligands, such as LCFAs, leukotrienes, and prostaglandins 
and plays an important role in their cellular uptake and targeting (Furuhashi 
and Hotamisligil, 2008).  
 
To investigate the in vivo role of aP2, Hotamisligil and colleagues generated 
aP2-deficient mice (aP2-/-) by targeted disruption of the aP2 gene. These 
animals were phenotypically, developmentally and metabolically normal when 
maintained on low-fat (4% fat) diets (Hotamisligil et al, 1996). The effects on 
adipocyte development were minor considering that aP2 makes up 5% of all 
the soluble cytosolic proteins of an adipocyte (Makowski and Hotamisligil, 
2004). This prompted the investigation of other FABPs expressed in 
adipocytes. Keratinocyte-FABP (K-FABP; FABP5; mal1) is normally 
expressed in AT at low, but detectable levels (approximately 100-fold lower 
than that of aP2) and has similar binding properties as aP2 as well as a 52% 
aa similarity. In adipocytes of aP2-/- animals 20–40-fold up-regulation of mal1  
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Figure 1.4: aP2 cellular functions. aP2 has been proposed to play a role in the 
transport of lipids to specific cell compartments: to LD for storage; to the ER for 
signalling, trafficking and membrane synthesis; to the mitochondria or peroxisomes 
for oxidation; to the nucleus for the control of lipid-mediated transcriptional programs 
via nuclear receptors or other transcription factors that respond to lipids. ER: 
endoplasmic reticulum, LD: lipid droplet (adapted from Furuhashi and Hotamisligil, 
2008).  
 
mRNA was detected, with the protein being increased 13-fold potentially 
compensating for the absence of aP2. However, mal1 was still expressed at a 
much lower level than that of aP2 in normal AT. Finally, mal1 was not up-
regulated to the same extent in macrophages of aP2-/- mice, where both aP2 
and mal1 are also expressed (Hotamisligil et al, 1996). Furthermore, in mal1-/- 
animals an equivalent up-regulation in aP2 expression was not observed in 
WAT or BAT. Mal1-/- animals as aP2-/- on a normal chow diet showed only 
modest differences when compared to their wild-type (wt) littermates (Maeda 
et al., 2003). 
 
When aP2-/- animals were challenged with a high-fat diet (HFD) (40% of 
calories from fat), they became slightly more obese than wild-type controls but 
did not develop insulin resistance or diabetes in contrast to their wt and 
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heterozygotic littermates (Hotamisligil et al, 1996). The same effects were 
observed when aP2 was disrupted in leptin-deficient (ob/ob) mice which are a 
model of severe genetic obesity and insulin resistance. ob/ob-aP2-/- animals 
gained 15% more weight compared with their ob/ob controls, but they were 
more insulin sensitive, as demonstrated by significantly lower plasma glucose 
and insulin levels and also had lower plasma TAG and cholesterol levels. 
Thus, a single disruption in aP2 created a genetic model to uncouple obesity 
and insulin resistance (Uysal et al., 2000).  
 
In contrast to aP2-/- mice, mal1-/- mice when fed HFD or placed on a severe 
genetic obesity and insulin resistant background (ob/ob) they were only 
moderately more insulin sensitive when compared with matched controls. On 
the other hand, mal1 overexpression in WAT had the opposite effect i.e. mal1-
transgenic mice showed a reduction in insulin sensitivity (Maeda et al., 2003). 
From these studies, we can conclude that the phenotype of the aP2-/- mice is 
not accounted for by a compensatory up-regulation of mal1, because mal1 
deficiency also improved components of the metabolic syndrome. 
 
Finally, in humans carrying a loss-of-function polymorphism in the aP2 locus 
resulted in decreased AT aP2 expression due to alteration of the C/EBP 
binding and reduced transcriptional activity of the aP2 promoter. In a cohort of 
7,899 participants, the individuals carrying this polymorphism had lower 
serum TAG levels and signiﬁcantly reduced risk for coronary heart disease 
and type 2 diabetes compared with subjects homozygous for the wild type 
allele (Tuncman, 2006). 
 
Studies in aP2-/- primary adipocyte cultures revealed that aP2 disruption does 
not alter the rate of FA inﬂux or esteriﬁcation, but revealed a role for aP2 in 
lipolysis since basal and isoproterenol-stimulated lipolysis was 40% reduced 
in adipocytes from knockout animals (Coe et al., 1999). This is in agreement 
with the blunted glycerol blood levels after β-adrenergic stimulation in aP2 null 
animals (Scheja et al, 1999) and also with the finding that aP2 physically 
interacts with hormone sensitive lipase (HSL) (Shen et al., 1999). Therefore, 
aP2–HSL interaction could result in the facilitation of FA efflux from the cell 
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and in the absence of aP2 FAs are not efficiently released from the adipocyte 
and accumulate intracellularly (Coe et al., 1999; Shen et al., 1999). 
 
As aP2 is also expressed in macrophages its role in atherosclerosis which is 
linked with lipid metabolism dysregulation and aberrant inflammatory 
responses was investigated. Makowski and colleagues addressed this 
question by crossing Apolipoprotein E deficient mice (ApoE–/–) mice with aP2-
/– mice and also performed bone-marrow transplantation experiments in which 
aP2–/–ApoE–/– mice were donors to recipient aP2+/+ApoE–/–. ApoE-deficient 
mice exhibited severe hypercholesterolemia and spontaneous atherosclerotic 
lesions whereas either aP2 total deficiency (ApoE–/–aP2–/– mice) or 
macrophage specific deficiency (transplantation experiments) resulted in mice 
with significant less atherosclerosis in the absence of significant changes in 
serum lipid, glucose or insulin levels. Thus, aP2 seems to have an important 
role in the development of the metabolic syndrome both through its 
expression in adipocytes and macrophages regulating lipid homeostasis and 
inflammatory responses, respectively (Makowski et al, 2001).  
 
Finally, double knockout mice for aP2 and mal1 showed a strong protection 
from diet-induced obesity, insulin resistance, type 2 diabetes and fatty liver 
disease, highlighting the central role of these FABPs in the development of 
key pathologies associated with metabolic syndrome (Maeda et al. 2005).  
 
One common feature of all FABP knockout models, aP2-/-, mal1-/- and double 
aP2-/--mal1-/- mice, is that they all show a minor but significant increase in 
serum FFA levels. Elevated FFAs are positively correlated with the 
development of obesity and insulin resistance, but adipocyte/macrophage 
FABP-deficient mouse models were insulin sensitive. This observation 
challenges the current dogma and indicates that individual FAs or metabolite 
action at the intracellular level rather than the absolute amounts may be more 
critical in pathological conditions. Thus, more detailed lipid profiling showed 
increased shorter-chain (C14) FAs and decreased longer-chain (C18 or C20) 
FAs in the muscle and adipose tissues of aP2-/--mal1-/- mice. These changes 
favoured enhanced insulin receptor signalling, insulin-stimulated glucose 
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uptake, adenosine monophosphate-activated protein kinase (AMPK) activity, 
and FA oxidation (Maeda et al, 2005). 
 
One very important question is what the true functional role of aP2 is since its 
expression promotes a dysfunction of metabolic and inﬂammatory nature 
when mice are challenged with stress stimuli (e.g. HFD). One explanation 
might lie in the role of aP2 on transcriptional regulation. It has been shown 
that aP2 is able to translocate to the nucleus in response to ligand binding 
(Tan et al., 2002) and to physically interact with PPARγ, transferring its ligand 
to the receptor enhancing its transcriptional activity (Tan et al., 2002; Wolfrum, 
2007). Thus, aP2 might be necessary to ﬁne-tune the balance of the available 
of lipid resources. On the one hand, lipid-ligand activated PPARγ induces the 
expression of aP2. On the other hand, aP2 can act as a ligand carrier for 
PPARγ but it can also act with a negative mechanism to sequester lipids from 
PPARγ. When aP2 is absent PPARγ is always activated since the signal is 
not attenuated resulting in a hyperactivated PPARγ. This model is further 
supported by the fact that aP2 knockout mice have a similar phenotype to 
mice or humans treated with TZDs, including improved glucose and lipid 
metabolism, and decreased insulin resistance, atherosclerosis, and 
inﬂammatory response (Makowski and Hotamisligil, 2004). 
 
Finally, Chen et al. demonstrated that aP2 is the major determinant of the FA 
source for adipocytes. In the presence of aP2, the main source of FAs 
supplying adipocytes is the diet whereas its absence de novo lipogenesis is 
the major source. As a consequence, the adipocyte FA composition changes 
and palmitoleate (an unsaturated FA) becomes the major FA produced in 
adipocytes. In this study, it was clearly demonstrated that the FA composition 
in AT determines the activity in other metabolic tissues such as liver and 
muscle. Thus, in specific AT aP2 deficient mice fed a HFD, palmitoleate 
suppresses hepatosteatosis and stimulates glucose transport in skeletal 
muscle regardless of the increased total FAs (Chen et 2008). These 
observations were confirmed in human studies where palmitoleate levels were 
strongly associated with insulin sensitivity (Stefan et al., 2010).  
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In conclusion, it is thought that aP2 is one of the genes involved in the ‗‘thrifty‘‘ 
phenotype since on a standard diet aP2-/- mice do not show any significant 
phenotype whereas they are more insulin sensitive under HFD. Thus, aP2 is 
essential when there is a limited amount of resources to survive famine 
whereas, it seems to be responsible for the development of obesity, diabetes, 
dyslipidaemia and atherosclerosis under caloric excess, making aP2 an ideal 
candidate for pharmacological intervention (Furuhashi et al., 2011).  
 
1.4 Fatty acid Metabolism 
 
1.4.1 Fatty acids and fatty acid trafficking 
Lipids are deﬁned as biological substances that are generally hydrophobic in 
nature and soluble in organic solvents. Biological lipids usually refer to a 
broad group of naturally occurring molecules which includes FAs, waxes, 
eicosanoids, glycerolipids (mono-, di- and triglycerides), phospholipids, 
sphingolipids, sterols, terpenes, prenols, fat-soluble vitamins (such as 
vitamins A, D, E and K) and others (Fahy et al., 2005). 
FAs represent the major lipid building block of complex lipids and they are one 
of the most fundamental categories of biological lipids. FAs are either 
saturated or unsaturated carboxylic acids with carbon chains varying between 
2 and 36 carbon atoms (Table 1.1). In animal and plant tissues, the most 
abundant FAs are those with 16 and 18 carbon atoms, i.e. palmitic, stearic, 
oleic and linoleic. FAs in mammalian organisms reach a chain-length of 12-24 
carbon atoms, with 0-6 double bonds whereas FAs with chain lengths shorter 
than 14 and longer than 22 carbon atoms are present only in minor 
concentrations (Tvrzicka et al., 2011).  
FAs have many different functions in an organism. They are a principal source 
of energy and have a central role in energy storage. They contain twice as 
much of energy value compared to proteins and carbohydrates and their 
storage in AT requires less water as they can be stored anhydrously as TAGs. 
They are the most important element for the formation of complex lipids such 
as phospholipids which are structural and functional components of cell 
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membranes. Finally, they are the precursors for the formation of hormones 
and signalling molecules that can influence signal transduction pathways and 
gene transcription (Fahy et al., 2005; Kremmyda et al., 2011). 
 
Table 1.1: Nomenclature, structure and level of saturation of different unbranched FAs. 
FAs are carbon chains with a carboxyl group at one end and a methyl group (designated 
omega, ω) at the other end. Saturated fatty acids have no double bonds whereas unsaturated 
have either one (monounsaturated) or more than one (polyunsaturated) double bonds. 
Unsaturated fatty acids are often expressed as a schematic formula CN:p n-x, where CN 
(carbon number) represents total number of carbon atoms, p – number of double bonds, x – 
position of the first double bond from the methyl terminus (ω). FAs: fatty acids, LA: linoleic 
acid, AA: arachidonic acid, α-LA: α-linolenic acid, EPA: eicosapentaenoic acid, DHA: 
docosahexaenoic acid (adapted from Tvrzicka et al., 2011). 
 
FAs can be obtained from the diet, but can also be released from adipocytes, 
or synthesized in the liver. The average western diet of a healthy adult person 
contains approximately 56-78g fat per day for a standard diet of 2000kcal/day. 
However, the fat intake can be as high as 40-45% of the total energy intake 
Fatty acids 
Structure  
Carboxyl end                                       Methyl end (ω) 
Saturation 
Stearic acid 
18:0 
 
Saturated 
Oleic acid 
18:1, ω-9 
 
Monounsaturated 
LA  
18:2ω-6 
 
Polyunsaturated 
AA 
 20:4ω-6 
 
Polyunsaturated 
α-LA  
18:3ω-3 
 
Polyunsaturated 
EPA  
20:5ω-3 
 
Polyunsaturated 
DHA  
22:6ω-3 
 
Polyunsaturated 
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depending on food resources and habitual consumption. Recommendations 
for the total fat intake have been set by various bodies worldwide and recently 
the European Food Safety Authority (EFSA) recommended that total fat 
should be between 20-35% of total energy intake by healthy adults (EFSA 
Panel on Dietetic Products, Nutrition and Allergens (NDA); 2010). 
 
Exogenous FAs are supplied to the body mainly as dietary TAGs and are 
digested into FAs and monoacylglycerols in the small intestine by pancreatic 
lipases. Then the digestion products are transferred through the luminal 
membrane of the intestinal epithelial cells, and reesterified into TAGs that are 
packaged into large lipoproteins called chylomicrons. Chylomicrons are 
relatively short-lived and are nearly absent in the fasting state. Once formed, 
they are secreted via the thoracic lymph duct into the blood for delivery to the 
other tissues in need of FAs. This is called the exogenous lipid transport 
pathway since the lipids originate from outside the body (Montgomery, 1996). 
 
Under resting conditions, the majority of chylomicrons go to WAT. FFAs are 
released by the enzymatic hydrolysis of TAGs contained in neutral lipid core 
of the chylomicrons by the lipoprotein lipase (LPL) which is a 448-amino acid 
glycoprotein synthesised by the adipocyte and transferred to the luminal pole 
of microvascular endothelial cells. After FAs enter the adipocyte, 
reesterification is necessary for lipid storage in TAGs until signals reach the 
adipocyte to hydrolyse part of their intracellular neutral lipids (Lafontan, 2008). 
 
In the case of excess circulating FAs, they are taken up by the liver where 
they are esterified into TAGs and packaged in very low density lipoproteins 
(VLDLs) and released to the blood. VLDLs subsequently transfer the 
esterified FAs to WAT and muscle (endogenous lipid transport pathway) 
(Montgomery, 1996). 
 
Energy requirements are constantly changing and cells must match substrate 
supply with demand, hence FAs are in constant ﬂux and need to enter and 
leave cells rapidly. In blood, FAs are solubilised and transported in millimolar 
concentrations (0.1-1) by binding to plasma albumin. The unbound FA (free 
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FA in equilibrium with albumin), is the species important for cellular uptake. Its 
concentration is determined by the molar ratio of FA to albumin and is 
computed based on FA:albumin binding constants. Because albumin binds 
FA with high affinity, cells should possess a high affinity mechanism allowing 
recruitment of FA from albumin avoiding its efflux back into the albumin-
containing medium (Abumrad et al., 1999; Thompson et al., 2010). 
 
In general, the uptake of FAs from the circulation into cells includes the 
sequence of three steps. The first step is called adsorption and involves the 
binding of FAs to the outer surface of the plasma membrane. First, FFAs are 
generated locally through hydrolysis of TAG-rich lipoproteins by lipases inside 
the endothelial lumen followed by their binding to albumin. FAs dissociate 
from albumin followed by binding to plasma membrane proteins or integration 
into the lipid bilayer. The second step involves the FA transport across the 
plasma membranes. This step is the most controversial as whether the 
mechanism of FA translocation is diffusion-mediated or protein-mediated. FAs 
can traverse the phospholipid bilayer by a rapid passive transport across the 
lipid bilayer (flip-flop) followed by a slower dissociation of the lipid from the 
membrane into the intracellular aqueous phase. However, protein-mediated 
uptake of FAs is also involved especially in cells with high FA demand. 
Several FA transporters have been identified with potential role in FA uptake 
such as FA translocase (FAT/CD36), plasma membrane fatty acid binding 
protein (FABPpm), caveolin-1 and fatty acyl-CoA synthetases (FATP and 
ACSL). FA transport in adipocytes is enhanced due to the rapid rates of lipid 
metabolism and incorporation into the TAG droplet which may represent a 
balance between diffusion-mediated and protein-mediated processes. Finally, 
the third step is called desorption and involves FAs leaving the cytosolic 
leaflet of the plasma membrane and interacting with intracellular FABPs and 
acyl-CoA binding proteins (ACBPs) (Hammilton, 1998; Doege and Stahl, 
2006; Thomson et al, 2010). 
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1.4.2 Triglycerol (TAG) synthesis 
 
In adipocytes, FAs produced by de novo lipogenesis (synthesis of FAs from 
non-lipid substrates), along with those transported into the cell, are used 
mainly for the synthesis of TAG. The two central enzymes of de novo 
lipogenesis, acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) use 
acetyl-CoA and malonyl-CoA to generate palmitate. Palmitate synthesised by 
de novo lipogenesis as well as dietary lipids, can be modified by endogenous 
elongase and desaturase enzymes to produce multiple lipid species (Sul and 
Wang, 1998).  
 
The first commitment step of TAG synthesis is the esteriﬁcation of fatty acyl-
CoA with glycerol-3-phosphate (G3P) at the sn-1 position to form 1-
acylglycerol-3-phosphate (lysophosphatidic acid), a reaction catalysed by 
glycerol-3-phosphate acyltransferase (GPAT) (Brasaemle and Wolins, 2012). 
 
In adipocytes, G3P was classically thought to be generated by insulin 
dependent uptake of glucose, its conversion to dihydroxyacetone phosphate 
(DHAP) in the glycolytic pathway and finally generation of G3P by 
glycerophosphate dehydrogenase (Salway, 2004). However, it has been 
shown that after TZD treatment adipocytes express glycerol kinase (GyK) that 
phosphorylates directly glycerol to produce G3P (Guan et al, 2002). Finally, 
glyceroneogenesis is another pathway that also supplies G3P and involves 
the carboxylation of pyruvate to oxaloacetate, decarboxylation of oxaloacetate 
to phosphoenolpyruvate by cytosolic phosphoenolpyruvate carboxykinase 
(PEPCK-C), and, subsequently, the production of G3P through a partial 
reversal of glycolysis (Chaves et al., 2006). PEPCK had also been shown (as 
GyK) to be strongly induced by TZDs revealing another mechanism of the 
anti-diabetic action of TZDs allowing the adipocyte to use the glycerol and 
FFA generated from lypolysis for re-esterification, lowering serum FFAs and 
eliminating their accumulation in ectopic tissues (Tordjman et al, 2003). 
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Lysophosphatidic acid is further esteriﬁed and converted into phosphatidic 
acid (PA) in the reaction catalysed by 1-acylglycerol-3-phosphate 
acyltransferase (AGPAT). PA is converted to the intermediate 1,2-
diacylglycerol (1,2-DAG) by the phosphatidic acid phosphatase (PAP) 
reaction. Diacylglycerol acyltransferase (DGAT) catalyzes the acylation of 1, 
2-DAG to form TAG (Figure 1.5) (Sul and Wang, 1998).  
 
All the enzymes involved in the TAG synthesis are located in the ER but the 
TAGs are eventually stored in LDs which are monophospholipid layered 
vesicles. The most widely accepted model of LD formation is that lipids 
accumulate between the cytosolic and the luminal leaflets of the phospholipid 
bilayer of the ER, followed by association of LD specific proteins and eventual 
separation of the growing LD from the ER (Hapala et al., 2011). 
 
1.4.3 Lipolysis 
 
During times of increased energetic demand, WAT has the ability to switch 
from being a FA storing tissue to a FA provider to the other organs. Lipolysis 
is the essential mechanism that releases FFAs and glycerol by the hydrolysis 
of TAGs stored in adipocytes (Duncan et al, 2007). Despite the essential role 
of FAs, a FA oversupply can cause different detrimental effects all described 
as lipotoxicity (Unger et al, 2010). Thus, lipolysis and lipogenesis are highly 
regulated processes releasing or re-esterify FA in a futile cycle in order to 
avoid non-physiological increases in FA concentrations (Duncan et al, 2007).  
 
Upon β-adrenergic stimulation PKA phosphorylates a protein localised on 
LDs, perillipin-1, which in the non-stimulated state interacts with comparative 
gene identification-58 (CGI-58). CGI-58 then dissociates from perillipin-1 and 
interacts with adipose triglyceride lipase (ATGL) which is the main TAG 
hydrolase. CGI-58 acts as a coactivator for ATGL which gains full activity and 
cleaves the first esterbond in a TAG to yield a DAG and a non-esterified FA. 
HSL is also phosphorylated by PKA and interacts with perillipin-1 to gain 
access into the LD. Then, HSL hydrolyses DAGs into monocylglycerols 
(MGs). HSL-phosphorylation and translocation coupled with ATGL activation 
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by CGI-58 increases the TAG hydrolysis more than 100-fold. Finally, the last 
step of lipolysis is the hydrolysis of MGs by MG lipase (MGL) (Zechner et al, 
2012). The FFAs liberated by lipolysis either exit the adipocyte to be oxidised 
in other tissues such as liver and muscle, or can be used for the synthesis of 
TAGs. 
 
Recently macroautophagy of LDs (or macrolipophagy) has been described as 
an alternative way to produce FFAs apart from lypolysis in long fasting 
periods (Singh et al, 2009). Macroautophagy is a non-selective lysosomal 
pathway for the degradation of cytosolic organelles and proteins. These 
cytoplasmic components are trapped inside double-membrane vesicles 
termed autophagosomes and fuse with lysosomes where their contents are 
degraded (Singh et al., 2009). In the case of LDs their lipids are degraded by 
lysosomal lipases found in lysosomes.  
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Figure 1.5: Adipocyte lipogenesis and lipolysis. Excess glucose is oxidized via 
glycolysis to acetyl-CoA in the adipocyte and then converted into acyl-CoA, which is 
esterified in the ER to TAGs. These are then translocated into the LD. FA obtained 
from lipoproteins are also esterified into TAG and stored. Under fasting conditions, 
lipolysis is activated by GPCRs resulting in an increase in cAMP and PKA activation 
that phosphorylates perilipin located in the membrane of the LD. PKA also 
phosphorylates HSL that translocates from the cytoplasm to the LD and induces the 
hydrolysis of DAGs produced by the ATGL to form MGs. MGs are then released to 
non-adipose tissues, mainly for energy purposes. Some glycolysis and 
glyceroneogenesis steps are also illustrated for the generation of G3P. ER: 
endoplasmic reticulum, TAG: triglyceride, LD: lipid droplet, GPCR: G-protein coupled 
receptor, PKA: protein kinase A, DAG: diacylglycerol, ATGL: adipose triglyceride 
lipase, MG: monocyalglycerol, G3P: glycerol-3-phosphate (adapted from Vázquez-
Vela et al., 2008) 
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1.5 Arachidonic acid metabolism 
 
Polyunsaturated fatty acids (PUFAs) are long chain FA (C16 and above) 
containing two or more double bonds. PUFAs can be classified in two 
categories, omega-6 (ω-6 or n-6) and omega-3 (ω-3 or n-3) based on the 
location of the last double bond relative to the terminal methyl end of the 
molecule. The precursors of the two classes, linoleic acid (LA; 18:2n-6) and α-
linolenic acid (ALA; 18:3n-3) cannot be synthesised endogenously. FAs can 
only be desaturated endogenously up to the Δ9 position due to lack of certain 
enzymes in humans (Δ12- and Δ15-desaturases). For this reason LA and ALA 
must be provided from the diet and are called essential FAs. Further 
elongation and desaturation of these FAs to produce long-chain PUFA, 
including eicosapentaenoic acid (EPA; 20:5n-3), docosahexaenoic acid (DHA; 
22:6n-3) and arachidonic acid (AA; 20:4n-6), is possible (with the two FA 
families competing for the same enzymes) but not very efficient in humans. 
Thus, these FAs (EPA, DHA and AA) may be characterised as conditionally 
essential depending on essential FA availability (Schimitz et al., 2008; 
Tvrzicka et al., 2011). Deficiency of PUFAs leads to different number of 
disorders such as growth retardation, infertility, skin lesions and dysopsia 
(Kremmyda et al, 2011). 
 
AA (5,8,11,14-eicosatetraenoic acid), can be synthesised from dietary LA or 
can be obtained directly from the diet as poultry (eggs and meat) and fish 
products are high in quantities of preformed AA. In westerns diets, it is 
calculated that the daily intake of AA is 0.2–0.3g whereas the intake of LA is 
10–20g per day, indicating that the formation of AA from LA exceeds the 
dietary supply of AA (Zhou and Nilsson, 2001). The recommended LA intake 
by EFSA is 4% of the total energy intake whereas there is not a set 
recommended dietary reference value for AA (ESFA, 2010).  
 
After consuming n-6 PUFAS, intestinal phospholipids containing AA and LA 
are taken up by the liver in the form of chylomicron remnants. In the liver, LA 
is converted to AA by successive actions of ∆6 desaturase, elongase, and ∆5 
desaturase. Once AA is obtained (from diet) or formed (in liver), it is 
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distributed in serum as FFA (complexed to albumin) or as part of complex 
lipids (phospholipid, TAGs and cholesterol esters) in lipoprotein vesicles. AA 
is then taken up by cells by a mechanism that is not entirely clear and may 
involve passive diffusion or facilitated protein-mediated transport (Chilton et 
al., 1996; Leslie 2004).  
 
There are high levels (500 nmol/ml) of AA (either FFA or complex lipid) in 
normal human serum (Chilton et al, 1996). Additionally, AA is also found in 
abundance incorporated into the cell membrane phospholipids particularly 
choline phospholipids (PCs) ethanolamine phospholipids (PEs), and 
phosphatidylinositol (PI) which accounts for as much as 25% of all 
phospholipid FAs. Phospholipids contain FAs esteriﬁed to the glycerol 
backbone at the sn-1 and sn-2 positions. In general, the sn-1 fatty acyl group 
is saturated whereas the sn-2 fatty acyl group is monounsaturated or 
polyunsaturated such as AA. The double bond geometries of AA are cis, 
which introduces signiﬁcant distortion into the membrane bilayer and 
contributes to its ﬂuidity (Brown and Marnett, 2011).  
 
There are two pathways regulating the incorporation of AA into phospholipids. 
The first one is a high-afﬁnity pathway that occurs in the presence of low AA 
concentrations. The first enzymatic step for the incorporation of AA into 
phospholipids is catalyzed by the enzyme acyl-CoA synthetase (ACS), which 
activates the carboxyl group of AA by thioesterification with CoA moiety, as a 
result AA to be converted to arachidonoyl-CoA. The long-chain acyl-CoA 
synthetases ACSL3, 4 and 6 show marked preference to AA. Arachidonoyl-
CoA then is incorporated primarily into choline lysophospholipids (lysoPC) via 
a reaction catalysed by lysophospholipid CoA dependent acyltransferases 
resulting in the formation of PCs (Lands pathway). Once AA has been 
incorporated into phospholipids, a reaction carried out by CoA-independent 
transacylase (CoA-IT) transfers AA from PCs to PEs. Thus, despite PC being 
the preferred acceptor for exogenous AA, under equilibrium conditions, AA is 
more abundant in PE than in PC. This transacylation reaction seems to be 
important for membrane homeostasis but also for the appropriate cell 
response during physiological and pathophysiological activation (Astudillo et 
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al, 2012). The second pathway is a ―high-capacity, low afﬁnity‖ pathway that 
operates after the high affinity deacylation/reacylation pathway has been 
saturated due to the high AA concentration and leads via the de novo route for 
phospholipid biosynthesis to accumulation of AA into TAGs (Kennedy 
pathway) (Figure 1.6) (Chilton et al., 1996; Pérez-Chacón et al., 2009). The 
incorporation of AA into the TAG pool is postulated to have two roles, one is 
the utilisation of AA for the production of eicosanoids since prostaglandin 
synthetases have been found at LDs and the second is a way to store excess 
AA in order to protect the cells from the toxic effects of high AA concentrations 
(Chilton et al., 1996). 
 
The production of free AA is a highly regulated process that represents a 
balance between two competing reactions. On the one hand, phospholipases 
deacylate phospholipids yielding free AA and on the other hand CoA-
dependent acyltransferase re-acylates and re-incorporates AA into 
phospholipids. Depending on the state of the cell one kind of reaction will 
dominate over the other. In resting cells, reacylation dominates and the 
majority of cellular AA is found in the esteriﬁed form, keeping free AA at low 
levels. However, under stimulated conditions (e.g. cytokines, growth factors, 
mechanical trauma etc) phospholipases are activated and catalyse the 
hydrolysis of phospholipids generating free AA. Three enzymes can catalyse 
the deacylation reaction: phospholipase A2 (PLA2), phospholipase C (PLC), 
and phospholipase D (PLD) which have different sites of action on the 
phospholipid backbone. PLA2 catalyses the hydrolysis of phospholipids at the 
sn-2 position releasing free AA in a single-step reaction. By contrast, PLC and 
PLD generate lipid products containing AA (DAG and PA, respectively), which 
are released subsequently by DAG- and MG-lipases. Thus, in stimulated 
cells, the dominant reaction is the phospholipase-mediated deacylation, which 
results in the release of free AA. However, under activation conditions AA 
reacylation is still very signiﬁcant, as only a minor fraction of the AA is 
released by phospholipases and the remainder is incorporated back into 
phospholipids (Pérez-Chacón et al., 2009).  
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Figure 1.6: AA incorporation in phospholipids. AA is obtained directly from diet or 
synthesized from LA. AA is incorporated into the sn-2 position of phospholipids PCs 
and PIs and later subjected to remodeling processes via CoA-IT reactions 
transferring AA from PCs to PEs. This pathway is a high affinity pathway called 
Lands pathway whereas the Kennedy pathway is a low affinity pathway leading to the 
incorporation of AA to TAGs. AA: arachidonic acid, LA: linoleic acid, PI: 
phosphatidylinositol, CoA-IT: CoA-independent transacylase, PC: choline 
glycerophospholipid, PE: ethanolamine glycerophospholipid (adapted from Pérez-
Chacón et al., 2009; Astudillo et al, 2012). 
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The release of AA from phospholipids is the first step and the overall rate-
limiting step, for the biosynthesis of AA metabolites or eicosanoids (from the 
Greek eicosa = twenty; for twenty carbon fatty acid derivatives). Despite the 
fact that other phospholipases can catalyse the reaction for the release of AA 
from phospholipids, type IV cytosolic PLA2α (cPLA2α) phospholipase shows 
speciﬁcity for phospholipid substrates containing AA. Thus, cPLA2α is crucial 
for eicosanoid production and cells lacking cPLA2α are generally devoid of 
eicosanoid synthesis (Funk, 2001). Moreover, mice lacking cPLA2α exhibit a 
number of striking phenotypes that can be explained by defects in eicosanoid 
mediated pathways (e.g. reduced airway inﬂammation (asthma, ARDS, and 
ﬁbrosis), impaired implantation and parturition in female reproduction, 
increased intestinal ulcer, delayed blood coagulation, renal dysfunction after 
aging, protection from Alzheimer‘s disease, protection from metabolic 
syndrome (atherosclerosis, obesity and hepatic steatosis) (Murakami et al., 
2011).  
 
After its release from phospholipids, the non-esterified AA is rapidly 
oxygenated in a cell-specific manner by cyclooxygenases (COXs), 
lipoxygenases (LOXs) and cytochrome P450 monoxygenases (MOXs) and 
give rise to different eicosanoids which have a short half-life (ranging from 
seconds to minutes) (Figure 1.7) (Funk, 2001).  
 
There are two COX isoforms, COX-1 and -2, which are also known as 
prostaglandin endoperoxide synthases -1 and -2 (PGHS-1 and -2). COX-1 is 
constitutively expressed in most tissues and it is responsible for the basal 
activity, whereas COX-2 is the inducible isoform. COXs catalyse the rate-
limiting step in the biosynthesis of prostanoids i.e. prostaglandins (PGs) and 
thromboxane A2 which is the incorporation of molecular oxygen to AA forming 
prostaglandin G2 (PGG2). PGG2 is subsequently reduced to PGH2 by two 
electrons by the action of the peroxidase active site. PGH2 is the common 
precursor of all prostanoids and does not accumulate in cells but rather is 
converted rapidly to downstream products by the action of specific PGs and 
thromboxane synthases. These synthases give rise to different 2-series PGs 
such as PGE2, PGD2, prostacyclin (PGI2), PGF2α (―2‖ stands for the number 
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of carbon-carbon double bonds in the product) and thromboxane A2 (TXA2). 
PGs are not stored intracellularly but are synthesized de novo from 
phospholipid-released AA every time cells are activated by various stimuli. 
PGs, once formed, act either by an autocrine and/or paracrine manner by 
binding to specific surface GPCRs or by directly binding to nuclear receptors 
(Smith et al., 2000; Smith et al, 2011).  
 
5, 12 and 15 LOX enzymes catalyze the oxygenation of AA (the numbers 
correspond to the carbon position of AA oxygenation) each forming a distinct 
hydroperoxy-eicosatetraenoic acid (HPETE). HPETEs are unstable and can 
be reduced by peroxidases to the corresponding hydroxyeicosatetraenoic 
acids (HETEs). 5-LOX is the initial enzyme in the synthesis of leukotrienes 
and catalyses two enzymatic reactions. The first one involves the addition of 
molecular oxygen to carbon-5 of AA to form 5-HPETE. The second reaction 
involves the conversion of 5-HPETE into leukotriene A4 (LTA4). LTA4 is quite 
unstable and becomes a substrate for two discrete enzymes, LTA4 hydrolase 
which converts LTA4 into leukotriene B4 (LTB4), and leukotriene C4 synthase 
which converts LTA4 into leukotrienes C4, D4, and E4 (Zimmer et al.,  2004).  
 
Finally, MOXs oxygenate AA to form four epoxyeicosatrienoic acids (EETs) 
which are converted to dihydroxyeicosatrienoic acids (DHETs) by epoxide 
hydrolases. EETs have been associated with anti-inflammatory properties in 
cardiovascular diseases which function primarily as autocrine and paracrine 
effectors in the cardiovascular system and kidney (Astudillo et al., 2012). 
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Figure 1.7: The three pathways for AA metabolism into eicosanoids. AA serves 
as a substrate for cyclooxygenases (COX-1 and COX-2), lipoxygenases (LOX-5, 
LOX-12 and LOX-15), or P450 monooxygenases (adapted from Astudillo et al., 
2012). 
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1.6 Arachidonic acid and adipogenesis 
 
Dietary fat has always been associated with obesity since it has been shown 
that HFDs can increase both adipocyte number (hyperplasia) and adipocyte 
size (hyperotrophy) (Faust et al., 1978). Adipocyte size can increase a lot in 
response to HFD but has a deﬁned limit of expansion for any given individual. 
According to the AT expandability hypothesis, when an individual gains weight 
there is a point that adipocytes cannot expand to store more fat and thus AT 
can no longer act as a lipid buffering tissue. Once AT storage capacity is 
exceeded then the levels of circulating NEFAs increase and are deposited 
ectopically in myocytes, hepatocytes and β-cells where they have lipotoxic 
effects such as insulin resistance and apoptosis (Virtue and Vidal-Puig, 2010).  
 
However, it is now clear that the effect of dietary fat depends on the nature of 
FAs i.e. chain length, position and number of the double bonds. In general, it 
seems that saturated FAs (SFAs) are more cytotoxic in comparison to 
unsaturated FAs (UFAs) and EFSA recommendation for SFAs is that the 
consumption should be as low as possible (EFSA, 2010). Evidence coming 
from β-cells revealed that treatment of these cells with SFAs is more lipotoxic 
than when treated with unsaturated FAs and also unsaturated FAs could 
counteract SFA toxicity in vitro (Diakogiannaki, et al, 2007). Dyslipidaemia, 
inflammation, oxidative stress and other metabolic abnormalities such as 
metabolic syndrome and type 2 diabetes, are often accompanied with 
changes in FA composition in plasma and particularly decreased content of 
PUFAs and increased content of SFAs (Kremmyda et al., 2011). 
 
PUFAs seem to have different effects on obesity. In vivo data demonstrate 
that dietary intake of n-3 PUFA may reduce body fat accumulation, when 
exposed to a high fat diet (Hainault et al, 1993), and reduce body weight in 
adult animals that are already obese (Perez–Matute et al., 2007). On the 
other hand, animal studies using mice fed diets rich in n-6 PUFA, yielded 
conflicting results with some studies claiming that n-6 PUFA decrease 
adipose mass (Matsuo et al., 2002), whereas others associate n-6 PUFA with 
an increased propensity for obesity (Massiera et al, 2003). Finally, it seems 
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that the ratio between n-3 and n-6 PUFAs is crucial for the effect of total fat on 
obesity. Over the last two decades the total amount of ingested fat 
consumption has not changed but the consistency of the fat has changed 
dramatically. For example, in France, from 1960 to 2000, an increase in the 
consumption of LA (2.5-fold) and AA (2.3-fold) has been estimated, whereas 
the consumption of ALA has decreased by 40%, leading to a 2.9-fold and a 
4.2-fold increase in the ratios of n-6/ n-3 PUFAs and LA/LNA, respectively 
(Ailhaud et al., 2006a). This was also associated with the change in the 
PUFAs ratio in breast milk which was correlated with increased childhood 
obesity (Ailhaud et al., 2006b). This notion was confirmed in animal studies 
were mothers fed either LA or LA and ALA showed that the pups coming from 
mothers fed LA were more obese in adult life in comparison with the LA/ALA 
counterparts (Massiera et al., 2003).  
 
Apart from hyperotrophy, HFD also increases the adipocyte number 
(hyperplasia). Adipocyte number is controlled by the rate of adipogenesis. 
Adipogenesis as already described is a complex process which includes 
changes in gene expression in response to different stimuli including lipid 
mediators. Feeding mice and rats with a HFD for 52 weeks increased the 
proliferation of pre-adipocytes, thereby increasing adipocyte number. The 
same results were confirmed in Pima Indians fed for 2 weeks with HFD which 
doubled the population of the small, adipocytes that appear to be recruited 
from a pool of pre-adipocytes. These observations suggest that hypertrophy 
and hyperplasia, take place in response to a HFD both in adult rodents and 
humans (Ailhaud et al., 2008). 
 
Pre-adipocytes and adipocytes have all the machinery for metabolising AA. 
Several classes of prostanoids are synthesised in pre-adipocytes acting as 
local hormones at different stages of adipogenesis in response to external 
signalling molecules or nutritional status, which are involved in regulating 
differentiation. Pre-adipocytes express COXs which catalyse the first rate-
limiting step for AA metabolism. COX-1 is constitutively expressed in pre-
adipocytes, as in most cells but COX-2 which is the inducible form is 
transiently activated in the early stages of adipogenesis (Fujimori et al, 2010). 
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In vitro studies of the effect of COX-2 on adipogenesis gave contradictory 
results. Chu et al., showed that expressing COX-2 antisense mRNA resulted 
in enhanced adipogenesis whereas Fajas et al, showed that COX-2 inhibitors 
impaired adipogenesis through an inhibition of the clonal expansion step 
(Fajas et al., 2003; Chu et al., 2010). Finally, COX-2 knockout mice show 
attenuated adipocyte differentiation (Ghoshal et al, 2011).  
 
AA itself has been described to be a ligand for PPARγ (Kliewer et al., 1997) 
making it a good candidate regulating adipogenesis. However, different in 
vitro models gave different results e.g. Gaillard et al. using Ob1771 cells have 
shown that AA is able to promote their differentiation (Gaillard et al., 1989) 
whereas Madsen et al. using 3T3-L1 cells showed that AA prevents their 
differentiation (Madsen et al., 2005). This diversity observed in studies for 
COX-2 and AA indicate that AA metabolism during adipogenesis is a process 
governed at multiple levels suggesting a complex role for PGs during fat cell 
development.  
 
Indeed, it has been shown that PGs have opposing effects on adipogenesis 
some of them promoting and some of them inhibiting adipogenesis (Figure 
1.8). PGI2 stimulates terminal differentiation of Ob1771 adipocytes using the 
stable analogue of PGI2, carbaprostacyclin (Vassaux et al, 1992). After 
secretion from pre-adipocytes, prostacyclin acts externally via the prostacyclin 
receptor (IP-R) on the cell surface. IP-R seems to be coupled to both Gs and 
Gq resulting in increased cAMP formation and calcium signalling, respectively 
(Vassaux et al., 1992). IP-R is transiently expressed at the pre-adipocyte 
stage and prostacyclin synthesis ceases in mature adipocytes (Ailhaud et al., 
2008). In order to address the effect of PGI2 in adipose tissue development, 
IP-R-/- mice were fed with HFD rich in LA during the gestation and suckling 
period. The pups from IP-R-/- mice did not gain any body weight regardless of 
the diet indicating that PGI2 is responsible for the enhanced fat mass 
development of the wild type pups (Massiera et al., 2003). PGI2 has been 
shown to be pro-adipogenic through two different pathways. PGI2 can up-
regulate the expression C/EBPβ and C/EBPδ via the PKA pathway (Belmonte 
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et al., 2001) or can act as a ligand for PPARβ/δ which, in turn, upregulates the 
expression of PPARγ (Figure 1.8) (Matsusue et al, 2004). 
 
PGJ2 derivatives are the products of the non-enzymatic dehydration of PGD2 
to generate 15- deoxy-Δ12,14 -PGJ2 (15d-PGJ2) and Δ
12 -PGJ2 through PGJ2 
as an intermediate (Kliewer, et a., 1995). 15-deoxy-Δ12,14 -PGJ2 has been 
shown to act as a direct ligand for PPARγ and as expected it is a very potent 
inducer of adipocyte differentiation in vitro, since exogenous addition to the 
culture converts fibroblasts into adipocytes (Forman et al., 1995; Kliewer, et 
al., 1995). There have been conflicting reports as to the significance of 
endogenous production of 15d-PGJ2 during adipocyte differentiation in vitro. 
Bell-Parikh et al. and Xie et al. show that the levels of 15d-PGJ2 detected in 
the medium of 3T3-L1 cultures do not change during the differentiation and 
that the absolute concentrations are not sufficient to activate PPARγ making it 
less possible to act as a natural ligand (Bell-Parikh et al., 2003; Xie et al., 
2006). In contrast, Mazid et al. examining the same cell type show an 
increase in 15d-PGJ2 production during differentiation which contributes to the 
stimulation of adipogenesis during the maturation phase of 3T3-L1 cells 
(Mazid et al., 2006). 
 
PGE2 acts by binding to four different GPCRs designated subtypes EP1, EP2, 
EP3, and EP4. There are four human EP3 spice variants (EP3A, EP3B, EP3C 
and EP3D) generated by alternative splicing of the C-terminal tail. The mouse 
equivalents are designated as EP3α, EP3β and EP3γ (Sugimoto and 
Narumiya, 2007). EPs show poor sequence homology and trigger different 
signalling pathways. EP1 mediates PGE2 action triggering an increase in 
intracellular calcium levels through a yet unidentified protein. EP2 and EP4 
receptors are coupled to Gs and mediate increases in cAMP concentration 
whereas the major signalling pathway of the EP3 receptor is inhibition of 
adenylate cyclase (AC) via Gi (Sugimoto and Narumiya, 2007). However, the 
splice variants of the EP3 receptor are coupled to different signalling 
pathways for example, EP3A receptor is coupled to Gi and induces the 
inhibition of AC, whereas the EP3B and EP3C receptors are coupled to Gs and 
act to increase levels of cAMP. The EP3D receptor is coupled to Gq, in 
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addition to Gi and Gs (Sugimoto and Narumiya, 2007). PGE2 has been shown 
to inhibit adipogenesis via EP4 receptor which is the only EP receptor isoform 
to be expressed in pre-adipocytes in a cAMP-dependent pathway (Sugimoto 
et al., 2004; Tsuboi et al., 2004). However, in vivo data from EP4-/- mice are 
lacking as these mice die shortly after birth and the few that survive do not 
show any adipose tissue phenotype (Sakuma et al., 2000). 
 
PGF2α is shown to inhibit adipogenesis of primary adipocyte precursor 
cultures (Serrero et al, 1992a), 1246 cells (Serrero et al, 1992b) and 3T3-L1 
cells (Liu and Clipstone, 2007). This result was replicated by using PGF2α 
analogs, fluprostenol and cloprostenol (Serrero and Lepak, 1997) which act 
as potent agonists for PGF2α GPCR receptor called FP receptor. PGF2α binds 
to its membrane FP receptor which is coupled to Gq leading to elevated 
intracellular calcium levels. The best characterised downstream effector of Gq 
is PLCβ, which catalyses the hydrolysis of PI 4,5-bisphosphate (PIP2) 
releasing inositol 1,4,5 triphosphate (IP3) and DAG. In consequence, IP3 
causes an increase of intracellular calcium concentration from the ER. The 
combination of DAG and increased levels of calcium lead to the activation of 
protein kinase C (PKC). PKC activates the Raf/MEK/MAP kinase signalling 
pathway affecting various cellular responses (Rhee, 2001). In the context of 
adipogenesis this activation of MAPK has been shown to phosphorylate 
PPARγ leading to the inhibition of its activity and as a result the inhibition of 
the terminal differentiation (Reginato et al., 1998). 
 
Finally, AA eicosanoids derived from the LOX pathway have been shown to 
affect adipogenesis as inhibition of the LOX pathway, prevents adipocyte 
differentiation of 3T3-L1 cells (Madsen et al., 2003). Leukotriene B4 (LTB4), 
8(S) hydroxyeicosatetraenoic acid [8(S)- HETE] have been shown to bind 
PPARα, indicating a possible role in FA metabolism (Kliewer et al., 1997; Krey 
et al., 1997),  
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Figure 1.8: Opposing actions of AA metabolites on adipocyte differentiation. 
PGI2 and PGJ2 activate PPARγ and promote adipocyte differentiation. PGF2α and 
PGE2 inhibit adipocyte differentiation with the former by inhibiting PPARγ action and 
the latter by a yet unknown mechanism. PGI2: Prostacyclin, PGJ2: prostaglandin J2 
PGF2α: prostaglandin F2α, PGE2: prostaglandin E2, PPARγ: peroxisome proliferator-
activated receptor γ. 
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1.7 Hypothesis and Aims 
 
AT has been recognised to play a central role in energy balance regulation. 
Besides the genotype, environmental factors such as the diet have been 
implicated in the development of obesity which is considered to be the 
modern global epidemic. Obesity is a major risk factor for diet-related 
diseases, and its health consequences range from increased risk of 
premature death to chronic conditions such as type 2 diabetes and 
cardiovascular diseases. 
 
AA is a major n-6 PUFA which is abundant in the western diet. AA itself has 
been found to be a direct ligand of nuclear receptors but also its metabolites 
are significant signalling molecules regulating gene expression. However, the 
role of AA in adipocity and consequently adipocyte differentiation has been 
ambiguous. Therefore, it was hypothesised that AA can regulate the 
differentiation potential of pre-adipocytes.  
 
To address this hypothesis the specific aims of this Thesis are:  
 
 To identify the signalling pathways and molecular mechanisms 
leading to the regulation of AA responsive genes at the early stages 
of adipocyte differentiation  
 To investigate whether the changes triggered by AA at the early 
stages of differentiation can affect the differentiation potential of 
pre-adipocytes 
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2.1 Materials 
 
2.1.1 Antibodies  
 
2.1.1.1 Primary antibodies 
 
α‐tubulin (Sigma T5168) 
aP2 (Cell Signalling 3544) 
ATG7 (Cell Signalling 2631) 
BiP (Cell Signalling C50B12)  
C/EBPβ (Santa Cruz sc-150) 
C/EBPδ (Santa Cruz sc-636) 
C-Jun (Cell Signalling 9165) 
COX-2 (Santa Cruz sc-1745) 
ERK (Cell signalling 9102) 
Fra-1 (Santa Cruz sc-605) 
GAPDH (Millipore MAB374)  
IgG (Santa Cruz sc-2027) 
IRE1α (Cell Signalling 14C10)  
JNK (Cell Signalling 9252) 
JunB (Santa Cruz sc-46) 
JunD (Santa Cruz sc-271938) 
LC3 (Novus Biologicals NB100-2220) 
mTOR (Cell Signalling 7C10) 
PERK (Cell Signalling D11A8) 
phosho-c-Jun (Cell Signalling 9164) 
phospho-ERK (Cell Signalling 9101) 
phospho-JNK (Cell signalling 4671) 
phospho-mTOR Ser2448 (Cell signalling D9C2) 
phospho-p38 (Cell Signalling 9215) 
phospho- PPARγ S112 (Millipore MAB3632) 
PPARγ (Santa Cruz sc-7196) 
p38 (Cell Signalling 9212) 
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SREBP1 (Novus Biologicals NB100-2215) 
 
2.1.1.2 Secondary antibodies 
 
HRP conjugated Goat Anti-rabbit IgG (Invitrogen 656120) 
HRP conjugated Rabbit Anti-goat IgG (Dako P0449) 
HRP conjugated Rabbit Anti-mouse IgG (Invitrogen 626520) 
 
2.1.2 Plasmids 
 
pcDNA3.1 (+) (Invitrogen)  
pGL3 basic (Promega) 
pGL3 basic- ap2 promoter and enhancer (generated during PhD) 
pGL3 basic-fra-1-peak2 (generated during PhD) 
pGL3-tk-fra-1-peak1 (generated during PhD) 
pcDNA3.1 (+) c-jun (generated during PhD) 
pcDNA3.1 (+) Fra-1 (generated during PhD) 
pcDNA3.1 (+) JunB (generated during PhD) 
pcDNA3.1 (+) JunD (a kind gift from Agarwal SK) 
pcDNA-GAL4DBD- PPARγLBD 
pcDNA-PPARγ (a kind gift from Spiegelman B.) 
pcDNA- PPARγ–S112A (a kind gift from Spiegelman B.) 
pCMV-D8.91 (a kind gift from Chandrashekran A.) 
PGK (pCCL.sin.PPT.hPGK.GFPWpre) (a kind gift from Cuervo A.) 
pMDG2-vsvg (a kind gift from Chandrashekran A.) 
pMSCV - FLAG-HA- PPARγ (a kind gift from Spiegelman B.) 
pMSCV - FLAG-HA- PPARγ Q286P (a kind gift from Spiegelman B.) 
pMSCV - FLAG-HA- PPARγ E499Q (a kind gift from Spiegelman B.) 
pCMV- Renilla (generated in the lab) 
PSG5- PPARγ (generated in the lab) 
siATG7 (shATG7- pCCL.sin.PPT.hPGK.GFPWpre) (a kind gift from Cuervo 
A.)  
UASx4-TK-luc reporter (generated in the lab) 
3xPPRE-tk-Luc reporter (generated in the lab) 
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2.1.3 siRNA 
 
ON-TARGETplus SMARTpool, Mouse FOSL1 (Dharmacon L-040704-00-
0005) 
ON-TARGETplus SMARTpool, Mouse PTGFR (Dharmacon L-060399-00-
0005) 
ON-TARGETplus SMARTpool, Mouse PTGER4 (Dharmacon L-048700-00-
0005) 
Negative control siRNA (Qiagen) 
 
2.1.4 Chemicals and Reagents 
 
15-deoxy-Δ12,14 PGJ2 (Sigma) 
10mM dNTPs (Invitrogen) 
3-Methyadenine (3-MA) (Sigma) 
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Sigma) 
10x MMLV buffer (Sigma) 
17-ODYA (Cayman Chemical) 
100x ROX reference dye (Sigma) 
5X Reporter lysis buffer (Promega) 
AA (Cayman Chemical) 
AdipoRed (Cambrex)  
Agarose, molecular biology grade (Sigma) 
AL 8810 (Cayman Chemical) 
Ammonium persulphate (APS) (Sigma) 
Ampicillin (Sigma) 
Baicalein (Cayman Chemical) 
BAPTA-AM (Tocris Bioscience) 
Beta-mercaptoethanol (Sigma) 
Bovine serum albumin (BSA) and BSA free-fatty acid (Sigma)  
Bromophenol blue (Sigma) 
Carbaprostacyclin (Cayman Chemicals) 
CAY-10441 (Cayman Chemical) 
Chloroform (Sigma)  
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Coelenterazine (LUX) 
Complete EDTA-free protease inhibitors tablets (Roche) 
COX-1 inhibitor (SC-560) (Sigma) 
COX-2 inhibitor (SC-236)(Sigma) 
Dexamethasone (Sigma) 
DHA (Sigma) 
Dharmafect 3 (Dharmacon) 
Diethylpyrocarbonate (DEPC) - treated water (Sigma) 
Dimethyl sulfoxide (DMSO) (Sigma) 
Dithiothreitol (DTT) (Sigma) 
DNase I, amplification grade (Invitrogen) 
Dynabeads Protein G for Immunoprecipitation (Invitrogen) 
EPA (Sigma) 
Ethanol (BDH) 
Ethylenediaminetetraacetic acid (EDTA) 
Formaldehyde 16% (w/v) (Thermo Scientific) 
Forskolin (Enzo Life Sciences) 
Glycine (Sigma) 
H89 (Tocris Bioscience) 
IBMX (Sigma) 
Imidazole (Sigma) 
Indomethacin (Sigma) 
Insulin (Sigma) 
Jumpstart SYBR Green I Mix (Sigma) 
L-161,982 (Cayman Chemical) 
LA (Sigma) 
Lipofectamine 2000 (Invitrogen) 
Luciferase Assay Reagent (Promega) 
Methanol (Sigma) 
MMLV Reverse Transcriptase (Sigma) 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
(Invitrogen) 
Non-fat milk powder (Sigma) 
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Nonidet P-40 (NP-40) (BDH) 
Paraformaldehyde (PFA) (Sigma) 
PBA (Sigma) 
PD 98059 (Enzo Life Sciences) 
PGE2 (Sigma) 
PGF2α (Sigma) 
Phenylmethylsulfonyl fluoride (PMSF) (Sigma) 
Phosphatase inhibitors cocktail 2 and 3 (Sigma) 
PKC inhibitor (GF109203X) (Enzo Life Sciences) 
Polybrene (Sigma) 
Potassium Chloride (Sigma) 
PPARα antagonist (GW-7647) (Sigma) 
PPARγ antagonist (GW-9662) (Sigma) 
PPARδ agonist (GW-501516) (Sigma) 
PPARδ antagonist (GSK-0660) (Sigma) 
Propan-2-ol (BDH) 
propidium iodide (PI) (Sigma) 
Proteinase K (Sigma) 
Protogel 30% acrylamide ( 37.5:1 acrylamide to bisacrylamide) (National 
Diagnostics) 
Puromycin (Sigma) 
Random hexamers (Invitrogen) 
Rapamycin (Cayman Chemical) 
Restriction endnucleases and buffers (New England Biolabs) 
RNAse A (Sigma) 
RNAse OUT Ribonuclease inhibitor (Invitrogen) 
Rosiglitazone (Enzo Life Sciences) 
SC-51089 (Tocris Bioscience) 
Sodium azide (Sigma) 
Sodium chloride (Sigma) 
Sodium deoxycholate (BDH) 
Sodium dodecyl sulphate (SDS) (BDH)   
SYBR safe DNA gel stain (Invitrogen) 
Tetramethylethylenediamine (TEMED) (Sigma) 
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TRI reagent (Sigma) 
tris(hydroxymethyl)aminomethane (Tris) (Sigma) 
Triton X-100 (Sigma) 
Tween-20 (Sigma) 
U0126 (Enzo Life Sciences) 
WY-14643 (Sigma) 
α-tocopherol (Sigma) 
 
2.1.5 Kits 
 
Amplification grade DNase I kit (Sigma) 
BCA kit (Thermo Scientific) 
cAMP EIA kit (Enzo Life Sciences) 
Fluo-4 Direct™ Calcium Assay Kit (Invitrogen) 
GenElute DNA Gel extraction kit (Sigma) 
HiSpeed Maxiprep kit (Qiagen) 
KOD DNA polymerase (Novagen) 
PCR array (SaBiosciences) 
PGF2α EIA kit (Enzo Life Sciences) 
Profection Mammalian cell Transfection kit (Promega) 
QIAprep Spin Miniprep kit (Qiagen) 
QIAquick PCR Purification Kit. (Qiagen) 
T4 DNA ligase (Invitrogen) 
 
2.1.6 Cell culture Materials 
 
Dulbeco‘s Modified Eagle Medium containing L-glutamine (DMEM) 
(Invitrogen) 
Heat Inactivated Fetal Bovine Serum (FBS) (Invitrogen) 
Heat Inactivated Newborn Calf Serum (NCS) (Invitrogen) 
100x Penicillin (100 U/mL)/ Streptomycin (50 μg/ml) (Invitrogen) 
Tissue Culture Plasticware and cell culture plates/dishes (Corning) 
0.05% Trypsin-EDTA (Invitrogen) 
Optimem reduced serum medium (Invitrogen) 
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2.1.7 Cell lines 
 
3T3-L1 Mouse embryo fibroblast cell line  
aP2-/- 3T3-L1 cells (a kind gift from Bernlohr D.) 
PPARγ-/- 3T3-L1 cells (a kind gift from Virtue S.)  
NIH-3T3 mouse cells 
HEK293 human embryonic kidney cells 
293FT packaging cells (Invitrogen) 
 
2.1.8 Buffers and solutions 
 
2.1.8.1 ChIP buffers 
 
Elution Buffer 
1% SDS 
100 mM NaHCO3 
 
High Salt Buffer 
20 mM Tris-HCl pH 8.1 
500 mM NaCl 
2 mM EDTA 
0.1% SDS 
1% Triton-X100 
 
IP Buffer 
16.7 mM Tris-HCl pH 8.1 
16.7 mM NaCl 
1.2 mM EDTA 
0.01% SDS 
1.1% Triton-X100 
 
Lithium Chloride Buffer 
10 mM Tris-HCl pH 8.1 
250mM LiCl 
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1 mM EDTA 
1% Nonidet p40 
1% Deoxycholate 
 
Low Salt Buffer 
20 mM Tris-HCl pH 8.1 
150 mM NaCl 
2 mM EDTA 
0.1% SDS 
1% Triton-X100 
 
SDS Lysis Buffer 
0.5 M Tris-HCl pH 8.1 
10 mM EDTA 
1% SDS 
1% Triton-X100 
0.5% Deoxycholate 
 
Swelling Buffer 
25 mM HEPES pH 7.9 
1.5 mM MgCl2 
10 mM KCl 
0.1% Nonidet 
 
Tris-EDTA (TE) buffer  
10 mM Tris, pH 8.0 
1 mM EDTA, pH 8.0 
 
2.1.8.2 New England Biolabs Restriction Endonuclease Buffers (10x) 
 
NEBuffer 1  
10mM Tris Propane-HCl pH 7.0, 10mM MgCl2, 1mM DTT 
 
NEBuffer 2  
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10mM Tris-HCl pH 7.9, 10mM MgCl2, 50mM NaCl, 1mM DTT 
 
NEBuffer 3  
50mM Tris-HCl pH 7.9, 10mM MgCl2, 100mM NaCl, 1mM DTT 
 
NEBuffer 4 
20mM Tris-Acetate pH 7.9, 10mM MgCl2, 50mM potassium acetate, 1mM 
DTT 
 
2.1.8.3 Qiagen Buffers 
 
Plasmid prep suspension buffer P1  
50 mM Tris-HCl, pH 8.0 
10 mM EDTA 
100 mg/ml RNase A 
 
Plasmid prep lysis buffer P2  
200 mM NaOH 
1 % w/v SDS 
 
Plasmid prep neutralization buffer P3  
3 M KAc pH 5.5 
 
Plasmid prep equilibration buffer QBT  
750 mM NaCl 
50 mM MOPS, pH 7.0 
15 % v/v isopropanol 
 
Plasmid prep wash buffer QC  
1 M NaCl 
50 mM MOPS, pH 7.0 
15 % v/v isopropanol 
 
Plasmid prep elution buffer QF  
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1.25 M NaCl 
50 mM Tris-HCl, pH 8.5 
15 % v/v isopropanol 
 
Plasmid prep elution buffer EB  
10 mM Tris-HCl, pH 8.5 
 
Tris-EDTA (TE) buffer  
10 mM Tris, pH 8.0 
1 mM EDTA, pH 8.0 
 
2.1.8.4 Western Blotting Buffers 
 
Blocking Solution  
5% (w/v) non-fat milk powder in TBS-T or 5% (w/v) BSA in TBS-T 
 
NuPAGE® Tris-Acetate SDS Running Buffer 
Tris base 50 mM pH 8.24 
Tricine 50 mM 
SDS 0.1% 
 
SDS Running buffer 
25mM Tris 
190mM glycine 
0.1% (w/v) SDS 
 
Transfer Buffer  
48 mM Tris-base 
39 mM Glycine 
0.037% (w/v) SDS 
20 % (v/v) methanol 
 
Tris Buffered Saline (TBS) 
130mM NaCl,  
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20mM Tris, pH 7.6 
 
Tris Buffered Saline- Tween 20 (TBS-T) 
130mM NaCl,  
20mM Tris, pH 7.6, 
0.1% Tween 
 
2.1.8.5 Miscellaneous Buffers 
 
10x DNA loading buffer 
0.2% (w/v) Bromophenol blue 
40% (v/v) Glycerol 
100mM EDTA pH 8.0 
 
10x DNAase I Reaction Buffer (Sigma) 
200 mM Tris-HCl, pH 8.3 
20 mM MgCl2 
 
10x M-MLV Reverse Transcriptase Buffer (Sigma) 
500 mM Tris-HCl, pH 8.3 
500 mM KCl,   
30 mM MgCl2 
 50 mM DTT 
 
2x Laemmli loading buffer 
50 mM Tris-HCl, pH 6.8 
50 mM Imidazole, pH 6.8 
1% (w/v) SDS 
10% (v/v) Glycerol 
2% (v/v) 2-Mercaptoethanol 
0.002% (w/v) Bromophenol blue 
 
5x T4 Ligase Buffer (Invitrogen) 
250mM Tris HCl Ph7.6 
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50mM MgCl2 
5mM ATP 
5mM DTT 
25% (w/v) polyethylene glycol-8000 
 
Antibody Dilution buffers 
5% non-fat milk in TBS-T with 0.1% (v/v) NaN3 
5% BSA in TBS-T with 0.1% (v/v) NaN3 
 
DNase Stop solution 
50 mM EDTA 
 
Oil Red O Stock solution  
0.7g Oil Red O  
200ml isopropanol  
 
Oil Red O Working solution 
6 Parts of Oil Red O Stock and 4 of dH20 
 
Phosphate Buffered Saline (PBS)  
140mM NaCl 
2.5mM KCl 
1.5mM KH2PO4 pH7.2  
10mM Na2HPO4 pH7.2 
 
Protein lysis buffer 
1% Triton-X 
Tris pH 7.0 
150mM NaCl 
1mM PMSF 
1x protease inhibitor cocktail 
1x phosphatase inhibitor cocktail 2 and 3 
 
Renilla Buffer  
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0.5M HEPES pH 7.8 
40mM EDTA 
 
Stripping Buffer (Protein)  
100mM beta- Mercaptoethanol 
 2% (w/v) SDS, 
62.5mM Tris-HCl pH 6.7 
 
Tris Borate EDTA (TBE) 
90mM Tris Borate 
2mM EDTA pH 8.0 
 
2.1.9 Bacterial strains and Media 
 
L-agar 
1% (w/v) Bactotryptone, 
0.5% (w/v) Yeast Extract, 
0.5% (w/v) NaCl, 
0.1% (w/v) Glucose, 
1.5% Bactoagar 
 
LB-broth 
1% (w/v) Bactotryptone, 
0.5% (w/v) Yeast Extract, 
0.5% (w/v) NaCl, 
0.1% (w/v) Glucose 
 
S.O.C Medium (Invitrogen) 
2% Bactotryptone 
0.5% Yeast Extract 
10 mM NaCl 
2.5 mM KCl  
10 mM MgCl2 
10 mM MgSO4 
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20 mM glucose 
 
DH5α chemically competent and electrocompetent  
 
F–Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, 
mK+) phoA supE44 λ– thi-1 gyrA96 relA1 
 
2.1.10 SDS gels  
 
Resolving gels 
375 mM Tris-HCl, pH 8.9 
0.1 % w/v SDS 
10 %, 12% or 14% v/v acrylamide/bis-acrylamide (37.5:1) 
0.03 % w/v APS 
0.06% v/v TEMED  
 
Stacking gels 
80 mM Tris-HCl, pH 6.8 
80 mM Imidazole pH 6.8 
0.1 % w/v SDS 
4.1 % v/v acrylamide/bis-acrylamide (37.5:1) 
0.09 % v/v APS 
0.09 % v/v TEMED  
 
2.1.11 Miscellaneous 
 
Amicon 10,000 NMWL centrifugal filter units (Millipore) 
ECL Plus Western Blotting Detection System (Thermo Scientific) 
Electroporation Cuvettes (Cell projects) 
Hyperladder I and IV DNA ladders (Bioline) 
Immobilon Polyvinylidene difluoride (PVDF) membrane (Millipore) 
Oil Red O (Sigma) 
Oligonucleotides (Invitrogen) 
Optically clear adhesive seal sheets (Appleton Woods) 
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PageRuler pre-stained protein ladder (Fermentas) 
RNase ZAP (Ambion) 
Super RX autoradiography film (Fujifilm) 
384-well plates for qRT-PCR (Applied Biosystems) 
NuPAGE® Novex 7% Tris-Acetate Gel 1.5 mm, 10 Well 
 
2.2 Methods 
 
2.2.1 Cell culture  
 
Wild type, PPARγ-/- and aP2-/- 3T3-L1 pre-adipocytes were maintained in 
subconfluent cultures in DMEM, containing 10% NCS, 100 U/ml penicillin, and 
100 μg/ml streptomycin. For PPARγ-/- and aP2-/- 3T3-L1 cells 2μg/ml 
puromycin was also added to maintain the selection. NIH-3T3, HEK293 and 
293FT cells were maintained in DMEM, containing 10% FBS, 100 U/ml 
penicillin and 100 μg/ml streptomycin. All cells were grown on 175cm2 tissue 
culture flasks at 37oC in a humid atmosphere maintained at 5% (v/v) CO2. Cell 
cultures were divided twice or three times a week depending on growth rate. 
The medium was removed and the cells were washed once with 10ml PBS 
before 2 ml of pre-warmed Trypsin/EDTA was applied. The cells were 
incubated at 37oC for 1 minute. The flask was gently tapped and 10ml pre-
warmed DMEM was added (10% (v/v) FBS/NCS) to neutralise the trypsin. 
The cell suspension was transferred to a sterile 50ml tube and centrifuged at 
1000rpm for 5 minutes. The pellet was gently re-suspended in prewarmed 
medium and cultured at a suitable dilution. 
 
Cells were also prepared for storage in liquid nitrogen. Cells were trypsinized 
and pelleted as described above. The pellets were resuspended in media 
containing 10%v/v DMSO. 1 ml aliquots of cells were placed in cryogenic vials 
and then placed in Mr. Frosty, which is an isopropanol-filled freezing 
container, to ensure a constant cooling rate of 1 °C/min at -80 °C. The next 
day the vials were transferred into liquid nitrogen for long term storage. Cells 
recovered from liquid nitrogen were thawed in a 37 °C water bath and added 
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to 15 ml of prewarmed 10% (v/v) FBS/NCS DMEM in a 75cm2 flask. The 
medium was changed the next day. 
 
For the differentiation, cells were cultured until confluence and two days post-
confluence (Day 0), the cells were stimulated to differentiate in DMEM 
supplemented with 10% FBS in the presence of 170nM insulin, 0.5 mM IBMX, 
and 250nM DEX for 2 days (D2). Cells were then treated with DMEM, 10% 
FBS and 170nM insulin until the end of the differentiation program. The 
medium was replaced every 2 days with fresh medium.  
 
2.2.2 Preparation of Albumin-bound Fatty Acid  
 
10 mM stock solution of AA was prepared by diluting the free fatty acid in 
ethanol and precipitating it with the addition of NaOH (final concentration of 
0.25 M). The precipitated sodium salt was then evaporated under nitrogen 
gas, reconstituted with 0.9% (w/v) NaCl, and stirred at room temperature for 
10 min with defatted BSA in 0.15 M NaCl. The solution was stored in multiple 
aliquots at -20 °C protected from light in tubes evacuated under nitrogen gas. 
Control solution containing NaOH and fatty acid-free BSA was similarly 
prepared. The FFA/BSA molar ratio was 4:1 (Ou et. al., 2001). All AA 
treatments (and BSA control) contained 0.22mM α-tocopherol to prevent lipid 
peroxidation (Kim et. al., 2006). The same procedure was followed for EPA, 
DHA and LA conjugation. 
 
2.2.3 Oil Red O staining 
 
Differentiated and undifferentiated 3T3-L1 cells were stained with Oil Red O. 
The culture medium was removed and the cells were washed with PBS. Cells 
were then fixed with 4% paraformaldehyde in PBS for 15 min at room 
temperature. The fixative was discarded and the cells were washed with PBS. 
Oil Red O working solution (made up with isopropanol) was applied for 1h at 
room temperature. The cells were then rinsed with 60% isopropanol and PBS. 
Stained lipid droplets were visualized under light microscope. For Oil Red O 
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quantification, the dye was extracted in 100% isopropanol, transferred to a 
white 96-well plate and the absorbance was measured at 510nm. 
 
2.2.4 RNA extraction 
 
Total RNA was isolated from cells using TRI Reagent. Samples were 
processed according to the manufacturer‘s protocol. TRI Reagent is a mono-
phasic solution of phenol and guanidine thiocyanate that maintains the 
integrity of RNA during cell lysis, whilst at the same time disrupting cells and 
dissolving cellular components. To avoid ribonuclease (RNAase) 
contamination RNAase-free tips, eppendorfs and DEPC-treated water were 
used. Moreover, disposable gloves were worn at all times and the surfaces 
and pipettes were cleaned with RNAase Away. 
 
1ml TRI Reagent was added per well o af 6-well plate to lyse the cells and the 
lysate was transferred to a 1.5ml microcentrifuge tube. When cells were 
cultured in smaller formats the volume of TRI Reagent was adjusted 
accordingly. Samples were incubated at room temperature for 5 minutes to 
allow dissociation of protein complexes with nucleic acid. 0.2ml chloroform 
(kept at -20oC) per ml of TRI Reagent was added to each sample, which were 
then shaked vigorously by hand for 15 seconds before incubating for 2-15 
minutes at room temperature. Samples were then centrifuged at 13,000rpm 
for 15min at 4oC. Following centrifugation, the mixture separated into a lower 
organic red, phenol-chloroform phase, an interphase, and a colorless upper 
aqueous phase. RNA remained exclusively in the aqueous phase while DNA 
and proteins remained in the interphase and in the organic phase 
respectively. Thus, the total RNA isolated by TRI Reagent is free of protein 
and DNA contamination. The aqueous phase was then transferred to new 
1.5ml tubes and total RNA was precipitated by the addition of 0.5 ml of 
isopropyl alcohol (stored at -20ºC), and mix. The samples were left at room 
temperature for 10 minutes, and then centrifuged 13,000 rpm for 15 minutes 
at 4ºC. The supernatant solution was discarded and the precipitated RNA 
pellets were washed with at least 1 ml of 75% ethanol (stored at -20%) and 
centrifuged at 13,000 rpm for 5 minutes at 4ºC. Purified RNA was briefly air-
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dried and re-dissolved in RNase-free water. The RNA concentration and purity 
were determined by Nanodrop ND1000 spectophotometer and samples were 
stored at -80ºC. 
 
2.2.5 cDNA synthesis 
 
Synthesis of cDNA was performed by using Moloney Murine Leukemia Virus 
Reverse Transcriptase (M-MLV RT) following the manufacturer‘s instructions. 
Before the cDNA synthesis RNA was treated with DNase I to remove any 
genomic DNA which would be amplified along with the target mRNA. Briefly, 1 
μg of total RNA was digested using 0.5U DNase I for 15 minutes at room 
temperature. The reaction was then inactivated by adding 0.5μl of 25mM 
EDTA pH 8.0 and the samples were then incubated at 65oC for 10 minutes. 
50ng of random primers and 1μl of 10mM dNTP mix were added to the 
samples and the volume was adjusted to 12μl with DEPC-treated water. The 
samples were incubated at 65oC for 5 minutes and then placed on ice for 2 
minutes. 4μl of 5x first strand RT buffer, 2μl of 0.1M DTT and 40U of 
RNaseOUT™ Recombinant Ribonuclease Inhibitor were added to the 
samples which were then incubated for 2 minutes at 37oC. 1 μl (200 units) of 
M-MLV RT was added to each sample and incubated for 10 min at room 
temperature followed by incubation for 50 min at 37°C. Finally, the reaction 
was inactivated by heating at 70°C for 15 min. The synthesized cDNA was 
then used for quantitative real-time PCR (qRT-PCR) or stored at -20oC. 
 
2.2.6 Quantitive Real-Time PCR 
 
QRT-PCR was carried out using 7900HT Fast Real-Time PCR System 
(Applied Biosystems). SYBR® Green JumpStart™ Taq ReadyMix™ for 
Quantitative PCR was used as a fluorescent dye which has undetectable 
fluorescence in its free form but emits fluorescence once incorporated into 
double stranded DNA. Therefore as the PCR progresses and more double 
stranded DNA product accumulates, the more fluorescent signal is produced. 
The fluorescent signal is detected in each sample following each cycle of the 
PCR reaction. The data is analysed by the setting of threshold within the 
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linear phase of the reaction, termed Ct value, and determining the number of 
cycles required for the fluorescent signal to reach the threshold. The Ct value 
is seen to decrease with increasing target cDNA.  
 
The reactions were prepared in 384-well plate format. Each reaction 
contained 4μl of 2x SYBR Green master mix, the appropriate ratio of primers, 
0.3 μl of cDNA made up to a total volume of 8μl with DEPC-treated water. 
Negative controls of reaction mix without cDNA template were included. All 
reactions were carried out in duplicate with the following thermocycler 
conditions: 94oC for 2 minutes, 94oC for 15 seconds, 60oC for 1 minute and 
72°C for 1 minute for a total of 40 cycles. Data were analysed with the SDS 
2.3 software (Applied Biosystems). 
 
The method used for quantification was the comparative Ct method which 
calculates the relative expression of a gene compared to that of a 
housekeeping gene (L19) and of a calibrator sample. Briefly, the mean Ct 
value was calculated from the duplicates of the qRT-PCR reactions. Then the 
ΔCt value was calculated by subtracting the mean Ct for L19 from the mean 
Ct of the target gene [∆Ct = Ct (target gene) – Ct (L-19)]. Then a cDNA 
sample was selected to act as a calibrator sample in order to relate all other 
samples to. The ΔΔCt value was calculated by subtracting the ΔCt of the 
calibrator sample from the ΔCt values of all the other samples [∆∆Ct = ∆Ct 
(sample) - ∆Ct (calibrator)]. ΔΔCt values were then converted to fold 
differences using the function 2-ΔΔCt.  
 
Primers were designed to give a product of approximately 100bps crossing 
intron exon boundies to eliminate the amplification of genomic DNA. 
Sequences were obtained from Ensembl mouse genome database and 
applied to the software Primer Design or Primer 3. Primers were dissolved in 
DEPC-treated water to a final concentration of 100pmol/μl, this is then diluted 
again to a working concentration of 20pmol/μl. The primers used for qRT-PCR 
are listed in the Appendix. 
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2.2.7 PCR array 
 
Two days post-confluent 3T3-L1 cells were treated with AA 1mM for 24h and 
the total RNA was isolated with TRI Reagent as described above. Then 1μg 
RNA was DNase treated on column using the Qiagen RNeasy Mini kit. cDNA 
synthesis was conducted according to the manufacturer‘s guidelines using the 
RT2 First Strand kit. cDNA was loaded into the a 96-well containing the 96-
primer set panel together with the qPCR master mix provided. QRT- PCR was 
conducted using the Step-One ABI PCR cycler using a two-step cycling 
program: 95oC for 10min and 40 cycles of 95oC for 15sec and 1 min of 60oC.  
 
2.2.8 Sodium Dodecyl Sulfate polyacrylamide gel electrophoresis (SDS-
PAGE)  
 
The BioRad MiniProtean system was used to cast gels. Resolving gels were 
poured by combining the components mentioned above. The gel solution was 
added between the glass plates and overlaying with ethanol and allowed to 
set for at least 20min. Stacking gel was then poured over the set resolving gel 
and a comb was inserted and allowed to set for 20min. 
 
Whole protein extracts were extracted by lysing the cells with protein lysis 
buffer containing 1x protease inhibitor cocktail, 1mM PMSF and 1x 
phosphatase inhibitors. Cells were scraped with a cell scraper on ice and 
transferred to 1.5 ml microcentrifuge tubes. Lysates were rotated for 10min at 
4oC and centrifuged at 13,000rpm for 5min at 4oC. Supernatants were 
transferred to new eppendorf tubes and either snap frozen for storage at -
80oC or the protein concentration was measured. Quantification of total 
protein was performed using the BCATM Protein Assay Kit. The concentrations 
of the unknown protein samples were determined based on a standard curve 
generated from a series of dilutions of known concentrations of Bovine Serum 
Albumin (BSA; 2mg/ml). 
 
Protein extracts were mixed 1:1 with 2x Laemmli buffer and heated for 5 min 
at 95oC. At the same time the gels were assembled onto the electrophoresis 
Chapter 2  Materials & Methods 
 73 
equipment in a tank with SDS running buffer. Samples were briefly centrifuged 
and loaded into the gel wells using gel loading pipette tips together with 5 l of 
the rainbow ladder. Gels were run at 70V for around 10min and at 100-120V 
until the marker was sufficiently separated. 
 
For PPARγ protein analysis 70μg of lysate was loaded in a 7% Tris-Acetate 
Novex pre-cast gel. The gel was run in 1x NuPAGE® Tris-Acetate SDS 
running buffer at 150V until the dye front had migrated to the bottom of the gel 
 
2.2.9 Western Blotting  
 
Following SDS-PAGE, protein samples were transferred to a PVDF 
membrane using the wet blotting method. Gels were removed from the glass 
plates and PVDF membrane was activated by soaking in methanol for 10sec. 
A ‗sandwich‘ was assembled which consisted of a pad, one Whatman filter 
paper, the gel, the activated PVDF membrane, another piece of Whatman 
filter paper and another pad. The paper, pad and PVDF had all been pre-
equilibrated in western transfer buffer, and the ‗sandwich‘ is put together 
carefully under the buffer to make sure no air bubbles were present. The 
‗sandwich‘ was then placed in a blotting cassette and inserted in the blotting 
tank immersed in cold western transfer buffer with the PVDF towards the 
anode and the gel towards the cathode Transfer was performed for 
approximately 2h at 4oC at 100V at 4oC. After the transfer, PVDF membranes 
were removed, allowed to air-dry, re-soaked to methanol and put in blocking 
buffer for 1h at room temperature with gentle shaking. 
 
After blocking, membranes were incubated with primary antibodies in 50mi 
tubes at 4oC with constant rolling. Typically, the anti-fungal agent sodium 
azide was added to allow the storage of diluted antibody at 4oC for 
subsequent experiments. Consequently, membranes were washed in 1x TBS-
T three times for 10 minutes and then incubated for one hour at room 
temperature with the appropriate secondary antibodies horseradish 
peroxidase – conjugated diluted at 1:5,000. The membranes were washed in 
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1x TBS-T three times for 10 minutes. Finally, the signal was detected using 
enhanced chemiluminescence substrates following manufacture‘s instructions 
and the light emission was captured and visualized by exposing the blot to 
film. Densitometry was carried out by analysing Western blot images with 
ImageJ software. Densitomentry was performed only for the western blot 
images of p-ERK and total-ERK, to confirm that the stripping of the membrane 
was efficient, as these two proteins have the same sizes. Densitomentry for all 
other proteins was not performed, as different film exposure times and often 
saturation, make densitomentry an unreliable protein quantification method.  
 
2.2.10 Bacterial propagation of plasmids 
 
2.2.10.1 Transformation of chemically competent DH5α E.Coli by heat 
shock 
 
For the preparation of large plasmid DNA quantities, chemically competent 
DH5α cells were thawed on ice (typically 50μl). In an eppendorf tube bacteria 
were mixed with the relevant plasmid (less than 1ng DNA). After 30 minutes 
on ice, cells were heat shocked in a 42oC water bath for 30 seconds and then 
placed on ice for a further two minutes. Then 200 μl of SOC medium was 
added to the reaction and the cells incubated at 37oC for 1 hour. The cells 
were then spread on L-agar plates containing 100μg/ml ampicillin to select for 
tranformants. The plates were inverted and incubated at 37oC overnight and 
the next day colonies were picked. 
 
2.2.10.2 Transformation of electrocompetent DH5α E.Coli by 
electroporation 
 
Electrocompetent DH5α cells were thawed on ice. 50μl of bacteria was mixed 
with the ligation in a pre-chilled 1mm electroporation cuvette and 
electroporated using a Bio-Rad gene pulser, at 1.67kV, giving a time constant 
of approximately 4 milliseconds. Following electroporation, 200μl SOC 
medium was added and the cells were incubated at 37oC for 1h. The cells 
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were then spread on L-agar plates containing 100μg/ml ampicillin, inverted 
and incubated at 37oC overnight and the next day colonies were picked. 
 
2.2.10.3 Small-scale preparation of plasmid DNA (Miniprep) 
 
Individual bacterial colonies of possible recombinant bacteria were used to 
inoculate 5 ml of LB containing 50μg/ml ampicillin and allowing the bacteria to 
grow in a shaking incubator at 37oC overnight. Bacteria were then pelleted by 
centrifugation for 15 min, at 3900 rpm at 4oC. Plasmid DNA was purified by 
using QIAprep Spin MiniPrep Kit. Cells were resuspended in 250 μl buffer P1 
and lysed under alkaline conditions by the addition of 250 μl buffer P2. The 
lysates were subsequently neutralised and adjusted to high-salt binding 
conditions by the addition of 350 μl of buffer N3. Samples were centrifuged 
and the supernatants were passed through a silica membrane. The 
membrane allowed selective adsorption of plasmid DNA under the high-salt 
conditions, while RNA, cellular proteins, and metabolites flow through. 
Endonucleases were removed by a wash step with buffer PB to ensure 
plasmid DNA was not degraded. The membrane was then desalted by the 
addition of 750 μl of buffer PE. Plasmid DNA was eluted with 50 μl elution 
buffer. Eluted DNA was suitable for diagnostic digestion or sequencing.  
 
2.2.10.4 Large-scale plasmid DNA preparation (Maxiprep) 
 
Higher amounts of correct recombinant plasmids were prepared by using the 
Qiagen HiSpeed Maxi Kit and were suitable for mammalian cell transfection. 
As described above, a single colony was picked and 5 ml of LB broth 
containing 50µg/ml ampicillin was inoculated and grown at 37oC for 
approximately 8 h with continuous shaking. This was then diluted into 200 ml 
of LB broth with 50µg/ml ampicillin, which was incubated overnight at 37oC 
with constant shaking. Bacteria were recovered by centrifugation at 3900 rpm 
for 15 min at 4oC. Supernatants were removed and pellets were processed 
according to the manufacturers protocol. The protocol is based on a modified 
alkaline lysis procedure in which bacterial cells (suspended in buffer P1) were 
lysed in sodium hydroxide/SDS in the presence of RNase A (buffer P2). SDS 
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solubilised the phospholipid and protein components of the cell membrane, 
leading to cell lysis. Sodium hydroxide denatured chromosomal DNA, plasmid 
DNA and proteins, while RNase A digested the liberated RNA. The lysate was 
neutralized by the addition of acidic potassium acetate (buffer P3). The high 
salt condition caused SDS to precipitate with the denatured proteins, 
chromosomal DNA and cellular debris, trapped in salt-detergent complexes. 
The smaller, covalently closed plasmid DNA re-natured and remained in 
solution. The lysates were passed through a pre-equilibrated (buffer QBT) 
anion-exchange resin operating by gravity flow under low salt and low pH 
conditions to trap the plasmid DNA, RNA, protein, dyes and low-molecular 
weight impurities were removed by a medium salt wash (buffer QC). Plasmid 
DNA was eluted in a high salt buffer (buffer QF) and then concentrated and 
desalted by isopropanol precipitation. The purified DNA was washed with 70 
% v/v ethanol, air-dried and redissolved in TE buffer. 
 
2.2.11 Molecular Cloning 
 
2.2.11.1 Restriction digests 
 
Restriction enzyme digests were performed using enzymes from New 
England Biolabs at 37oC in the buffers recommended by the manufacturer 
supplemented with 100x BSA where required. DNA was digested with excess 
of enzyme. For analysis of digestion products, reactions were terminated by 
the addition of 10x DNA loading buffer and analysed by gel electrophoresis. 
For cloning, bands were cut from the gel and purified a DNA gel extraction kit.  
 
2.2.11.2 PCR for cloning 
 
The KOD Hot Start DNA polymerase was used to amplify the fragments 
needed to be cloned. KOD polymerase is a high-fidelity, proofreading and has 
3‘ to 5‘ exonuclease activity, so PCR products are of high fidelity. In 0.2ml 
PCR tubes 1 ng plasmid DNA or 200 ng genomic DNA or 2 µl of a 20-µl 
reverse transcriptase reaction mix was mixed with 5 µl of 10X PCR Buffer for 
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KOD Hot Start DNA Polymerase, 3µl of each forward and reverse primers (at 
final concentration of 0.3µM), 5 µl dNTPs (final concentration 0.2 mM), 2 µl 
MgSO4 (final concentration 1 mM), 1µl KOD Hot Start DNA Polymerase (1 
U/µl) and PCR grade water to a final volume of 50µl. At the same time non-
template control reactions were set up. PCR were run with the following 
conditions: 95oC for 2min, followed by 35 cycles of 95°C for 20 sec, 55°C for 
10 sec and 70°C for 10 sec/15sec/20sec/25sec/kb according to the size of the 
amplified fragment.  
 
2.2.11.3 DNA agarose gel electrophoresis 
 
Molecular biology agarose was dissolved in 1x TBE in a canonical flask to 
give the appropriate percentage gels around 1-2 % (w/v). The suspension was 
heated in a microwave oven until boiling. The solution was allowed to cool, 
0.5μg/ml ethidium bromide was added, and poured into appropriate trays with 
combs. Once set, the gel was submerged in 1x TBE buffer in a gel tank. DNA 
samples were mixed with 10x DNA loading buffer and loaded into the wells 
along with the appropriate DNA ladder. Electrophoresis was carried out at 
100V. DNA was visualised by illumination on a long wave UV light box and 
photographed.  
 
2.2.11.4 Gel extraction of DNA 
 
Restriction fragments were purified from TBE agarose gels using GenElute 
DNA Gel Extraction kit according to manufacturer‘s protocol. DNA bands of 
the desired molecular weight were cut from the gel with a clean scalpel under 
UV light. The gel sliced was weighted and 3 volumes of gel solubilisation 
solution were added. The gel mixture was incubated at 50oC for 10min with 
occasional mixing until the gel slice is completely dissolved. At the same time, 
the binding column was prepared by adding 500μl of column preparation 
solution and centrifuging at 13,000rpm for 1min and discarding the flow-
through. 1 gel volume of 100% isopropanol was added and mixed. The 
solubilized gel solution was loaded to the prepared binding column and 
centrifuged at 13,000rpm for 1min. DNA binds to silica membrane and was 
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washed with 700μl of wash solution. Residual ethanol was removed by 
centrifugation for 1min. DNA was eluted by adding 30-50μl of elution buffer to 
the membrane , allowing to stand for 1min and centrifuging at 13,000rpm for 
1min. 
 
2.2.11.5 Ligations 
 
Ligation of insert and vector was carried out with T4 DNA ligase. Before the 
ligation digested vector and insert were electrophoresed on an agarose gels 
to asses their concentrations. Ligations were performed using a 1:1 -1:6 molar 
ratio of vector to insert DNA. All ligation reactions were performed in a final 
volume of 20μl which contained 1x T4 DNA ligase buffer and 1μl T4 DNA 
ligase. All reactions were incubated overnight at 16oC. 
 
2.2.11.6 DNA sequencing  
 
Plasmid DNA was mixed with 3.2 pmol of sequencing primer to a total volume 
of 10μl. The Core Genomics Facility performed the DNA sequencing and the 
chromatographs were analysed with the 4Peaks software. 
2.2.12 Transient transfections 
 
2.2.12.1 Transfection of HEK293 cells using the calcium phosphate 
method 
 
30,000 cells were seeded in 96-well plates in 100μl 10%FBS DMEM. The 
following day, the transfection mixes were prepared as follows: in a tube the 
required amount of reporter constructs and expression vectors was mixed with 
nuclease-free water and 2M calcium chloride whereas in a separate tube an 
equal volume of 2x HEPES-buffered saline was added. The calcium 
phosphate mix was added dropwise to 2x HEPES-buffered saline while 
vortexing. The mix was incubated at room temperature for 20 min to allow 
formation of calcium phosphate precipitate and then was added to HEK293 
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cells and incubated with the precipitate for 24h. The following day, cells were 
treated and harvested 48h post-transfection. 
 
2.2.12.2 Transfection of 3T3-L1 and NIH-3T3 cells using Lipofectamine 
2000 
 
3T3-L1 or NIH-3T3 cells were transiently transfected in 24 or 12-well plates 
using the Lipofectamine 2000 reagent. 80%90 % confluent monolayers were 
seeded in 10 % FBS/DMEM without antibiotics. The following day, the 
transfection mixes were prepared as follows: in an appropriate size tube DNA 
was diluted in 50μl/100μl Opti-MEM® I reduced serum medium and mixed 
gently, whereas in a separate tube the appropriate volume of lipofectamine 
2000 reagent was diluted in Opti-MEM® I reduced serum medium, mixed and 
incubated at room temperature for 5 min. The diluted DNA and diluted 
lipofectamine were combined, gently mixed and incubated for 20 minutes to 
allow DNA-lipofectamine complexes to form. The transfection mix was then 
added to each well. After 24h the cells were treated and harvested 48h post-
transfection. 
 
2.2.12.3 Dharmafect transfection of siRNA 
 
3T3-L1 cells in 12-well /6-well plates were transfected with 100nM siRNA 
using Dharmafect3. 80%90 % confluent monolayers were seeded in 10 % 
FBS/DMEM. The following day, the transfection mixes were prepared as 
follows: in an appropriate size tube siRNA was diluted in Opti-MEM® I 
reduced serum medium and mixed gently, whereas in a separate tube the 
appropriate volume of Dharmafect3 reagent was diluted in Opti-MEM® I 
reduced serum medium, mixed and incubated at room temperature for 5 min. 
The siRNA mix and the diluted Dharmafect3 were combined, gently mixed 
and incubated for 20 minutes to allow DNA-lipofectamine complexes to form. 
The transfection mix was then added to each well containing cells and 
medium. The cells were treated on the third day after transfection and either 
harvested after 24h or re-transfected and harvested at the end of the 
differentiation program.  
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2.2.13 Generation of Lentiviruses Containing ATG7 shRNA 
 
Lentiviral particles containing PGK vectors were packaged in 293FT cells. The 
cells were seeded in 10cm dishes so as the next day to be 80% confluent in 
10%FBS/DMEM. The following day the cells were transfected with 15µg 
PGK/siATG7 vector, 10µg pCMV-Δ8.91 and 5µg pMDG2-vsvg per plate using 
the calcium phosphate method described above, The following day, the 
transfection mix was exchanged for 7ml per plate. Supernatants were 
harvested at 24 h and 48 h after the first media change and stored at -80°C. 
Supernatants from both time points were thawed, pooled and centrifuged at 
1000rpm for 5 min to pellet any cells. Viral supernatants were next 
concentrated to a final volume of 200µl/plate utilizing Amicon 10,000 NMWL 
centrifugal filter units, and aliquoted for storage at -80°C. Viral titer was 
calculated using serial dilutions of PGK-GFP-expressing plasmid to infect 
3T3-L1 cells in 12-well plates in the presence of 8µg/ml polybrene. GFP was 
analyzed 72 h later by fluorescence activated cell sorting (FACS), and the 
minimum volume of virus required to give 90-100% GFP-positive 3T3-L1 cells 
then used in subsequent experiments.  
 
For experiments, 50,000 3T3-L1 cells were seeded in 12-well plates. After 4-
5h of seeding, the cells were infected in the presence of polybrene (8µg/ml)., 
Cells were treated on the third day after infection.  
 
2.2.14 Reporter Gene assays 
 
Transfected cells in 96-well plates or 24-well plates were washed with PBS 
and lysed in 25 μl or 50 μl 1x Reporter lysis buffer, respectively. The plates 
were then placed on a shaker for 5min and then placed at -80oC for storage or 
for a freeze-thaw step which is required for the appropriate lysis of the cells. 
Plates were then thawed and 10 μl of each lysate was transferred to a white 
96-well plate. 50 μl of the luciferase assay reagent was then added to each 
well and immediately the luciferase activity was measured by reading 
luminescence on Victor2 plate reader (Perkin Elmer). The remaining lysates 
were used to measure Renilla luciferase activity to normalise firefly luciferase 
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activity measurements. Thus, 10 μl of each lysate was transferred to a white 
96-well plate together with 50 μl of Colenterazine in Renila buffer. Plates were 
incubated in dark at room temperature for 20 minutes and then read as 
described above. Each firefly luciferase activity was divided by renilla activity 
to correct for variations in the transfection efficiency.  
 
2. 2.15 Chromatin Immunoprecipitation  
 
3T3-L1 cells were grown in 175cm2 culture dishes, fixed with 1% 
formaldehyde and incubated for 10 minutes at 37°C. The fixation was stopped 
with 125 mM glycine. Then, 1 ml of swelling buffer was added per dish and 
the cells were scraped and homogenized with a dounce homogenizer in order 
to isolate the nuclei. The lysates were then rotated at 4°C for 10 minutes. The 
samples were centrifuged for 3 minutes at 13,000rpm at 4°C and the nuclei, 
collected in a pellet. The pellets were resuspended in 500 μl SDS lysis buffer 
and sonicated for 5 minutes (with 30 second cycles) at 4°C on high power on 
the Diagenode Bioruptor sonicator. The resulting suspension was centrifuged 
for 20 minutes at 13,000rpm at 4°C and the supernatant contained the 
sonicated chromatin. The suspension containing the chromatin was diluted 
ten times in IP buffer and then precleared at 4°C for 3 hours with 50 μl of 
Protein G Dynabeads. At the same time, 5 μg of antibody was mixed with 50 
μl of Protein G Dynabeads in IP buffer and incubated at 4°C for 3 hrs. 10% of 
the precleared chromatin was transferred into a clean microfuge tube and 
frozen at -80°C, which will then be used as the input. The remaining 
chromatin was then mixed overnight at 4°C with the antibody bound to the 
Dynabeads. The beads antibody-chromatin complex was then washed with 
the following buffers: Low Salt Buffer, High Salt Buffer, Lithium Chloride 
Buffer, TE buffer before eluting the chromatin with 250 μl Elution buffer and 
incubated at room temperature for 15 minutes.  To reverse crosslink the 
proteins and the DNA 200 mM NaCl were added to the samples and to the 
input. The samples and the input were incubated overnight at 65°C and10 mM 
EDTA, 40 mM Tris-HCl pH 8 and 40 μg/ml Protease K were added and 
incubated for a further hour at 55°C. DNA was then purified using QIAquick 
PCR Purification Kit. The purified DNA was amplified by RT-qPCR and the 
data normalized to the input. 
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2.2.16 Calcium mobilisation assay 
 
3T3-L1 cells were seeded into 35mm tissue culture treated dishes maintained 
in medium containing 10% NCS/DMEM in an incubator (5% CO2 at 37°C). 
Cells were assayed when become two days post-confluent for the calcium 
mobilization assay. On the day of the assay the dye was prepared according 
to the manufacturer‘s instructions. 2x calcium sensitive Fluo-4 Direct buffer 
was mixed with the same volume of differentiation cocktail (MDI) and cells 
were incubated for 30min in an incubator (5% CO2 at 37°C). The cells were 
removed from the incubator and incubated for another 30min at room 
temperature. Plates were then placed for live cell imaging on the SP5 confocal 
microscope (Leica) using the LAS‐AF program. Dishes were left for 1 min to 
gain a basal value before being applied with AA 10μM for approximately 15 
min. The data exported from the program as values based on the 
fluorescence omitted by the experiment. These values were exported and the 
basal average intensity from the first 1min was subtracted.  
 
2.2.17 PGF2α ELIZA 
 
Two days post-confluent 3T3-L1 cells were treated with 100μM, 500μM or 
1mM AA and 24h in the presence of MDI. Supernatants were collected and 
immediately frozen for PGF2α ELIZA. PGF2α ELISA kit was used according to 
manufacturer‘s instructions. This assay is based on the competition between 
the PGF2α included in the samples and a conjugated PGF2α with 
acetylcholinesterase (PGF2α tracer). Because the amount of the tracer is 
constant whereas the PGF2α amount in our samples varies the amount of the 
tracer that will bind to the PGF2α -specific rabbit antiserum will be inversely 
proportional to the concentration of the PGF2α level in the sample. The plate 
was washed and the substrate for the acetylcholinesterase was added. The 
product of this reaction had a yellow color and absorbed at 412nm. Thus, the 
amount measured spectophotometrically was direct proportional to PGF2α 
tracer concentration and inversely proportional to the free PGF2α in each well. 
The PGF2α in our samples were then calculated according to the instructions 
based on a standard curve of known PGF2α standards. 
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2.2.18 cAMP assay 
 
3T3-L1 cells were seeded onto 24 well plates. After two days of post-
confluency, cells were pre-treated with IBMX, a phosphodiesterase inhibitor, 
at 500 μM for 5 min. Cells were then treated with 10μM, 100 μM or 1mM AA 
for 30min. The experiment was terminated with the addition of 0.1 % HCl- 
Triton X-100. cAMP was measured using a competitive enzyme immunoassay 
according to the manufacturer‘s instructions and normalised to protein 
concentration. 
 
2.2.19 Fluorescence-activated cell sorting (FACS) 
 
Two days post-confluent 3T3-L1 cells were treated with 100μM, 500 μM or 
1mM AA for 24 h in the presence of MDI. Cells were then trypsinized and 
centrifuged at 1000 rpm for 5min. The pellet was resuspended in medium 
centrifuged at 1000 rpm for 5min. The pellet was resuspended in PBS, 
centrifuged and fixed with 5 ml of ice-cold 70% ethanol for at least 1 h at -
20°C. The fixed cells were then centrifuged and washed twice in 2 ml of cold 
PBS. The cells were centrifuged and resuspended in 500μl of PBS solution 
containing RNase (0.2mg/ml) and PI (50mg/ml). After incubation at room 
temperature for 30min, the stained cells were analysed in a fluorescence-
activated cell sorter (FACSCalibur, BD Biosciences, San Jose, CA, USA) with 
a 488-nm laser line for excitation. Red fluorescence (4600 nm) and side 
scatter were measured and at least 10000 events were collected. Debris and 
residuals of necrotic cells was recognized and gated-off.  
 
2.2.20 MTT assay 
 
3T3-L1 cells were seeded on 96-well plates. After two days of post 
confluency, cells were treated with 100μM, 1mM AA or 1% Triton X-100 for 24 
h in the presence of MDI. MTT was dissolved in PBS (5 mg/ ml) and 20μl was 
added per well. The plate was then placed on a shaker to thoroughly mix the 
MTT into the media. The cells were then incubated for 1h at 37oC. The 
medium was then removed until dry and 200μl DMSO was added per well. 
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MTT is reduced by metabolically active cells to insoluble purple formazan dye 
crystals and DMSO solubilises the crystals. Samples were read directly in the 
wells using a spectrophotometer at 570 nm.  
 
2.2.21 LDH assay 
 
Two days post-confluent 3T3-L1 cells of were treated with 100μM, 500μM AA 
or 2% Triton X-100 for 24 h in the presence of MDI. 100μl of supernatants 
were added into 96-well plate and 100μl of the reaction mix was added in 
each well according to the manufacturer‘s instructions and incubated for 
30min at room temperature. Then the lactate dehydrogenase (LDH) activity 
was measured with a spectrophotometer at 490nm. LDH activity is directly 
proportional to cell death and cell lysis, since LDH is released from the cytosol 
of damaged cells into the supernatant. 
 
2.2.22 AdipoRed assay 
 
AdipoRed is a solution of the hydrophobic stain Nile Red. Nile Red when 
partitioned in a hydrophobic environment becomes fluorescent. AdipoRed 
enables the quantification of intracellular LDs in a high-throughput manner. 
Thus, cells were seeded in a 96-well plate and cultured until ready to be 
assayed. The plate was then removed form the incubator and allowed to cool 
to room temperature. The cells were washed once with PBS and then filled 
with 200μl of PBS per well. With a multichannel pipette 5 μl of the AdipoRed 
dye was distributed in each well and immediately mixed. After 10minutes the 
fluresence was measured using Victor2 plate reader. 
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Results: Arachidonic Acid effects on the early 
stages of adipocyte differentiation 
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3.1 Introduction 
 
It is apparent that not only the quantity but also the nature of FAs plays an 
important role on the effect of dietary fat on human health. In evolutionary 
terms, our diet has changed dramatically at disproportionate rates in 
comparison with our genes which have changed around 0.005% the past 
10,000 years (DNA mutation rate being 0.5% per million years) (Simopoulos, 
2002). Several studies suggest that humans evolved on a diet with a ratio of 
ω-6 to ω-3 FAs of around 1. However, the ω-6/ω-3 ratio in Western diets is 
15/1–16.7/1(Simopoulos, 2002). It is calculated that 85% of the total dietary 
PUFA intake in Western diets is ω-6 PUFAs and excessive amounts of ω-6 
PUFA has been correlated with the pathogenesis of many diseases, including 
cardiovascular disease, cancer, and inﬂammatory and autoimmune diseases 
(Simopoulos, 2002). Furthermore, studies in rodents link ω-6 PUFA 
deficiencies with skin conditions, growth retardation and infertility (Kremmyda 
et. al, 2011). In humans PUFA or AA deficiency has not been reported since 
LA and AA are found in most of the food sources and a completely PUFA free 
diet must be synthetic or largely so. 
 
Excess fat has been shown to increase both hyperplasia and hypertrophy in 
AT (Faust et. al., 1978). However, even if AA is accepted to be a very 
important element of our diets, its role in AT development is controversial. 
Animal studies have yielded conflicting results, with some studies 
demonstrating that a diet rich in ω-6 PUFAs decreases AT mass (Matsuo et. 
al., 2002), whereas others have associated intake of ω-6 PUFAs with an 
increased propensity for obesity (Massiera et al, 2003). Very little is known 
about the effects of AA and its derivatives at the early stages of differentiation 
and how the early events can affect the pre-adipocyte differentiation potential. 
In this chapter, experiments were designed to identify AA gene targets during 
the early stages of differentiation and the signalling and molecular events AA 
triggers to regulate their expression. To address this question 3T3-L1 cells 
were used as a pre-adipocyte cell system as it is a well characterised cell line 
that has been successfully used to identify the key factors for adipocyte 
differentiation.  
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3.2 Results 
 
3.2.1The effect of AA effect on aP2 expression 
 
3.2.1.1 The effect of AA on the adipocyte differentiation markers 
 
To address the effect of AA on the early stages of adipocyte differentiation, 
3T3-L1 cells were used. 3T3-L1 cells were maintained pre-confluent under 
growing conditions in medium containing 10% NCS. The differentiation 
protocol for these cells involves two-day post-confluent cells (D0) treated with 
0.5 mM IBMX, 250nM DEX and 170nM insulin (or MDI) for the first 48h (D2) in 
the presence of 10% FBS. Cells were then treated with 170nM insulin until the 
end of the differentiation program day 10 (D10) (Figure 3.1 A). In this chapter, 
cells will be assessed after the initial 24h after the induction of differentiation 
(D1), unless otherwise stated.  
 
During the growth phase 3T3-L1 cells had a fibroblast-like morphology (Figure 
3.1 B). After 24h of the addition of MDI their morphology changed as the cells 
became spindle-shaped (Figure 3.1 C). AA was added to D0 cells and during 
the first 24h of differentiation (D1) in the presence of MDI using three doses: 
10μM, 100μM and 1mM. FAs are typically found in fasting or fed mice at 
plasma levels in a range between 0.1 and 1.2 mM (Distel et al, 1992). Thus, 
the AA concentrations used were in the physiological range. Cells were 
stained with Oil Red O which is a dye that stains lipids. LDs could be 
visualised with increasing doses of AA; no LDs were present using the lowest 
concentration, 10μM AA (Figure 3.1 E), whereas appearance of LDs was 
observed with 100μM AA (Figure 3.1 F) and more LDs could be seen with the 
highest dose (1mM) (Figure 3.1 G).  
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Figure 3.1: 3T3-L1 pre-adipocytes showed enhanced LD formation after 24h of AA 
treatment. A) For the differentiation protocol of 3T3-L1 pre-adipocytes, cells were kept pre-
confluent in medium containing 10% NCS in the growing phase. The differentiation protocol 
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started with two-day post-confluent cells (D0) treated with 0.5 mM IBMX, 250nM DEX and 
170nM insulin (or MDI) for the first 48h (D2) in the presence of 10% FBS. MDI was then 
withdrawn and the cells were maintained in 10% FBS medium containing 170nM insulin until 
they were differentiated after 8-10 days. B-G) Oil Red O staining of 3T3-L1 cells at different 
stages of the differentiation and upon AA treatment for 24h. Cells were captured under a light 
microscope using 20x magnification. B) pre-confluent cells, C) two-day post-confluent cells 
(D0), D) treated cells with MDI for 24h and FA-free BSA (vehicle for AA) (D1), E) treated cells 
with 10μM AA in MDI (D1), F) treated cells with 100μM AA in MDI (D1), G) treated cells with 
1mM AA in MDI (D1).  
 
As discussed in Chapter 1, LD formation has been classically used as an 
adipocyte differentiation marker as it is an essential readout for adipocyte 
maturation. To assess if AA promotes the differentiation program of pre-
adipocytes after 24h of treatment, the expression of different mature adipocyte 
gene markers such as aP2, PPARγ2/γ1, C/EBPα, LPL,FAS, PEPCK, 
adiponectin and Glut4 was studied (Figure 3.2).  
 
There was not a significant change for FAS, LPL and C/EBPα expression in 
response to any AA concentrations used in comparison with the vehicle 
control (Figure 3.2 D, E, F). However, PPARγ2 and PPARγ1 expression was 
down-regulated only with the higher AA dose (1mM) (Figure 3.2 B, C). The AA 
effect was dramatic on aP2 expression. aP2 mRNA levels were up-regulated 
around 2-fold with 10μM , around 80-fold with 100μM and around 150-fold 
with 1mM of AA relative to the vehicle control (Figure 3.2 A). aP2 protein 
levels also increased in response to AA treatment (Figure 3.2 A). PEPCK, 
adiponectin and Glut4 expression was not detectable at this early stage of 
differentiation (data not shown). 
 
 
 
Chapter 3  Results 
 90 
 
 
 
 
Figure 3.2: The effect of AA on the expression of late adipocyte differentiation markers 
in 3T3-L1 pre-adipocytes. A) aP2 mRNA and protein, B) PPARγ2, C) PPARγ1, D) C/EBPα, 
E) FAS and F) LPL expression profile was monitored in two-day post-confluent 3T3-L1 cells 
(D0). The pre-adipocytes were incubated for 24h with fatty acid-free BSA vehicle (set as 
100%) or AA (10μM, 100μM or 1mM) in the presence of MDI. Total RNA was harvested and 
qRT-PCR was performed according to the Materials & Methods. Protein was also harvested 
at this time point, to monitor aP2 protein levels. Values shown are mean percentages of three 
independent experiments (n=3) and error bars represent ±SEM. **P < 0.01, ***P<0.001. The 
western blot is a representative of at least three independent experiments. 
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Moreover, the expression of C/EBPβ and C/EBPδ was assessed (Figure 3.3). 
These transcription factors are known to be expressed early in the 
differentiation program in response to the MDI induction and their expression 
declines during the adipocyte differentiation. AA treatment did not significantly 
change their expression with any dose used during the first 24h of the 
induction (Figure 3.3) 
 
 
 
   
Figure 3.3: AA did not affect the expression of early differentiation markers in 3T3-L1 
pre-adipocytes. 3T3-L1 cells (D0) were incubated for 24h with vehicle or AA (10μM, 100μM 
or 1mM) in the presence of MDI. qRT-PCR was performed for A) C/EBPβ and B) C/EBPδ 
mRNA transcripts. Values shown are mean percentages of the respective vehicle controls 
(set as 100%) from three independent experiments (n=3). Error bars represent ±SEM. 
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3.2.1.2 Kinetics of the effect of AA on the adipocyte differentiation 
markers 
 
To further elucidate the effect of AA on the early stages of the differentiation 
program, time course experiments were performed including time points 
earlier than 24h using 100μM AA. The expression of adipocyte differentiation 
markers was then assessed including SREBP1, a transcription factor with a 
role in stimulating the production of ligands for PPARγ (Kim et al., 1998). 
PPARγ2, C/EBPα, FAS, LPL and SREBP1 levels were not affected by the AA 
treatment during the early differentiation procedure (Figure 3.4 B, C, D, E, F). 
However, aP2 was the only late adipocyte differentiation marker which was 
affected by AA treatment. The aP2 mRNA expression was dramatically up-
regulated after 24h of treatment with AA, relative to the vehicle control, and 
not affected at earlier time points (Figure 3.4 A).  
 
The same time courses were conducted to assess the expression of the early 
differentiation markers C/EBPβ and δ. C/EBPβ is expressed in three different 
protein isoforms: full-length C/EBPβ (38-kDa) or liver-enriched activator 
protein* (LAP*), LAP (34kDa) and liver-enriched inhibitory protein (LIP, 
21kDa) which lacks most of the transactivation domain and acts as a 
dominant negative isoform. C/EBPβ protein levels increased after 4h of MDI 
treatment and continued to be expressed after 24h. In contrast, C/EBPδ was 
induced after 2h of the MDI treatment and the levels quickly declined after 4h 
of treatment (Figure 3.5 B, D). AA treatment did not alter C/EBPβ and δ RNA 
or protein expression level relative to the vehicle control at most of the time 
points. One exception is the 12h time point where AA increased LAP and LIP 
protein levels that returned to basal levels after 24h of treatment (Figure 3.5).  
 
In conclusion, 24h of AA treatment caused the up-regulation of aP2 mRNA 
levels which was a gene-specific event that did not affect the differentiation 
program.  
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Figure 3.4: The effect of AA on aP2 expression occurred after 24h of treatment in 3T3-
L1 pre-adipocytes. 3T3-L1 cells (D0) were treated with 100μM AA and total RNA or whole 
cell lysates were prepared at the indicated time points. A) aP2, B) PPARγ2, C) C/EBPα, D) 
FAS and E) LPL mRNA. F) Western blotting was performed using an anti-SREBP1 antibody. 
Values are all relative to the vehicle control treated cells (set as 100%). Data are presented 
as mean±SEM based on triplicate determinations from a representative experiment of two 
independent experiments. Student‘s t-test was performed for the 24h time point between the 
vehicle-treated and the AA-treated. 
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Figure 3.5: AA does not affect the kinetics of the early differentiation markers in 3T3-L1 
pre-adipocytes. 3T3-L1 cells (D0) were treated with AA (100μM or 1mM) and total RNA or 
whole cell lysates were prepared at the indicated time points. A) C/EBPβ mRNA levels and B) 
protein levels and C) C/EBPδ mRNA levels and D) protein levels. The graphs and the blots 
are representatives of two independent experiments. The error bars represent ±SD. 
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3.2.1.3 The effect of AA on aP2 expression is metabolite-, time- and 
condition-specific 
 
To determine if the effect of AA on aP2 expression is specific to AA, 3T3-L1 
cells (D0) were treated with EPA, DHA and LA PUFAs for 24h in the presence 
of MDI. EPA and DHA are both ω-3 PUFAs whereas LA is the precursor of AA 
and a major ω-6 PUFA. EPA and DHA are both implicated in adipocyte 
differentiation as they can act as PPARγ ligands (Krey et al., 1997). All PUFAs 
were prepared using the same protocol described in Materials and Methods 
(Section 2.2.2). All the PUFAs tested were able to induce aP2 expression in 
comparison to the vehicle control. However, AA was the most potent PUFA 
inducing the expression of aP2 around 300-fold relative to the vehicle-control 
(set as 100). These data indicate that AA itself or an AA metabolite mediates 
this effect (Figure 3.6 A).  
 
To further, characterise the time frame of the up-regulation of aP2 expression, 
3T3-L1 cells were treated at earlier stages of the growth phase. Thus, cells 
were treated when pre-confluent, on day 0 of confluency, on day 1 of 
confluency or on day 2 of confluency with AA (1mM) for 24h in the presence 
of MDI (Figure 3.6 B). At all time points, AA up-regulated aP2 expression but 
was more potent when the treatment was initiated at two days post-
confluency.  
 
The role of factors included in the serum or in the differentiation cocktail on 
the up-regulation of aP2 expression by AA was investigated. A time course 
experiment was conducted with D0 cells without serum and in the presence of 
the differentiation cocktail (Figure 3.6 C). AA was able to induce aP2 
expression even in the absence of serum. Next, 3T3-L1 cells (D0), in serum, 
were treated with AA in combination with the different components of the 
differentiation cocktail and aP2 expression was determined after 24h of 
treatment (Figure 3.6 D). IBMX appeared to be important for the effect of AA 
on aP2 expression as AA in the presence of serum and IBMX alone could up-
regulate aP2 even higher than the MDI. In conclusion, increased cAMP levels, 
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achieved by the nonselective phosphodesterase inhibitor (IBMX), might be 
important in mediating AA effect on aP2 expression. 
 
 
 
 
 
 
Figure 3.6: AA up-regulated aP2 expression in 3T3-L1 pre-adipocytes after two days of 
post-confluency in an IBMX-dependent manner. A) 3T3-L1 cells (D0) were treated with 
AA, EPA, DHA and LA (1mM) for 24h in the presence of MDI. All PUFAs used were 
conjugated with BSA as described in materials and methods. B) Pre-confluent, day 0 
confluent, day 1 confluent and day 2 confluent 3T3-L1 cells were treated with AA (1mM) for 
24h. C) 3T3-L1 cells (D0) were treated with AA (100μM) in the presence of MDI and in the 
absence of serum for 24h. D) 3T3-L1 cells (D0) were treated with AA (100μM) together with 
the different components of the MDI or combinations. Total RNA was isolated and qRT-PCR 
was performed. All relative aP2 mRNA levels are presented as percentages of the respective 
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vehicle controls (set as 100%). The graphs are representatives of two independent 
experiments. The error bars represent ±SD. 
 
3.2.2 The effect of AA metabolites on aP2 expression 
 
3.2.2.1 COXs mediate the effect of AA on aP2 expression 
 
To examine if AA metabolites have a role in aP2 expression or this effect is 
due to AA itself, 3T3-L1 cells were treated with inhibitors targeting the three 
enzymes that can metabolise AA. Thus, 3T3-L1 cells were treated with 
indomethacin which is a general COX inhibitor, baicalein which is a 12/15 
LOX inhibitor and 17-octadecynoic acid (17-ODYA) which is a cytochrome 
P450 epoxygenase inhibitor (Figure 3.7). The effect of AA on aP2 expression 
was significantly blocked by indomethacin but also from the selective COX-2 
(SC-236) and COX-1 inhibitor (SC-560) (Figure 3.7 A, B). However, the AA 
effect was not blocked by the LOX or MOX inhibitors, indicating that PGs 
mediate AA on aP2 expression (Figure 3.7 C, D). 
 
COX-2, COX-1 and eLOX3 expression was determined by qRT-PCR in the 
presence of increasing doses of AA for 24h (Figure 3.8). The expression of 
both COX isoforms was increased upon AA treatment in a dose-dependent 
manner (Figure 3.8 A, B). In contrast, eLOX3 expression, which is the only 
LOX expressed in 3T3-L1s, (Madsen et al., 2003) was not affected by any AA 
dose (Figure 3.8 C). These data together with the fact that baicalein did not 
inhibit AA effect, indicates that the metabolites generated through the LOX 
pathway are not involved in the regulation of aP2.  
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Figure 3.7: The effect of AA on aP2 expression was inhibited by indomethacin. A) 3T3-
L1 cells (D0) were pre-treated with A) indomethacin (10μM), B) a selective COX-2 (SC-236, 
10μM) and a selective COX-1 inhibitor (SC-560, 10μM), C) 17-ODYA (10 μM) or D) baicalein 
(10 μM) for 30 min prior to AA (100 μM) treatment for 24h. Total RNA was isolated and qRT-
PCR was performed. All relative aP2 mRNA levels are presented as mean percentages of the 
respective vehicle controls (set as 100%) from three independent experiment (n=3). Error 
bars represent ±SEM. **P< 0.01, ***P<0.001. 
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Figure 3.8: COXs expression is increased upon AA treatment in 3T3-L1 pre-adipocytes. 
3T3-L1 cells (D0) were treated with 10μM, 100μM or 1mM of AA for 24h. Total RNA was 
isolated and qRT-PCR was performed for A) COX-2, B) COX-1 and C) eLOX3 mRNA 
transcripts. All relative mRNA levels are presented as mean percentages of the respective 
vehicle controls (set as 100%) from three independent experiment (n=3). Error bars represent 
±SEM.*P< 0.05, **P< 0.01, ***P<0.001. 
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3.2.2.2 PGs mediate the effect of AA on aP2 expression 
 
To further examine the role of PGs on aP2 expression, 3T3-L1 cells were 
treated with four different PGs for the first 24h of differentiation. A dose 
response experiment was carried out using the analogue of PGI2, 
carbaprostacyclin (cPGI2), PGF2α, PGE2 and 15-deoxy-Δ
12,14 PGJ2. From all 
the PGs tested, PGF2α seems to have a similar effect to AA on aP2 
expression (Figure 3.9, red line). Even at the lowest concentration (1nM) 
tested, PGF2α was able to up-regulate aP2 almost 100-fold. PGE2 had an 
effect after using 100nM (30-fold), cPGI2 had an effect after using 1μM (40-
fold) and at 10μM (150-fold) its effect was higher than PGF2α at this dose. 
Finally, 15-deoxy-Δ12,14 PGJ2 which is a direct PPARγ ligand, did not have any 
significant effect at all doses tested (Figure 3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: The effect of PGs on aP2 expression. 3T3-L1 cells (D0) were treated with 1nM, 
10nM, 100μM, 1μM or 10μM of PGF2α, PGE2, cPGI2 and 15-deoxy-Δ
12,14 
PGJ2 for 24h in the 
presence of MDI. Total RNA was isolated and qRT-PCR was performed for aP2 mRNA 
transcripts. All relative mRNA levels are presented as mean percentages of the respective 
vehicle controls (set as 100%) from three independent experiment (n=3). Error bars represent 
±SEM.  ***P<0.001. The red line is the PGF2α treatment.  
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Three of the four PGs tested exert their effects through binding to membrane 
GPCRs. In order to confirm that these GPCRs were expressed in pre-
adipocytes and whether AA had any effect on their expression, qRT-PCR was 
conducted after a 24h of treatment with 100μM AA. The PGF2α receptor called 
FP receptor, one of the PGE2 receptors the EP4 receptor and the PGI2 called 
IP receptor were all expressed at this stage (Figure 3.10 A-C). AA did not 
have any significant effect on the expression of the receptors. However, there 
was a trend to up-regulate the expression of the IP receptor and down-
regulate the expression of the FP receptor The PGE2 receptor EP1 was also 
expressed but the levels were low (Ct ~ 35) (Figure 3.10 D). The other PGE2 
receptors, EP2 and EP3-α-β-γ were not detected (Figure 3.10 F-H).  
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Figure 3.10: PG receptor expression after 24h treatment with AA. 3T3-L1 cells (D0) were 
treated with 100μM AA for 24h in the presence of MDI. Total RNA was extracted and 
subjected to RT-PCR analysis for the A) FP, B) EP4, C) IP, D) EP1, E) EP2, F) EP3α, G) 
EP3β and H) EP3γ mRNA transcripts. The relative expression for the FP, EP4, IP and EP1 
receptor is shown relative to the vehicle control (set as 100%). Mouse lung RNA was used as 
a positive control for EP2 and mouse kidney RNA was used for the three EP3 isoforms. 
Graphs are representatives of two independent experiments (n=2) and error bars represent ± 
SD. ND: Not detected. 
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3.2.3. The signalling pathway mediating the effect of AA on aP2 
expression 
 
3.2.3.1. ERK MAPK mediates the effect of AA on aP2 expression 
 
The next question addressed was which signalling pathway AA triggers in 
order to regulate aP2 expression. For this reason a number of MAP kinases 
that could be activated by AA were assessed. 3T3-L1s cells were treated with 
AA over the first 24h of differentiation in the presence of MDI and samples 
were taken at different time points. p- c-Jun N-terminal kinase (p-JNK) and p-
p38 MAPK were not present at high levels in pre-adipocytes and were not 
regulated by AA at this stage (Figure 3.11 A, B). Together with the 3T3-L1 
lysates, a positive control was examined for p-JNK in order to identify the 
correct bands. As shown in figure 3.11 A, two bands appeared for the 3T3-L1 
lysates, which were identical to the extracellular signal-regulated kinase (p-
ERK) instead of p-JNK, whereas the correct bands appeared for the positive 
control. This indicates that this antibody might recognise p-ERK instead of p-
JNK in this cell type. However, p-ERK was still expressed after 24h only in the 
presence of AA using either 100μM or 1mM AA (Figure 3.11 C, D).  
 
 
 
Figure 3.11: MAPKs expression after 24h of treatment with AA. 3T3-L1 cells (D0) were 
treated with 100μM AA for 24h in the presence of MDI. Whole cell lysates were extracted after 
0.5, 2, 8, 12 and 24h of AA treatment and analysed by Western blotting with antibodies 
A B 
C D 
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against A) p-JNK, total JNK and GAPDH, B) p-p38, total p38 and GAPDH. Similarly, 3T3-L1 
cells were treated with either 100μM AA (C) or 1mM AA (D) for 24h in the presence of MDI 
and whole cell protein extracts were analysed by Western blotting with antibodies against p-
ERK, total- ERK and GAPDH. +ve: positive control. 
 
To determine if this sustained activation of p-ERK has a role in the up-
regulation of aP2 expression after 24h of AA treatment; 3T3-L1cells were pre-
treated with PD98059 which is a potent and selective inhibitor of MAP kinase 
kinase (also known as MAPK/ERK kinase or MEK kinase). It mediates its 
inhibitory properties by binding to the ERK-specific MAP kinase MEK, 
therefore preventing phosphorylation of ERK1/2 (p44/p42 MAPK) by MEK1/2. 
PD98059 significantly blocked AA effect on aP2 mRNA and protein levels, 
indicating that ERK activation was occurring after AA treatment and was 
mediating aP2 up-regulation (Figure 3.12 A, B). 
 
 
 
 
Figure 3.12: ERK mediates the effect of AA on aP2 expression. 3T3-L1 cells (D0) were 
pre-treated with PD98059 (10μM) for 30 min prior to AA (100μM or 1mM) treatment for 24h. 
Total RNA was extracted and subjected to qRT-PCR for aP2 mRNA transcript (A) or whole 
cell lysates were extracted and subjected to Western blotting using antibodies against aP2 
and GAPDH (B). aP2 mRNA levels are presented as mean percentages of the respective 
vehicle controls (set as 100%) from three independent experiment (n=3). Error bars represent 
±SEM. *P<0.05.  
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3.2.3.2. ERK is activated immediately after AA stimulation 
 
To further elucidate the signalling pathway triggered by AA in pre-adipocytes 
to regulate aP2 expression, we studied the events taking place immediately 
after the addition of AA to the cells. To test the effect of MDI and/or serum on 
ERK activation, an experiment was conducted with the normal differentiation 
cocktail and samples were taken over a period of one hour. As expected, 
under these conditions the effect of AA was masked (Figure 3.13 A). 
Therefore, 3T3-L1 cells were serum starved overnight and then treated with 
AA (Figure 3.13 B). However, with serum-starved cells we reduced the AA 
concentration to 10μM as with 100μM AA the BSA used as the vehicle-control 
activated ERK after 10 or 15 min (Figure 3.13 B). Using this protocol, AA 
(10μM) significantly activated ERK after 5 minutes of treatment and its 
activation declined thereafter (Figure 3.13 C, D). Finally, a lower AA 
concentration was also tested (1μM) but the activation of ERK was very 
modest (Figure 3.13 E). 
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Figure 3.13: AA-induced ERK activation in 3T3-L1 pre-adipocytes. A) 3T3-L1 cells (D0) 
were treated with 100μM AA for 1h in the presence of MDI. Whole cell lysates were extracted 
after 5, 10, 15, 10 and 60min and analysed by Western blotting with antibodies against p-ERK, 
total- ERK and GAPDH. B) 3T3-L1 cells (D0) were serum starved overnight and treated with 
100μM AA for 1h. Whole cell lysates were extracted after 5, 10, 15, 10 and 60min and 
analysed by Western blotting with antibodies against p-ERK, total- ERK and GAPDH. C) 3T3-
L1 cells (D0) were serum starved overnight and lysates were extracted as described in B but 
were treated with 10μM AA for 1h. D) Densitometry results of three independent experiments 
using the protocol described in C. Densitometry was performed on scanned immunoblot 
images using the ImageJ software. Relative intensity for each sample was calculated by 
normalizing its p-ERK to the corresponding control total-ERK. *P< 0.05. E) The same protocol 
was used as described in C but cells were treated with 1μM AA for 5min. 
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3.2.3.3. ERK is activated immediately after PGF2α and PGE2 stimulation  
 
As it was shown in section 3.2.4, the effect of AA on aP2 expression was 
blocked with either indomethacin or selective COX inhibitors indicating a role 
for PG production. Therefore, to address whether the effect of AA on ERK 
activation is PGs mediated, 3T3-L1s cells were serum starved overnight, pre-
treated with indomethacin for 30min and stimulated for 5 min with AA (Figure 
3.14 A). Indomethacin completely blocked ERK activation by AA, indicating 
that this signalling pathway is PGs-dependent. To determine which PGs 
activate ERK, serum-starved 3T3-L1s cells were treated with PGF2α, PGE2 
and cPGI2. These PGs were chosen as they can signal though membrane 
GPCRs and could potentially activate ERK. From the three PGs tested, PGF2α 
and PGE2 activated ERK after 5 min of treatment (Figure 3.14 B-D). 
 
A full time course was conducted over an hour using PGF2α and PGE2 (Figure 
3.14 E, F). Both PGs activated ERK after 10 min of treatment and the 
activation declined after one hour of treatment. However, p-ERK levels were 
above the basal levels even after one hour of PGF2α treatment. It should be 
noted that the PG concentration used and able to activate ERK was 1000 
times lower than the AA concentration that achieved the same activation. The 
high concentration of AA required to activate ERK suggests that an AA 
metabolite rather than AA itself, exerted this effect. In conclusion, PGF2α and 
PGE2 seem to be the PGs that activate ERK when cells are challenged with 
AA. 
 
 
 
Chapter 3  Results 
 108 
 
 
 
 
Figure 3.14: PGF2α and PGE2 activate ERK in 3T3-L1 pre-adipocytes. A) Serum-starved 
3T3-L1 cells (D0) were pre-treated with indomethacin (1μM) for 30min prior to 10μM AA 
stimulation for 5min. Whole cell lysates were extracted and probed with antibodies against p-
ERK and total-ERK. B), C), D) Serum-starved cells were treated with PGI2 (10nM), PGF2α 
(10nM) and PGE2 (10nM) for 5min. Whole cell lysates were extracted and probed with 
antibodies against p-ERK, total-ERK and GAPDH. E) and F) Serum-starved cells were 
treated with PGF2α (10nM) and PGE2 (10nM) for 1h. Whole cell lysates were extracted after 5, 
10, 15, 30 and 60min of stimulation and probed with antibodies against p-ERK, total-ERK and 
GAPDH. 
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3.2.3.4. The FP receptor mediates AA-induced ERK activation  
 
To determine which PG GPCRs are activated upon AA treatment and lead to 
activation of ERK, 3T3-L1 cells were pre-treated with selective antagonists 
against the PGs receptors expressed during the early stages of differentiation 
(see figure 3.10 A-C). Serum-starved cells were pre-treated for 30 min with AL 
8810, a selective antagonist for FP receptor (PGF2α receptor), L-161,982, 
selective for EP4 receptor (PGE2 receptor), SC-51089, for selective EP1 
receptor (PGE2 receptor) and CAY- 10441, selective for IP receptor (PGI2 
receptor). Then the cells were treated with AA or the corresponding receptor 
agonists (as a positive control) for 5 min and the phosphorylation of ERK was 
assessed (Figure 3.15). Only the FP receptor antagonist (AL 8810) could 
significantly block the phosphorylation of ERK by AA, indicating that PGF2α is 
the PG that mediates AA effect on the phosphorylation of ERK.  
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Figure 3.15: The FP receptor mediates the AA-induced ERK activation in 3T3-L1 pre-
adipocytes. A), D), G) and I) 3T3-L1 cells (D0) were serum-starved overnight pre-treated 
with AL 8810 (10μM, 1μM), L-161,982 (10μM, 1μM), CAY-10441 (10μM) or SC-51089 (10μM, 
1μM) for 30min prior to AA (10μM) 5min stimulation. Whole cell lysates were extracted and 
probed with antibodies against p-ERK and total-ERK. B) and E) Densitometry results of three 
independent experiments. p-ERK relative to total-ERK were calculated from experiments pre-
treated with AL 8810 and L-161,982 respectively prior to the AA stimulation. C) 3T3-L1 cells 
(D0) were serum starved overnight pre-treated with AL 8810 (10μM, 1μM) for 30min prior to 
PGF2α (10nM) 5min stimulation and p-ERK and total-ERK expression was determined. F) 
3T3-L1 cells (D0) were serum starved overnight pre-treated with L-161,982 (10μM, 1μM) for 
30min prior to PGE2 (10nM) 5min stimulation and p-ERK and total-ERK expression was 
determined. H) 3T3-L1 cells (D0) were serum starved overnight pre-treated with CAY-10441 
(10μM) for 30min prior to cPGI2 (10nM) 5min stimulation and p-ERK and total-ERK expression 
was determined. *P<0.05. Error bars represent ±SEM. 
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3.2.3.5. The FP receptor mediates the effect of AA on aP2 expression  
 
To address if there is any correlation between PG-induced ERK activation and 
aP2 expression at 24h, two days post-confluent cells were pre-treated with the 
antagonists against the FP receptor, the EP4 receptor and the IP receptor for 
30 min prior to 24h AA treatment and aP2 mRNA levels were assessed. Only 
the FP receptor antagonist, AL 8810 could significantly block the ability of AA 
to increase aP2 mRNA levels whereas L-161,982 and CAY- 10441 had no 
effect on AA-dependent induction of aP2 (Figure 3.16 A-C). 
 
To investigate the role of the FP receptor on aP2 expression, the FP receptor 
was depleted by a targeting siRNA (siFP). After 24h of treatment with AA, the 
up-regulation of aP2 expression was blocked in the presence of siFP (Figure 
3.16 D). At the same time FP receptor mRNA levels were assessed and its 
expression was reduced around 80% (Figure 3.16 E). In addition, ERK 
activation was reduced in the absence of the FP receptor when AA was added 
for 24h (Figure 3.16 F). As a negative control, cells were transfected with the 
siRNA targeting the EP4 receptor (siEP4). Knocking down EP4 receptor 
(around 50%) did not block the ability of AA to induce aP2 expression but on 
the contrary enhanced aP2 expression around 2-fold, indicating that PGE2 
does not mediate the effect of AA (Figure 3.16 G, H). In conclusion, the AA–
dependent induction of aP2 expression is mediated by PGF2α which acts 
through its membrane GPCR, the FP receptor.  
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Figure 3.16: The FP receptor mediates the effect of AA on aP2 expression. A), B) and C) 
3T3-L1 cells (D0) were pre-treated with AL 8810 (10μM), L-161,982 (10μM) or CAY-10441 
(10μM) for 30 min prior to 100μM AA treatment for 24h. Total RNA was extracted and 
subjected to qRT-PCR for aP2 mRNA transcript. D) and E) 80% confluent 3T3-L1 cells were 
transfected with a non targeting control (siControl) siRNA or an siRNA targeting the FP 
receptor (siFP). On the third day after transfection, cells were treated with 100μM AA for 24h 
in the presence of MDI. Cells were harvested and total RNA was isolated and qRT-PCR was 
conducted for aP2 mRNA and FP receptor transcripts. F) Cells were transfected with siFP as 
described in D and E and treated with 500μM AA for 24h in the presence of MDI. Whole 
lysates were harvested and probed for p-ERK and total-ERK. G) and H) Cells were 
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transfected with an siRNA targeting EP4 receptor (siEP4) as described in D and E and aP2 
and EP4 receptor transcripts were measured. All mRNA levels are presented as mean 
percentages of the respective vehicle controls from three independent experiment (n=3). Error 
bars represent ±SEM. *P<0.05, ***P<0.001. 
 
3.2.3.6. PGF2α induces aP2 expression  
 
To confirm that PGF2α is produced after AA treatment, 3T3-L1 cells were 
treated with increasing doses of AA in the presence of MDI and supernatants 
were collected and assayed for PGF2α levels. PGF2α was produced after AA 
treatment in a dose-dependent manner (Figure 3.17 A). A time-course 
experiment was performed using PGF2α over a course of 24h and aP2 mRNA 
levels were measured (Figure 3.17 B). PGF2α could increase aP2 mRNA 
expression in a time-dependent manner and the up-regulation was significant 
at the 12h and 24h time points. This correlated with the dose-dependent 
increase of the PGF2α synthase in 3T3-L1 cells, aldo-keto reductase 
(AKR)1B3 (Fujimori et al., 2010), when cells where challenged with AA  
(Figure 3.17 C).However, the FP receptor mRNA levels were not significantly 
affected by AA treatment (Figure 3.17 D). 
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Figure 3.17: PGF2α up-regulates aP2 expression. A) 3T3-L1 cells (D0) were treated with 
AA (100μM or 500μM) in the presence of MDI for 24h. Supernatants were collected and 
assessed for PGF2α levels with EIA. B) 3T3-L1 cells (D0) were treated with PGF2α (10nM) in 
the presence of MDI for 24h. Total RNA was isolated and aP2 transcript was measured. C) 
and D) 3T3-L1 cells (D0) were treated with increasing doses of AA for 24h in the presence of 
MDI. Total RNA was isolated and qRT-PCR was conducted for AKR1B3 and FP receptor 
transcripts. All relative mRNA levels are presented as mean percentages of the respective 
vehicle controls (set as 100%) from three independent experiment (n=3). Error bars represent 
±SEM. *P< 0.05, ***P<0.001. 
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3.2.3.7. AA increases intracellular cAMP levels 
 
The next step in elucidating the signalling pathway was to investigate which is 
the second messenger that the FP receptor triggers after AA treatment. The 
two most abundant second messengers are cAMP and Ca2+. Thus, cAMP 
levels were measured using two days post-confluent 3T3-L1 cells, serum 
starved overnight and pre-treated with a phosphodiesterase inhibitor (IBMX) 
for 5 min prior to treatment with increasing doses of AA for 30min (Figure 3.18 
A). AA stimulated an increase in cAMP levels with all doses tested, therefore 
the lowest of 10μM was used for the following experiments. To determine if 
the rise of cAMP levels was PG-mediated, cells were pre-treated with 
indomethacin the general COX inhibitor (Figure 3.18 B). Indomethacin 
completely blocked the effect of AA on cAMP levels. Finally, to identify the PG 
GPCR mediating the increase in cAMP levels by AA, cells were pre-treated 
with the FP, EP4 and IP receptor selective antagonists prior to the AA 
stimulus. Only the EP4 receptor antagonist (L-161,982) could block the effect 
of AA on cAMP levels (Figure 3.18 C).  
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Figure 3.18: AA increases intracellular cAMP levels via the EP4 receptor in 3T3-L1 pre-
adipocytes. A) 3T3-L1 cells (D0) were serum starved overnight, pre-treated, with IBMX for 5 
min and incubated with AA (10μM, 100μM or 1mM) for 30 min. Cells lysed with 0.1 % HCl / 
Triton X- 100. cAMP levels were measured using an EIA system. All relative cAMP levels are 
presented as mean percentages of the respective vehicle controls (set as 100%) from three 
independent experiment (n=3). Error bars represent ±SEM. B) 3T3-L1 cells (D0) were serum 
starved overnight, pre-treated with indomethacin for 60 min before stimulation with 10μM AA 
for 30 min. Cells were lysed and cAMP was measured as described above. The graph is 
representative of one of the two experiments performed. C) 3T3-L1 cells were serum starved 
overnight and pre-treated with AL 8810 (10μM), L-161,982 (10μM) and CAY-10441 (10μM) 
for 60 min before stimulation with 10μM AA for 30 min. Cells were lysed and cAMP was 
measured as described above All relative cAMP levels are presented as mean percentages of 
the respective vehicle controls (set as 100%) from three independent experiment (n=3). Error 
bars represent ±SEM. *P<0.05, **P<0.01.  
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3.2.3.8 AA increases intracellular calcium levels 
 
To assess if AA triggers an increase of intracellular calcium levels, calcium 
mobilisation studies were performed. Two days post-confluent 3T3-L1cells 
were loaded with the calcium dye Fluo-4 and treated with 10μM AA during live 
cell imaging. Addition of AA induced a rapid and robust increase in calcium in 
cultured 3T3-L1 cells (Figure 3.19 A). This effect was PG-mediated as pre-
treatment with indomethacin completely blocked the mobilization of calcium 
stores (Figure 3.19 B). The FP receptor antagonist (AL 8810) was able to 
block the effect of AA on the intracellular calcium levels (Figure 3.19 C). This 
was consistent with previous reports illustrating that the FP receptor is 
coupled to Gαq leading to an increase in intracellular calcium concentrations 
(Liu and Clipstone, 2007).  
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Figure 3.19: AA increases intracellular calcium levels via the FP receptor in 3T3-L1 pre-
adipocytes. A) 3T3-L1 cells (D0) were loaded with calcium sensitive Fluo-4 before 
stimulation with 10μM AA or BSA as vehicle control and calcium mobilisation was determined 
by confocal microscopy. Single image of calcium loaded 3T3-L1 cells after a vehicle or AA 
(10μM) treatment. (B) Cells were pre-treated with 10μM indomethacin for 30min before the 
stimulation with 10μM AA. (C) Cells were pre- treated with 10μM AL 8810 for 30min prior 
10μM AA stimulation. A representative experiment is shown (n = 3). 
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3.2.3.9 Calcium mediates the effect of AA on aP2 expression and ERK 
activation 
 
To correlate the calcium response with the regulation of aP2 expression at 
24h of treatment, cells were pre-treated with a membrane-permeant calcium 
chelator BAPTA-AM to establish an intracellular zero free calcium level. 
BAPTA-AM significantly blocked the up-regulation of aP2 expression by AA 
but also the activation of ERK (Figure 3.20 A, B, C). Finally, to determine if the 
calcium signalling influences the cAMP production, cells were pre-treated with 
BAPTA-AM prior to the AA stimulation and the cAMP intracellular levels were 
assessed (Figure 3.20 D). BAPTA-AM did not have any effect on cAMP 
production, indicating that these signalling pathways are independent. From 
these data can be concluded that calcium is the second messenger that 
mediates the effect of FP receptor leading to the increase in aP2 expression. 
 
 
 
 
 
 
 
 
 
 
Chapter 3  Results 
 120 
 
 
Figure 3.20: Calcium mediates the effect of AA on aP2 expression and ERK activation. 
A) 3T3-L1 cells (D0) were pre-treated with BAPTA-AM (30μM), for 30 min prior to 100μM AA 
treatment for 24h. Total RNA was extracted and subjected to qRT-PCR for aP2 mRNA 
transcript. mRNA levels are presented as mean percentages of the respective vehicle 
controls (set as 100%) from three independent experiment (n=3). Error bars represent ±SEM. 
***P<0.001. B) Serum-starved 3T3-L1 cells (D0) were pre-treated with BAPTA-AM (10μM) for 
30min prior to AA (10μM) 5min stimulation. Whole cell lysates were extracted and analysed 
by Western blotting with antibodies against p-ERK, total-ERK and GAPDH. C) Densitometry 
results of three independent experiments performed as described in B. p-ERK relative to total-
ERK were calculated and plotted. Error bars represent ±SEM. *P<0.05. D) Serum-starved 
3T3-L1 cells (D0) were pre-treated BAPTA-AM (10μM) for 60 min before stimulation with 
10μM AA for 30 min. The experiment was terminated and lysed with 0.1 % HCl / Triton X- 
100. cAMP was measured using an EIA system. All relative cAMP levels are presented as 
mean percentages of the respective vehicle controls (set as 100%).  
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3.2.3.10 PKC mediates the effect of AA on aP2 expression and ERK 
activation 
 
Finally, it was addressed which protein kinase is important for the regulation of 
aP2 expression. Thus, 3T3-L1 cells were pre-treated with a PKA inhibitor 
(H89) for 30min prior to the 100μM AA treatment for 24h. H89 did not 
significantly block the effect of AA on aP2 expression (Figure 3.21 A). In 
addition, a PKC inhibitor (GF 109203X) was used to pre-treat the cells. The 
induction of aP2 and the ERK activation was completely blocked by pre-
incubation with the PKC inhibitor prior to AA treatment. These data indicate 
that PKC is activated downstream of the FP receptor and the calcium release 
(Figure 3.21 C, D). 
 
 
Figure 3.21. PKC mediates the effect of AA on aP2 expression and ERK activation. A) 
3T3-L1 cells were pre-treated with H89 (10μM) for 30 min prior to 100μM AA treatment for 
24h. Total RNA was extracted and subjected to qRT-PCR for aP2 mRNA transcript. mRNA 
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levels are presented as mean percentages of the respective vehicle controls (set as 100%) 
from three independent experiment (n=3). Error bars represent ±SEM. B) Cells were treated 
as described in A but they were pre-treated with GF109203X (10μM) for 30 min prior to 
100μM AA treatment for 24h. mRNA levels are presented as mean percentages of the 
respective vehicle controls (set as 100%) from three independent experiment (n=3). Error 
bars represent ±SEM. ***P< 0.001. C) Cells were treated as described in B but whole cell 
lysates were subjected to western blotting and probed for antibodies against p-ERK and total-
ERK. The blot shown is a representative of two independent experiments. 
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3.2.4 The effect of AA on aP2 expression is PPARγ-mediated 
 
3.2.4.1 PPARs and aP2 expression 
 
aP2 is one of the best characterised gene targets of PPARγ as it was the ﬁrst 
PPARγ target gene identiﬁed (Tontonoz et al, 1994a). aP2 has a 518bp 
enhancer element from -5.4kb to -4.9kb relative to the transcription start site, 
that drives gene expression in AT (Ross et. al., 1990). In this enhancer region 
two PPRE elements are present (Graves et. al., 1992), where the heterodimer 
PPARγ2/RXRα binds and drives adipose-specific aP2 expression (Tontonoz 
et. al., 1994a). For this reason it was hypothesised that PPARγ could be the 
transcription factor mediating the effect of AA. However, PPARδ and PPARα 
are also expressed in 3T3-L1 cells and could also bind to PPRE elements 
present at the aP2 enhancer. To elucidate the role of PPARs on AA-
dependent aP2 transcription, two days post-confluent 3T3-L1s were treated 
with rosiglitazone, GW7647 and GW501516 which are synthetic agonists 
selective for PPARγ, PPARα and PPARδ, respectively. Rosiglitazone had the 
strongest effect of all the PPAR agonists, up-regulating aP2 expression 
around 20-fold. PPARδ agonist also had a small effect around 2-fold and the 
PPARα agonist did not have any effect (Figure 3.22 A, B, C).  
 
To further elucidate the role of PPARs in mediating the effect of AA on aP2 
expression, HEK293 cells were transfected with a reporter construct 
containing three copies of a functional PPRE or the aP2 reporter construct 
containing both promoter and enhancer sequences. The cells were then 
treated with AA (1mM) in the presence or absence of PPARs. The respective 
agonist for each PPAR was also included as a positive control. AA treatment 
induced the PPRE promoter activity in the presence of all PPARs (Figure 3.22 
D, E, F). However, the effect of AA on the aP2 promoter construct was less 
pronounced than observed for the PPRE construct. AA enhanced reporter 
gene activity from both reporter constructs in the presence of PPARγ (Figure 
3.22 D, G), whereas only for the PPRE construct could AA increase its activity 
in the presence of PPARα or PPARδ (Figure 3.22 E, F).  
 
 
Chapter 3  Results 
 124 
 
 
Figure 3.22: PPARs and aP2 expression. A) Two-day post-confluent 3T3-L1 cells were 
treated with a PPARγ agonist (rosiglitazone, 10μM) for 24h in the presence of MDI. Total RNA 
was extracted and subjected to qRT-PCR. The plot represent the mean values of three 
independent experiment (n=3). Error bars represent ±SEM. ***P< 0.001. B) and C) 3T3-L1 
cells were treated with a PPARα agonist (GW 7647, 100nM) or a PPARδ agonist (GW 
501516, 10μM), respectively for 24h in the presence of MDI. Total RNA was extracted and 
subjected to qRT-PCR. The plots are representative of two independent experiments (n=2), 
Error bars represent ±SD. D), E) F) HEK293 cells were transfected using the calcium 
phosphate method with the 3x-PPRE luciferase reporter construct (PPRE-luc) and a renilla 
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construct  together with the expression vector for PPARγ, PPARα and PPARδ respectively or 
an empty vector. The next day, cells were treated with AA (1mM) or the respective PPAR 
agonist i.e a PPARγ agonist (rosiglitazone, 10μM), a PPARα agonist (WY14643, 100μM) and 
a PPARδ agonist (GW 501516, 44μM) for 24h. The cells were harvested and the luciferase 
activity was measured. Activation of the luciferase reporter is expressed relative to the vehicle 
control (set as 100) after normalisation for the renilla luciferase activity. The plots are 
representative of two experiments (n=2). Error bars represent ±SD. G), H) and I) HEK293 
cells were transfected and treated as described above but this time with the aP2-luciferase 
(aP2-luc) was transfected. The plots are representative of two experiments (n=2). Error bars 
represent ±SD. 
 
3.2.4.2 PPARγ absence prevents AA-dependent induction of aP2 
 
Since the selective agonists for PPARγ and PPARδ were able to up-regulate 
aP2 expression and since they were the PPARs that enhanced the effect of 
AA on both promoter constructs, it was hypothesised that these PPARs most 
likely mediate AA effect. To test this hypothesis, 3T3-L1s were pre-treated 
with a PPARγ (GW 9662) or a PPARδ selective antagonist (GSK 0660) for 
30min before AA (100μM) treatment for 24h (Figure 3.23 A, B). Only the 
PPARγ antagonist could significantly block the ability of AA to induce aP2 
expression (Figure 3.23 A), indicating that PPARγ is the nuclear receptor 
mediating the effect of AA.  
 
To further confirm this observation, PPARγ was stably silenced in 3T3-L1 
cells. A cell line expressing shPPARγ displayed a reduction of PPARγ 
expression more than 90% compared to cells expressing a non-specific 
shRNA (shScrambled) (Figure 3.23 E). Two days post-confluent shPPARγ 
and shScrambled 3T3-L1 cells were treated with AA (100μM) for 24h and the 
aP2 mRNA and protein levels were assessed. The effect of AA on aP2 
expression was significantly blocked in the absence of PPARγ, indicating that 
PPARγ is essential for this up-regulation (Figure 3.23 C, D). As a positive 
control the same experiment was repeated but the cells were treated with the 
PPARγ selective agonist, rosiglitazone. The ability of rosiglitazone to induce 
aP2 levels was also prevented in the absence of PPARγ (Figure 3.23 E). 
Finally, shPPARγ and shScrambled expressing cell lines were treated with 
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PGF2α (10nM) (Figure 3.23 F). The effect of PGF2α on aP2 levels also 
prevented by the absence of PPARγ.  
 
 
 
Figure 3.23: PPARγ mediates the effect of AA on aP2 expression. A) 3T3-L1 cells (D0) 
were pre-treated with a selective PPARγ antagonist (GW 9662, 10μM) for 30min before the 
AA (100μM) treatment in the presence of MDI for 24h. Total RNA was isolated and analyzed 
using qRT- PCR. Relative aP2 mRNA levels were expressed as percentage to the respective 
negative control stimulated with vehicle only (set as 100%). The plot represent the mean 
values of three independent experiment (n=3). Error bars represent ±SEM. *** P< 0.001. B) 
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As in A but cells pre-treated with a selective PPARδ antagonist (GSK 0660, 10μM). The plot 
is a representative of two independent experiments (n=2). Error bars represent ±SD C) Two 
days post-confluent PPARγ knockdown 3T3-L1 cells (shPPARγ) together with the negative 
control cells (shScrambled), were treated with 100μM AA for 24h in the presence of MDI. The 
total RNA of the cells was isolated and analyzed using qRT- PCR. Relative aP2 mRNA levels 
were expressed as percentage to the respective negative control stimulated with vehicle only 
(set as 100%). The plot represents the mean values of three independent experiment (n=3). 
Error bars represent ±SEM. *** P< 0.001. D) As in C but whole cell extracts were isolated and 
subjected to western blotting using antibodies again aP2 and GAPDH. E) As in C. Relative 
PPARγ mRNA levels in the basal conditions of the shPPARγ cells were expressed as 
percentage to the respective negative control (shScrambled). The plot represent the mean 
values of three independent experiments (n=3). Error bars represent ±SEM. *** P< 0.001. F) 
and G) As in C but cells were treated with rosiglitazone (10μM) or PGF2α (10nM) 
respectively, for 24h in the presence of MDI. Relative aP2 mRNA levels were expressed as 
percentage to the respective negative control stimulated with vehicle only. The plots are 
representatives of two independent experiments (n=2). Error bars represent ±SD. 
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3.2.4.3 PPARγ expression enhances the AA-dependent induction of aP2 
expression 
 
An alternative approach was used to address the role of PPARγ in the AA-
mediated aP2 induction. PPARγ was overexpressed in wild type 3T3-L1 cells 
and endogenous aP2 expression was measured after 24h of AA treatment. 
PPARγ was expressed around 15-fold more than the empty vector control in 
basal conditions (Figure 3.24 A). aP2 mRNA levels were up-regulated in the 
presence of PPARγ and there was a pronounced increase in the presence of 
AA (around 4-fold) (Figure 3.24 B). 
 
These data indicate that PPARγ is the PPAR that mediates the effect of AA on 
aP2 expression. The next step was to determine if this regulation is direct or 
indirect. For this reason ChIP experiments were conducted using a PPARγ 
antibody (data not shown) and primers designed to amplify the PPREs on aP2 
enhancer. None of the experiments performed yielded any enrichment of the 
target sequences with the PPARγ antibody and the reason might lie in the 
decrease of PPARγ protein levels upon AA treatment (Figure 3.24 C).  
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Figure 3.24: PPARγ expression enhances the effect of AA on aP2 expression. A) and B) 
80% confluent 3T3-L1 cells were transfected with a PPARγ expression vector (pSG5- 
PPARγ) or an empty vector (pcDNA) as a negative control and the next day were treated with 
AA (100μM) in the presence of MDI for 24h. The total RNA of the cells was isolated and 
analyzed using qRT-PCR for PPARγ and aP2 transcripts, respectively. These are 
representative graphs of two independent experiments (n=2). All expression levels are 
relative to the empty vector vehicle control set as 100. Error bars represent ±SD. C) 3T3-L1 
cells were treated with 1mM AA for 24h. Whole cell extracts were isolated and subjected to 
western blotting using antibodies against PPARγ and GAPDH. PPARγ migrates as two 
closely spaced bands on an SDS–polyacrylamide gel, the upper band is PPARγ2 and the 
lower band is PPARγ1. This antibody also recognises one unspecific band (ub) lower than 
PPARγ1. 
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3.2.4.4 PPARγ LBD mediates the effect of AA on aP2 expression 
 
Finally, the last question that was addressed was which domain of PPARγ 
was involved in the signalling of AA. These experiments were carried out in 
NIH-3T3 cells as they have been used previously to investigate the role of 
PPARγ in adipogenesis (Hu et al., 1996). Cells were transfected with wild type 
and different mutant versions of PPARγ expression vectors, treated for 24h 
with AA (1mM) and the endogenous aP2 expression was assessed (Figure 
3.25).  
 
The PPARγ2-S112A mutant expresses a PPARγ2 form that cannot be 
phosphorylated at the serine 112, the PPARγ2-E499Q mutant express a 
PPARγ2 form with a disrupted α-helix as a result a disrupted ligand-
dependent conformational change of the AF2 region and/or docking of 
cofactors (Hauser et al., 2000; Walkey and Spiegelman, 2008). Finally, the 
mutation of the PPARγ2-Q286P is in the middle of α-helix 3 of the LBD, which 
forms the backbone of the ligand-binding pocket. This mutant is unable to bind 
or be activated by all known agonists (Walkey and Spiegelman, 2008). 
 
As can be seen in figure 3.25 B and C, AA enhanced endogenous aP2 
expression with the empty vector control in comparison with the vehicle 
control and its effect was further increased when the cells were transfected 
with the wild type PPARγ2. When cells were transfected with the AF-2 mutant 
(PPARγ2-E499Q) the effect of AA on aP2 was lower in comparison with the 
wild type PPARγ2, whereas when transfected with the LBD mutant (PPARγ2-
Q286P) the effect of AA was similar to the basal levels. In addition, when cells 
were transfected with the phosphorylation site mutant (PPARγ2-S112A), the 
ability of AA to induce aP2 expression was not affected. These data indicate 
that the effect of AA on aP2 is mediated thorough PPARγ2 in a LDB-
dependent manner.  
 
Finally, to confirm the importance of the LBD, pre-confluent 3T3-L1 cells were 
transfected with a UASx4-TK-luc reporter plasmid, a Gal4-DBD–PPARγ-LBD 
expression plasmid and a renilla normalisation vector. The cells were 
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subsequently grown to confluence and induced to differentiate using the MDI 
protocol in the presence or absence of 100μM AA. Cells were harvested at 4, 
8, 12 and 24h time points and luciferase activity was measured and 
normalised to renilla activity. Normalised luciferase activity increased 
approximately 2-fold during the first 24h of the differentiation process in the 
presence of AA. These data indicate that AA could enhance the production of 
endogenous PPARγ ligands during this period (Figure 3.25 D). 
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Figure 3.25: PPARγ-LBD mediates the effect of AA on aP2 expression. A) Schematic 
representation of PPARγ with indications of the sites of the point mutations. B) and C) pre-
confluent NIH-3T3 were transfected with expression plasmids for PPARγ wild-type or PPARγ 
mutants. 24h after transfection, the cells were treated for 24h with or without 1mM AA. Total 
RNA was isolated and subjected to qRT-PCR for endogenous aP2. The graphs are 
representative of two independent experiments. Error bars represent ±SD. D) Pre-confluent 
3T3-L1 cells were transfected with a UASx4-TK-luc reporter plasmid, a Gal4-DBD– PPARγ -
LBD expression plasmid and renilla normalization vector, re-plated and subsequently induced 
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to differentiate in the presence or absence of 100μM AA. Cells were harvested at the 
indicated time points and analysed for luciferase and renilla activities. At each time point, 
luciferase activity was normalized to renilla activity.  The plot represent the mean values of 
three independent experiment (n=3). Error bars represent ±SEM. * P< 0.05, **P<0.01.  
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3.2.5 The function of aP2 increase after AA treatment 
 
3.2.5.1 The role of aP2 increase in FA metabolism 
 
aP2 has been suggested to have role on the distribution of lipids between the 
different compartments of the cell, such as to the LD for storage; to the ER for 
signalling, trafficking and membrane synthesis; to the mitochondria or 
peroxisome for oxidation; to cytosolic or other enzymes to regulate their 
activity; to the nucleus for lipid-mediated transcriptional regulation; or even 
outside the cell to signal in an autocrine or paracrine manner. Thus, it was 
hypothesised that the role of the aP2 increase at the early stages of 
differentiation after AA treatment could be related to changes in lipid 
metabolism. To investigate this, a PCR array was conducted on two days 
post-confluent 3T3-L1 cells after treatment with AA (1mM) for 24h. By using 
this PCR array we could monitor any changes in gene expression in 84 genes 
involved in FA catabolism, FA transport, FA biosynthesis regulation, 
ketogenesis and TAG catabolism (Figure 3.26). In figure 3.26 the fold 
increase of the genes after AA treatment in comparison with the BSA control 
used as a vehicle is shown. For significant changes we considered that a 
gene would have to change more than 2 fold (dotted line). In addition to aP2 
that showed around a 200-fold increase in comparison with the vehicle 
control, two other genes were found up-regulated by AA, changing around 3-
fold, Acsl4 and carnitine palmitoyltransferase 1A (CPT1a). To confirm the 
results taken from the PCR array, qRT-PCR was conducted in two days post-
confluent cells treated with increasing doses of AA. Acsl4 and CPT1a mRNA 
levels were increased but the up-regulation was significant only after 24h of 
treatment with the higher dose of AA. This result indicates that AA overload 
may regulate β-oxidation (Figure 3.27).  
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Figure 3.26: The effect of AA on lipid metabolism. A) PCR array was conducted in two 
days post-confluent 3T3-L1 cells treated with 1mM AA for 24h in the presence of MDI. RNA 
and cDNA was prepared according to the manufacturer‘s guidelines. The expression of genes 
involved in different aspects of lipid metabolism was assessed A) Relative expression of 
genes involved in FA catabolism, B) in FA transport, C) in FA biosynthesis regulation, D) in 
ketogenesis and E) in TAG catabolism. The graphs represent the mean values of duplicate 
samples. 
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Figure 3.27: The effect of AA on Acsl4 and CPT1a gene expression. A) and B) Two days 
post-confluent 3T3-L1 cells were treated with increasing doses of AA for 24h in the presence 
of MDI. Total RNA was isolated and subjected to qRT-PCR for Acsl4 and CPT1a, 
respectively. The graphs represent the mean normalized to vehicle control values of three 
independent experiments (n=3). Error bars represent ±SEM. **P< 0.01, ***P<0.001.  
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3.2.5.2 The role of aP2 increase in ER stress 
  
It was shown that palmitate can induce ER stress and also aP2 expression in 
macrophages. Both of these effects could be rescued by treating the cells with 
the chemical chaperone 4-phenyl butyric acid (PBA) which alleviates ER 
stress, showing that ER stress is mediated by aP2 in these cells (Erbay et al., 
2009). In addition, palmitate does not induce ER stress in aP2-/- macrophages 
which do not have any defects in FA uptake or response to other ER inducers. 
The same results were confirmed in vivo (Erbay et al., 2009). 
 
We hypothesised that the increase in aP2 expression stimulated by AA in pre-
adipocytes could have the same role as in macrophages by mediating ER 
stress. For this reason, two day post-confluent 3T3-L1 cells were treated with 
increasing doses of PBA together with 100μM AA for 24h. PBA, as mentioned 
before, can alleviate ER stress and, hence, provides an experimental 
opportunity to approach the role of aP2 up-regulation by AA mediating ER 
stress in pre-adipocytes. In contrast to macrophages, PBA could not block the 
AA-induced up-regulation of aP2 levels, indicating that in pre-adipocytes the 
role of aP2 is not connected with ER stress (Figure 3.28 A). Finally, to 
investigate if AA was inducer of ER stress, the expression of three ER 
markers were monitored after AA treatment (Figure 3.28 B, C). IRE1α, BiP 
and PERK expression was not regulated by any dose of AA, confirming that 
the aP2 up-regulation by AA is not correlated with ER stress.  
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Figure 3.28: The effect of AA effect on ER stress. A) Two-day post-confluent 3T3-L1 cells 
were treated with increasing doses of PBA (100μM, 5mM and 10mM) together with 100μM 
AA for 24h in the presence of MDI. Total RNA was isolated and subjected to qRT-PCR for 
aP2. B) and C) Two-day post-confluent 3T3-L1 cells were treated with 1mM or 100μM AA and 
whole cell lysates were subjected to western blotting with antibodies against IREα, BIP and 
PERK. 
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3.2.5.3 The role of aP2 increase in autophagy 
 
Macroautophagy is a lysosomal pathway for the degradation of cytosolic 
organelles and proteins. Macroautophagy can either be non-selective where a 
cytosol cargo with any content present is sequestered or it can be selective 
(mitophagy, ribophagy, lipophagy, aggregophagy, etc.). Thus any cargo 
(whole organelles or portions of cytosol) is engulfed by double-membrane-
bound structures termed autophagosomes that translocate to lysosomes for 
fusion to form autolysosomes and sequestered intra-autophagosomal 
components are degraded by lysosomal hydrolases (Singh and Cuervo, 
2011). Macroautophagy has been implicated in adipocyte differentiation. 
Knocking down a critical macroautophagy gene autophagy-related 7 (Atg7) in 
3T3-L1 cells resulted in inhibition of differentiation. The same observation was 
confirmed in adipocyte-selective Atg7-/- knockout mice which displayed 
reduced WAT mass (Singh et al., 2009a). Moreover, in hepatocytes inhibition 
of autophagy increased lipid accumulation, confirming that autophagy and 
lipid metabolism are interrelated (Singh et al., 2009b). We hypothesised that 
since the intracellular FA content is increasing with AA treatment then the 
increase in aP2 expression is a homeostatic mechanism for the transport of 
excess FA load to the autophagosomes for degradation.  
 
To investigate if AA-induced aP2 expression is related to the regulation of 
autophagy, 3T3-L1 cells were treated either with an inhibitor of 
autophagosome formation (3-methyladenine, 3MA) or an inducer of 
autophagy (rapamycin) and aP2 expression was monitored. 3MA enhanced 
the AA-dependent induction of aP2 expression whereas rapamycin inhibited 
AA effect on aP2 expression (Figure 3.29 A, B). To further confirm the 
pharmacological inhibition of autophagy on aP2 mRNA levels, 3T3-L1 cells 
were stably infected with an empty lentiviral vector (PGK) or with a vector 
expressing an shRNA to target the essential autophagy gene Atg7 (siATG7). 
Levels of Atg7 were markedly decreased in siATG7 cells after 24h of the 
differentiation induction (Figure 3. 29 D). PGK or siATG7 3T3-L1 cells were 
treated with AA (100μM) or PGF2α (10nM) for 24h in the presence of MDI and 
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the aP2 expression was assessed. In both AA and PGF2α treatments aP2 
expression was induced when autophagy was prevented (Figure 3.29 E).  
 
 
Figure 3.29: Inhibition of autophagy enhances the effect of AA on aP2 expression. A) 
3T3-L1 cells pre-treated with rapamycin (10μM) for 30min before the treatment with 100μM 
AA for 24h in the presence of MDI. Total RNA was isolated and subjected to qRT-PCR for 
aP2 transcipts. B) Cells were pre-treated with 3MA (10mM) prior to the AA (100μM) 
treatment. C) 3T3-L1 cells were treated as described in A and B and whole cell lysates were 
subjected to western blotting using antibodies against aP2 and GAPDH. D) 80% confluent 
3T3-L1 cells were infected with empty lentiviral vector (PGK) or with vector expressing an 
shRNA targeting Atg7 (siATG7). Total protein was isolated from PGK and siATG7 cells and 
immunoblotted with antibodies for Atg7 and GAPDH. E) On the third day after the infection, 
PGK and siATG7 3T3-L1 cells were treated with 100μM AA or 10nM PGF2α for 24h in the 
presence of MDI. Total RNA was isolated and subjected to qRT-PCR for aP2. All graphs are 
representatives from two independent experiments (n=2). Error bars represent ±SD. 
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To investigate whether aP2 has a role in autophagy we investigated 
responses in 3T3-L1 cells depleted of aP2 with a targeting shRNA. aP2 was 
increased upon AA treatment in the shSrambled cells whereas aP2 levels 
markedly decreased in shaP2 3T3-L1 cells  with or without AA treatment 
(Figure 3.30 A). ShScrambled and shaP2 cells were treated with 100μM AA 
for 24h in the presence of MDI and the expression of microtuble-associated 
protein light chain 3 (LC3) was determined. LC3 is a reliable marker of 
autophagosomes. Upon induction of autophagy, cytosolic LC3 I is conjugated 
to PE through two consecutive ubiquitylation-like reactions conducted by 
ATG7 and ATG3 to form LC3 II which is targeted to autophagic membranes. 
During the fusion of autophagosomes with the lysosomes LC3 II is also 
degraded by the lysosomal proteases. Thus, the amount of LC3-II correlates 
well with the number of autophagosomes and this characteristic conversion of 
LC3 can be used to monitor autophagic activity (Tanida et al., 2008).  
 
As it can be seen in figure 3.30 B, LC3 II levels were reduced in the absence 
of aP2 indicating that aP2 is required for autophagy. This effect does not 
seem to be AA related as treatment with AA does not influence autophagy. To 
further confirm that observation a time course experiment was conducted in 2-
days post-confluent wild-type 3T3-L1 cells treated with 100μM AA for 24h and 
LC3 and ATG7 levels were assessed (Figure 3.31 A, B). Autophagy as it can 
be assessed by LC3 II levels or ATG7 levels was declining over the period of 
24h and was not regulated by the presence of AA. Finally, the activity of the 
mammalian target of rapamycin (mTOR) which inhibits autophagy was not 
altered as determined by the phosphorylation status (Figure 3.31 C). 
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Figure 3.30 aP2 is required for autophagy. Two days post-confluent shaP2 and 
shScrambled 3T3-L1 cells were treated with 100μM or 500μM AA for 24h in the presence of 
MDI. Whole lysates were extracted and subjected to western blot using antibodies against A) 
aP2 and GAPDH. B) and C) LC3 and GAPDH. 
 
 
 
 
 
A 
B C 
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Figure 3.31 AA treatment does not affect autophagy. 3T3-L1 cells were treated with 
100μM or 1mM AA for 24h in the presence of MDI. Whole cell lysates were subjected to 
western blotting with antibodies against A) LC3 and α-tubulin B) ATG7 and GAPDH, C) p-
mTOR, total-mTOR and GAPDH. 
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3.2.6 The effect of AA on Fra-1 expression  
 
3.2.6.1 AA increases Fra-1 expression 
 
Fra-1 is an AP-1 transcription factor that is expressed early in adipocyte 
differentiation (Stephens et al., 1992), and Fra-1 transgenic mice show 
lipodystrophy. It has been shown to be induced by FAs and in particular oleate 
at the early stages of differentiation through transcriptional regulation (Distel et 
al, 1992).  
 
To determine if AA had any effect on Fra-1 expression during the early stages 
of adipocyte differentiation, 3T3-L1 cells were treated with increasing doses of 
AA in the presence of MDI and harvested after 24h of treatment. Fra-1 mRNA 
levels were increased with increasing doses of AA (Figure 3.32 A). Similarly, 
Fra-1 protein levels were increased by AA at 1mM and 100μM doses in the 
first 24h of the differentiation procedure. The effect of AA on Fra-1 protein was 
detectable after only 4h of treatment which was more evident after 8h (Figure 
3.32 B, C). 
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Figure 3.32 AA increases Fra-1 expression. A) 3T3-L1 cells were treated with increasing 
doses of 10μM, 100μM or 1mM AA for 24h in the presence of MDI. Total RNA was isolated 
after 24h of treatment and qRT-PCR was performed. All relative Fra-1 mRNA levels are 
presented as mean percentages of the respective BSA (set as 100%) controls from three 
independent experiment (n=3). Error bars represent ±SEM. **P< 0.01, ***P<0.001. B) Cells 
were treated as described in A and whole lysates were harvested and probed with antibodies 
against Fra-1 and GAPDH. The blots are representative of two independent experiments.  
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3.2.6.2 The effect of AA on Fra-1 expression is PG-mediated 
 
To determine if this effect is due to AA itself or its metabolites 3T3-L1 cells 
were pre-treated with indomethacin (a general COX inhibitor) or selective 
inhibitors for COX-2 (SC-236) and COX-1 (SC-560) for 30min and then 
treated with AA 100μM for 24h. Similarly, cells were pre-treated with a 12/15 
LOX inhibitor (baicalein) and a general P450 monoxygenase inhibitor (17-
ODYA). 17-ODYA did not have any effect on Fra-1 expression whereas 
baicalein increased levels of Fra-1, indicating unspecific effects (Figure 3.33 
C, D). The effect of AA on Fra-1 expression was substantially reduced by 
COX inhibitors indicating that PGs mediate the effect of AA on Fra-1 
expression (Figure 3.33 A, B). 
 
To determine which PG is important for Fra-1 up-regulation, a dose–response 
experiment was conduced treating pre-adipocytes with increasing doses of 
cPGI2, PGF2α, PGE2 and 15-deoxy-Δ
12,14 PGJ2 and Fra-1 expression was 
assessed. Only PGF2α increased significantly Fra-1 levels using the 10nM 
concentration (Figure 3.34 A). A time course experiment was conducted using 
10nM PGF2α and RNA and protein were harvested at different time points 
over a period of 24h. Fra-1 mRNA levels were increased with AA over time 
peaking at 24h (Figure 3.34 B). However, the kinetics for Fra-1 protein levels 
were different from the RNA data showing an increase at 8h, then declining at 
12h and then rise again at 24h (Figure 3.34 C). 
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Figure 3.33: The effect of AA on Fra-1 expression is PG-mediated. A) 3T3-L1 cells were 
pre-treated with A) indomethacin (10μM), B) a selective COX-2 (SC-236, 10μM) and a 
selective COX-1 inhibitor (SC-560, 10μM), C) baicalein (10μM) or D) 17-ODYA (10μM) for 30 
min prior to AA (100μM) treatment for 24h. Total RNA or whole cell lysates were isolated and 
qRT-PCR or western blot was performed. All relative Fra-1 mRNA levels are presented as 
mean percentages of the respective vehicle controls (set as 100%) from two independent 
experiment (n=2). Error bars represent ±SD. The antibodies used were against Fra-1 and 
GAPDH. The blot is representative of two independent experiments. 
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Figure 3.34 PGF2α increases Fra-1 expression. A) Two days post-confluent 3T3-L1 cells 
were treated with 1nM, 10nM, 100μM, 1μM or 10μM PGF2α, PGE2, cPGI2 and 15d-PGJ2 for 
24h in the presence of MDI. The total RNA was isolated after 24h of treatment and qRT-PCR 
was performed for Fra-1 mRNA transcripts. All relative mRNA levels are presented as mean 
percentages of the respective vehicle controls from three independent experiments (n=3). 
Error bars represent ±SEM.  **P<0.01. The red line is the PGF2α treatment. B) Two days post-
confluent 3T3-L1 cells were treated for 24h with 10nM PGF2α and B) RNA and C) protein 
were harvested at the indicated time points and subjected to qRT-PCR and western blot 
respectively. All relative mRNA levels are presented as mean percentages of the respective 
vehicle controls from three independent experiments (n=3). Error bars represent ±SEM. 
***P<0.001. 
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3.2.6.3 The effect of AA on Fra-1 expression is FP receptor-mediated 
 
To further confirm that PGF2α regulates Fra-1, cells were pre-treated with an 
FP receptor antagonist (AL 8810), an EP4 receptor antagonist (L-161,982) 
and an IP receptor antagonist (CAY-10441) before the AA treatment for 24h 
(Figure 3.35). Only the FP antagonist could significantly block the effect of AA 
on Fra-1 expression (Figure 3.35 A). In addition, Fra-1 up-regulation by AA 
was blocked completely when cells were depleted of the FP receptor using a 
targeting siRNA (siFP) when compared with siControl (Figure 3.35 B).   
 
 
 
Figure 3.35: The FP receptor mediates the effect of AA on Fra-1 expression. A), C) and 
E) 3T3-L1 cells were pre-treated with AL 8810 (10μM), L-161,982 (10μM) or CAY-10441 
(10μM) for 30 min prior to 100μM AA treatment for 24h. Total RNA was extracted and 
subjected to qRT-PCR for Fra-1 mRNA transcript. All relative mRNA levels are presented as 
mean percentages of the respective vehicle controls from three independent experiments 
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(n=3). Error bars represent ±SEM. **P<0.01. B) 80% confluent 3T3-L1 cells were transfected 
with a non targeting control siRNA (siControl), an siRNA targeting the FP receptor (siFP) On 
the third day after transfection, cells were treated with 100μM AA for 24h in the presence of 
MDI. Whole lysates were isolates and subjected to western blotting with antibodies against 
Fra-1 and GAPDH. The blot is a representative of three independent experiments. D) Cells 
were treated as described in B but cells were transfected with an siRNA targeting the EP4 
receptor (siEP4). Total RNA was extracted and subjected to qRT-PCR for Fra-1 mRNA 
transcript. Graph is a representative from two independent experiments. Error bars represent 
±SD. 
 
3.2.6.4 The signalling pathway mediating the effect of AA on Fra-1 
expression 
 
To elucidate the signalling pathway by which AA regulates Fra-1 expression, 
3T3-L1 cells were pre-treated with a PKA inhibitor (H89) or a PKC inhibitor 
(GF 109203X) prior to AA treatment for 24h (Figure 3.36 A-E). H89 
substantially blocked the ability of AA to induce Fra-1 expression. As a 
positive control, cells were pre-treated with H89 and then treated with forskolin 
for 24h (Figure 3.36 B, C). Forskolin activates adenylyl cyclase (AC) and 
causes the increase of the intracellular levels of cAMP. Forskolin was able to 
increase Fra-1 expression which was blocked with H89, indicating that cAMP 
increase is important in Fra-1 regulation. In addition, 3T3-L1 cells were pre-
treated with a PKC inhibitor (GF 109203X) prior to AA treatment (100μM) for 
24h. The PKC inhibitor blocked significantly the effect of AA on the increase in 
Fra-1 protein and mRNA levels (Figure 3. 36 D, E). In conclusion, both PKC 
and PKA inhibitors blocked the effect of AA on Fra-1 expression. 
 
Finally, Fra-1 is reported to be regulated by the ERK pathway both 
transciptionally and post-translationally (Casalino et al., 2003). Therefore, to 
investigate if ERK mediates the effect of AA on Fra-1 expression, 3T3-L1 cells 
were pre-treated with a MEK1 inhibitor (PD98059) or a MEK 1/2 inhibitor 
(U0126), before AA stimulation for 24h. PD98059 or U0126 blocked the ability 
of AA to induce Fra-1 expression, suggesting a role of ERK in Fra-1 up-
regulation by AA (Figure 3.36 F, G). 
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Figure 3.36: PKA, PKC and ERK mediate the effect of AA on Fra-1 expression. A) 3T3-
L1 cells were pre-treated with H89 (10μM) for 30 min prior to 100μM AA treatment for 
24h.Whole cell lysates were isolated and subjected to Western blotting using antibodies 
against Fra-1 and GAPDH. The blot is a representative of two independent experiments. 3T3-
L1 cells were pre-treated with H89 (10μM) for 30 min prior to Forskolin (10μM) treatment for 
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24h. Whole cell lysates (B) or total RNA (C) was isolated and subjected to Western blotting or 
qRT-PCR, respectively for Fra-1 expression. D) As described above but cells pre-treated with 
a PKC inhibitor (GF109203X) prior to AA (100μM) stimulation for 24h. F) and G) as described 
above but cells pre-treated with PD98059 (10μM) or a U0126 (10μM), respectively.  
 
3.2.6.5 The effect of AA on Fra-1 expression is PPARγ-mediated  
 
It has been suggested that Fra-1 might be regulated by PPARγ since its 
expression is elevated after rosiglitazone treatment in 3T3-L1 cells 
(Albrektsen and Fleckner, 2001). To investigate the role of PPARγ mediating 
the effect of AA on Fra-1 expression, 3T3-L1 PPARγ knockdown cells 
(shPPARγ) were treated with AA (100μM) or PGF2α (10nM) for 24h and Fra-1 
expression was assessed (Figure 3.37 A, B). In the absence of PPARγ, AA- 
or PGF2α–dependent induction of Fra-1 mRNA levels was significantly 
reduced, indicating that PPARγ is crucial for the regulation of Fra-1 by AA. We 
also examined Fra-1 expression in wild-type 3T3-L1 cells where PPARγ was 
overexpressed. PPARγ mRNA levels were increased around 15-fold (Figure 
3.24 A). Fra-1 mRNA levels were increased after AA treatment in the empty 
vector negative control whereas Fra-1 levels were enhanced in the presence 
of exogenous PPARγ and further increased with AA treatment (Figure 3.37 
C).  
 
To further characterise the regulation of Fra-1 by AA through PPARγ, two 
sequences of Fra-1 promoter were cloned upstream the luciferase gene. 
These sequences were chosen from a PPARγ ChIP sequencing experiment 
during the differentiation of 3T3-L1 that identified binding of PPARγ on the 
Fra-1 promoter at these sites (Nielsen R. personal communication) (Figure 
3.38 A). These sequences are upstream the transcription start site and likely 
to be regulatory elements. Peak 1 is designated the 736bps element found 
from -14,728 to -13,992bp and peak 2 is the 849bps element found -3,277 to -
2,488bp upstream Fra-1 transcription start site. 3T3-L1 cells were transfected 
with Fra-1 peak 1 and peak 2 luciferase constructs together with PPARγ and 
treated with AA (1mM) for 24h in the presence of MDI. Both reporter 
constructs responded to some extent to AA but Fra-1-peak 1 displayed a 
greater response to AA that was further enhanced by the presence of PPARγ 
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(Figure 3.38 B, C), indicating that this sequence might be important for the 
regulation of Fra-1 expression by AA via PPARγ.  
 
Figure 3.37: PPARγ mediates the effect of AA on Fra-1 expression. A) shPPARγ and 
shScrambled 3T3-L1 cells were treated with AA 100μM  for 24h in the presence of MDI. The 
total RNA was isolated and analyzed using qRT- PCR. Relative Fra-1 mRNA levels were 
expressed as percentage of the respective negative control stimulated with vehicle only. The 
plot represent the mean values of three independent experiment (n=3). Error bars represent 
±SEM. **P< 0.01. B) As in A, but cells were treated with PGF2α 10nM respectively, for 24h in 
the presence of MDI. Relative Fra-1 mRNA levels were expressed as percentage to the 
respective negative control stimulated with vehicle only. The plots are representatives of two 
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independent experiments (n=2). Error bars represent ±SD. C) 80% confluent wild-type 3T3-L1 
cells were transfected with a PPARγ expression vector (pSG5- PPARγ) or an empty vector 
(pcDNA) as a negative control and the next day were treated with 100μM AA in the presence 
of MDI for 24h. The total RNA of the cells was isolated and analyzed using qRT-PCR for Fra-
1 transcripts. The graph is a representative of two independent experiments (n=2). All 
expression levels are relative to the empty vector vehicle control set as 100. Error bars 
represent ±SD. 
 
 
Figure 3.38 PPARγ mediates the effect of AA on Fra-1 expression through sequences 
found upstream the transcription start site of Fosl1 gene. A) ChIP-seq data during 3T3-
L1 adipocyte differentiation showing PPARγ sites for Fosl1 locus. Base positions are 
indicated above. Green arrows indicate PPARγ binding (adapted from Nielsen R., personal 
communication). 80% confluent 3T3-L1 cells were transfected with Fra-1-peak 1 (B) and Fra-
1 peak 2 (C) luciferase constructs together with PPARγ expression vector and a renilla 
Fra-1-luc (peak 1)
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construct. The next day cells were treated with 1mM AA in the presence of MDI. After 24h the 
cells were harvested and the luciferase activity was measured. Activation of the luciferase 
reporter is expressed after normalisation for the renilla luciferase activity. The plots are 
representative of two experiments (n=2). Error bars represent ±SD. 
 
3.2.7 Regulation of aP2 expression by Fra-1  
 
aP2 and Fra-1 genes are both regulated from AA at the early stages of 
differentiation. The aP2 promoter has an AP-1 site where c-fos binds (Distel et 
al, 1987). Therefore, we hypothesised that in addition to PPARγ, Fra-1 might 
also regulate aP2 expression. ChIP experiments were conducted using two 
days post-confluent 3T3-L1 and treated with AA (1mM) for 24h and chromatin 
was immunopreciptated with a Fra-1 antibody. The data show that Fra-1 is 
bound to the aP2 promoter and binding is further enhanced by treatment with 
AA (Figure 3. 39 A). 
 
To further investigate the functional significance of the Fra-1 binding on aP2 
promoter, reporter assays were conducted using the aP2 promoter/enhancer 
construct, co-transfecting increasing doses of Fra-1 expression vector and 
treating with AA for 24h in the presence of MDI. aP2 promoter/enhancer 
activity was not enhanced by Fra-1 (Figure 3.39 B). However, Fra-1 binds on 
promoter/enhancer sequences as a heterodimer with a member of the Jun 
protein family. Thus, 3T3-L1 cells were transfected with Fra-1 in combination 
with different Jun proteins, treated with AA in the presence of MDI and 
endogenous aP2 mRNA levels were assessed. Only the Fra-1 and JunD 
combination was able to enhance the effect of AA on aP2 expression (Figure 
3.39 C).  
 
Finally, to confirm the role of Fra-1 on aP2 expression, Fra-1 was depleted by 
an siRNA targeting endogenous Fra-1, the cells were then treated with AA for 
24h and aP2 mRNA levels were assessed. Depleting cells from Fra-1 (around 
50%) did not have any effect on aP2 expression (Figure 3.39 D, E).  
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Figure 3.39 Regulation of aP2 expression by Fra-1. A) ChIP experiments were performed 
with cross-linked chromatin from two days post-confluent 3T3-L1 cells after treatment with 
1mM AA in the presence of MDI. Antibodies used were against Fra-1 and IgG as a negative 
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control. Precipitated DNA fragments were analysed by qRT-PCR and normalized to the input. 
The graph is a representative of three independent experiments. B) 80% confluent 3T3-L1 
cells were transfected with aP2 promoter/enhancer luciferase construct together with a Fra-1 
expression vector and a renilla construct. The next day cells were treated with 1mM AA in the 
presence of MDI. After 24h the cells were harvested and the luciferase activity was 
measured. Activation of the luciferase reporter is expressed after normalisation for the renilla 
luciferase activity. The plots are representative of two experiments (n=2). Error bars represent 
±SD.C) 80% confluent 3T3-L1 cells were transfected with Fra-1, JunB, JunD and c-jun 
expression vectors. The next day cells were treated with 100μM AA in the presence of MDI. 
After 24h the cells total RNA was isolated and subjected to qRT-PCR for aP2 expression. The 
graph is a representative of two independent experiment (n=2). Error bars represent ±SD. D) 
and E) 80% confluent 3T3-L1 cells were transfected with a non targeting control (siControl) 
siRNA or an siRNA targeting Fra-1 (siFra-1). On the third day after transfection, cells were 
treated with 100μM AA for 24h in the presence of MDI. Cells were harvested and total RNA 
was isolated and qRT-PCR was conducted for aP2 mRNA and Fra-1 transcripts. The graphs 
are representative of two independent experiments (n=2). Error bars represent ±SD. 
 
This observation indicates that maybe JunD is not expressed in sufficient 
concentrations upon AA treatment at this early time point of differentiation in 
order to interact with Fra-1 and regulate aP2. Based on this, the expression of 
different Jun proteins was examined by qRT-PCR and western blot (Figure 
3.40). JunB and c-Jun RNA levels were up-regulated with a high dose of AA 
(1mM) but JunD expression was not affected by any dose of AA. The protein 
levels of JunB and c-Jun were increased after 30min of the MDI induction in 
an AA-independent way and then declined in the 24h time course. In contrast, 
JunD protein levels were increased with AA treatment in the first 4h and then 
declined. In conclusion, the protein levels of all Jun proteins are very low after 
24h of induction of differentiation, and are not affected by AA treatment, 
making difficult to define the partner of Fra-1. 
 
Another explanation for the lack of any effect of Fra-1 absence on aP2 
expression could be a compensatory increase of another fos protein. For this 
reason the expression of c-Fos, Fra-2 and FosB was examined with 
increasing doses of AA or in the absence of Fra-1 (Figure 3.41). Only Fra-2 
expression was up-regulated with a high dose of AA whereas the other two 
Fos proteins were not affected by any AA dose. In the absence of Fra-1 none 
of the Fos proteins expression tested was affected.  
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In conclusion, Fra-1 is present on aP2 promoter after AA treatment and could 
regulate aP2 expression but further experiments need to confirm if Fra-1 has 
an effect on aP2 expression 
 
 
 
 
 
 
Figure 3.40: Expression of the Jun proteins after AA treatment in the early stages of 
differentiation. 3T3-L1 cells were treated either with increasing doses of AA and RNA was 
harvested after 24h of treatment or treated with 100μM AA and harvested at the indicated 
time points and whole cell lysates were harvested. qRT-PCR or western blotting was 
conducted for A) c-Jun, B) JunB and C) JunD. The values are mean percentages relative to 
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vehicle control (set as 100) of three independent experiments (n=3). Error bars indicate 
±SEM. 
 
 
 
 
 
Figure 3.41: Expression of the Fos proteins after AA treatment and after Fra-1 
depletion. 3T3-L1 cells were treated either with increasing doses of AA and RNA was 
harvested after 24h of treatment or transfected with siFra-1 and treated with 100μM AA for 
24h. qRT-PCR was conducted for A) c-Fos, B) Fra-2 and C) FosB. The values are mean 
percentages relative to vehicle control (set as 100) of three independent experiments (n=3). 
Error bars indicate ±SEM. 
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3.3 Discussion 
 
Excess fat has been correlated with hyperplasia and hypertrophy of AT. AA is 
one of the major PUFAs that is found in abundance in western diets. 
However, the role of AA in adipogenesis is controversial. Pre-adipocytes are 
exposed to changing levels of FAs under various normal and pathological 
metabolic states. It is not currently known how AA affects gene expression in 
pre-adipocytes and how this effect can alter their function. In the following 
sections, it will be discussed how AA regulates gene expression in the early 
stages of differentiation. 
 
3.3.1 The effect of AA on adipocyte differentiation markers 
 
The first observation made following treatment of pre-adipocytes with AA was 
a dose-dependent LD formation. LDs are predominantly found at the later 
stages of adipocyte differentiation when adipocytes are mature enough to 
store TAGs. However, LDs exist in virtually all types of cells when faced with 
lipid overload. In non-adipocytes, LDs are believed to function as lipid storage 
sites for later β-oxidation, membrane biogenesis, hormone synthesis, and 
other cellular functions. To delineate a potential enhancement of the 
differentiation program, the expression and the kinetics of a number of early 
and late adipocyte markers was assessed. The genes examined have a well-
established role in adipocytes and some of them are also implicated in lipid 
metabolism.  
 
It was found that AA altered the expression of only one late differentiation 
marker, aP2. The effect of AA on aP2 expression was dose- and also time-
dependent. This observation is in agreement with previous reports where the 
expression of aP2 in adipocytes has been shown to be transcriptionally 
controlled by FAs (Amri et al, 1991). In particular, it has been shown that aP2 
expression was increased by oleate treatment in pre-adipocyte lines (Distel et 
al, 1992).  
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Pre-adipocytes were treated with other PUFAs, such as EPA, DHA and LA to 
test the specificity of AA on aP2 expression. In vivo studies have shown that 
ω-3 PUFAs prevent HFD induced obesity in contrast to in vitro studies where 
EPA and DHA did not inhibit the differentiation program (Madsen et al., 2005; 
Manickam et al., 2010). However, there are no data describing the effect of 
these PUFAs on aP2 expression during the early stages of differentiation. All 
the PUFAs tested enhanced aP2 expression but AA seemed to be the most 
potent one. It should be noted that LA did not have a similar effect to AA on 
aP2 expression even though it is the precursor of AA. This might be because 
either the desaturases and elongases required to convert LA to AA are not 
highly expressed at this time point or these additional steps are delaying the 
potential effect of LA on aP2 expression.  
 
Finally, the effect of AA on adipocyte differentiation in combination with the 
different components of the differentiation cocktail has been reported 
previously. In this context, AA was a weak inducer of the differentiation in the 
presence of DEX, in the presence of insulin and DEX, AA was a promoter of 
differentiation, whereas in the presence of the full MDI, AA inhibited 
differentiation (Madsen et al, 2005). These results indicate that elevated 
cAMP levels (with the inclusion of IBMX) are central for the inhibitory effect of 
AA on differentiation. In the context of aP2 regulation by AA elevated cAMP 
levels seem to be also crucial.  
 
In conclusion, regulation of aP2 expression by AA is a gene-specific effect 
and does not alter the differentiation program. AA is a very potent PUFA 
enhancing aP2 expression and elevated cAMP levels might be important for 
this regulation. 
 
3.3.2 The AA effect on aP2 expression is PG-mediated 
 
Since AA can be metabolised by a number of enzymes to give rise to different 
eicosanoids, pre-adipocytes were treated with inhibitors of the three main 
enzymes using AA as a substrate. It has been shown before that these 
inhibitors can affect the adipocyte differentiation. Indomethacin is known to be 
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a direct ligand for PPARγ and is included in the differentiation cocktail for 
various pre-adipocyte lines (Lehmann et al, 1997) and as expected it does not 
inhibit adipocyte differentiation (Madsen et al, 2003). A concentration of 
baicalein between 10 and 20 μM has been shown to inhibit the differentiation 
of 3T3-L1 cells (Madsen et al, 2003). Finally, 17-ODYA does not have any 
effect on adipocyte differentiation (Madsen et al., 2003). From, these inhibitors 
only indomethacin blocked the induction of aP2 by AA, indicating that PGs 
mediate this effect. This observation is in agreement with previous reports, 
where PGs mediated the inhibitory effect of AA on adipocyte differentiation 
(Casimir et al., 1996). 
 
Further support for this observation is the fact that both COX-2 and COX-1 
mRNA expression was enhanced upon AA treatment. According to Pettersen 
et al., COX-2 and COX-1 are both expressed at the early stages of 
differentiation and they both peak during the first hours after the induction of 
differentiation and by 24h their expression decline. However, in the presence 
of AA, their expression is maintained after 24h of treatment (Pettersen et al., 
2003). Thus our data together with the previous reports indicate that products 
from both COX isoforms are necessary for mediating the effect of AA on aP2 
expression. 
 
PGs have been implicated in adipocyte differentiation and can have opposing 
effects. PGI2 and 15-deoxy-Δ
12,14 PGJ2 have a promoting effect whereas 
PGF2α and PGE2 have an inhibiting effect on adipocyte differentiation 
(Vassaux et. al, 1992; Forman et. al., 1995; Kliewer, et. al., 1995; Sugimoto 
et. al., 2004; Tsuboi et. al., 2004; Liu and Clipstone, 2007). The expression of 
different PG GPCRs was assessed and it was found that the FP, the EP4, the 
IP and the EP1 receptors are expressed at this stage of the differentiation. 
Our results are in agreement with previous publications where the expression 
of different PG receptor expression was tested during the differentiation of 
3T3-L1 cells (Tsuboi et al, 2004). However, the authors could not detect the 
EP1 expression early in the differentiation. This might be due to the fact that 
they used semi-quantitative PCR instead of qRT-PCR in combination with the 
low levels of the receptor. 
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3.3.3 The signalling pathway mediating the effect of AA on aP2 
expression 
 
To begin delineating the signalling pathway triggered by AA that leads to aP2 
expression regulation, the expression of different MAPKs was assessed. 
Using a p-JNK antibody we found that the bands detected are most likely 
attributable to ERK MAPK. This antibody is widely used and it was not 
possible to confirm with another one. In addition, AA did not show any effect 
on p-p38 MAPK activation. Although AA has been demonstrated to activate 
MAPKs in various cell types (Alexander et al, 2001; Talukdar et al, 2005), 
including p38 and JNK, there is relatively little reported about these pathways 
in the early stages of differentiation in adipocytes. Whereas the JNK pathway 
does not seem to be involved directly in adipocyte differentiation, p38 MAPK 
role remains unclear. There are conflicting results showing that p38 MAPK is 
essential for 3T3-L1 differentiation, whereas loss of p38 MAPK promotes 
adipogenesis in MEFs (Engelman et al., 1998; Aouadi et al., 2006). ERK 
MAPK signalling has been shown to be important for the early steps of the 
adipocyte differentiation program, whereas sustained activation of this 
signalling inhibits adipocyte differentiation (Prusty et al., 2002). Furthermore, it 
has been demonstrated that AA can activate ERK during the early stages of 
adipocyte differentiation (Pettersen et al, 2003). This is in agreement with our 
observations, where ERK was activated very early after the addition of MDI in 
the presence or absence of AA but its expression was above the basal levels 
when treated with AA. Finally, treating with a MEK inhibitor the effect of AA on 
aP2 expression was substantially blocked, showing that the ERK pathway is 
involved in the pathway triggered by AA to regulate aP2.  
 
The next step to define the signalling pathway activated by AA stimulation, 
leading to aP2 up-regulation was to determine the PG GPCR that mediates 
the effect of AA. GPCRs interact with G proteins composed of α, β and γ 
subunits. Agonist binding triggers a conformational change in the receptor, 
which catalyses the dissociation of Gα from Gβγ subunits. The α subunits of 
G proteins are divided into three main subfamilies: Gαs, Gαi and Gαq. A 
single GPCR can couple to either one or more families of Gα proteins. 
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Typically Gαs stimulates adenylyl cyclase (AC) and increases levels of cAMP, 
Gαi inhibits AC and lowers cAMP levels, and Gαq bind to and activate PLC, 
which cleaves PIP2 into DAG and IP3. IP3 triggers the release of calcium from 
intracellular stores, and DAG in conjunction with calcium ions recruits PKC to 
the membrane and activates it (Neves et al., 2002) (Figure 3.42). 
 
Figure 3.42: Schematic representation of some of the signalling pathways activated by 
GPCRs. GPCRs interact with G proteins subunits α, β and γ which are bound to GDP under 
resting conditions. Agonist binding results in dissociation of the GDP from the Gα subunit and 
binding to GTP whereas at the same time causes the dissociation of the Gα and Gβγ subunits 
from each other and from the GPCR. The Gβγ subunits can regulate certain downstream 
effectors, such as ion channels and PLC. The Gα subunits are divided into three subfamilies: 
Gαs, Gαi, Gαq. Typically the Gαs subunit activates AC leading to increases in intracellular 
cAMP, while Gαi subunit inhibits AC activity, decreasing cAMP levels. The Gαq subtype 
activates PLC, resulting in the production of IP3 and DAG. IP3, via its receptor, releases 
calcium from intracellular stores. These second messengers (cAMP, DAG and IP3) can 
modulate further downstream effectors, such as PKA and PKC (adapted from Ritter and Hall, 
2009). 
 
Either through pharmacological inhibition, by using a selective FP antagonist, 
or by depleting the FP receptor using siRNA, the effect of AA on ERK 
activation and aP2 up-regulation was blocked. Therefore, as ERK mediates 
the effect of AA on aP2 expression and since the FP receptor is essential for 
the ERK activation, then the FP receptor upon AA, signals to ERK which 
regulates aP2. This is in agreement with previous reports, showing that upon 
activation the FP receptor is triggering the MEK/ERK pathway to regulate the 
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expression of the COX-2 gene at the early stages of differentiation in 3T3-L1 
cells (Ueno and Fujimori, 2011). This report together with our data indicate 
that there is a positive feedback loop upon AA treatment COX-2 is induced 
which then elevates PG levels which in turn allow a further induction of COX-2 
and aP2 expression. 
 
In addition, AA causes the generation of two second messengers cAMP and 
Ca2+. We showed that the cAMP generation is through the EP4 receptor. This 
observation is in agreement with previous reports describing the EP4 to be 
Gαs coupled, activating AC to raise cAMP intracellular levels and through this 
pathway EP4 inhibits adipocyte differentiation (Tsuboi et al., 2004). We also 
show that the calcium generation is mediated through the FP receptor, as 
predicted for GPCRs coupled to Gαq. This observation is in accordance with 
reports that PGF2α inhibits adipocyte differentiation via a calcium-dependent 
signalling pathway (Liu and Clipstone, 2007). Therefore, AA treatment seems 
to activate both EP4 and FP receptors triggering different signalling pathways. 
These pathways do not appear to interact as a calcium chelator did not affect 
AA-mediated cAMP production. However, it cannot be excluded that cAMP 
could affect calcium signalling. Nevertheless, the calcium chelator blocked 
both ERK activation and aP2 up-regulation triggered by AA showing the 
importance of calcium as a second messenger for mediating responses to AA.  
 
As discussed in the previous section IBMX was the component of the 
differentiation cocktail necessary for the AA-dependent induction of aP2 
expression. This observation in combination with the fact that AA increases 
cAMP production, suggested that AA could act through a PKA-dependent 
pathway. However, when cells were treated with a PKA inhibitor, AA-induced 
aP2 up-regulation was not significantly blocked. On the other hand, both AA 
effects on aP2 and ERK were completely blocked when cells were treated 
with a PKC inhibitor. However, other targets of cAMP cannot be excluded. 
 
In conclusion, AA after its conversion to PGs by COXs, PGF2α is generated 
and binds to its membrane GPCR, the FP receptor. This binding causes the 
increase of intracellular calcium levels, which activate PKC and in turn 
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activates ERK. ERK signals through undefined steps to increase aP2 
transcription (Figure 3. 43).  
 
 
 
Figure 3.43: Schematic representation of the proposed mechanism triggered by AA to 
regulate aP2 expression in the early phase of adipogenesis AA is metabolised though 
COXs to PGs. PGF2α is generated and binds to the FP receptor which is coupled to Gαq 
triggering a calcium response. PKC is then activated and phosphorylate ERK which induces 
(through an unknown mechanism) aP2 transcription. It is also illustrated the pharmacological 
tools used to elucidate the signalling pathway. Indomethacin: COX inhibitor, GF109203X: 
PKC inhibitor, PD98059: ERK inhibitor, AL8810: FP antagonist, BAPTA-AM: calcium chelator.  
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3.3.4 The effect of AA on aP2 expression is PPARγ-mediated 
 
The importance of PPARγ in adipocyte differentiation is well recognised. 
Exogenous FAs are required for adipocyte differentiation since pre-adipocytes 
cannot differentiate in delipidated serum (Chawla and Lazar, 1994). Tzameli 
and colleagues have shown that PPARγ ligand(s) is produced early and 
transiently during adipocyte differentiation in a cAMP-dependent manner 
(Tzameli et al., 2004) However, the identity of the endogenous PPARγ 
ligand(s) promoting the early stages of adipocyte differentiation has so far not 
been identified. Studies showed that PGs can act as potential endogenous 
agonists promoting adipocyte differentiation. The naturally occurring 15d-PGJ2 
has been shown to activate PPARγ and promote adipocyte differentiation 
(Forman et al., 1995). However, there is evidence arguing that 15d-PGJ2 is 
not a bona fide endogenous agonist during adipocyte differentiation as the 
absolute levels detected in adipocyte cultures were not sufficient to activate 
PPARγ (Bell-Parikh et. al., 2003; Xie et. al., 2006). 
 
aP2 transcriptional regulation has been thoroughly described as both the aP2 
proximal promoter and enhancer have been well characterised. The aP2 
proximal promoter region contains binding sites for AP-1 at -120bp and 
C/EBPs at -140bp relative to the transcription start site (Christy et al, 1989). 
However, this proximal promoter is not sufficient or necessary to direct 
adipose-specific gene expression. Further upstream there is a 518bp 
enhancer element from -5.4kb to -4.9kb that drives gene expression to AT 
(Ross et. al., 1990). In this enhancer region two PPRE elements were found 
(Graves et. al., 1992), where the heterodimer PPARγ2/RXRα binds and drives 
adipose-specific aP2 expression (Tontonoz et. al., 1994a). 
 
Here we show that PPARγ mediates the effect of AA on aP2 expression in the 
early stages of adipocyte differentiation. The effect of AA on aP2 expression 
was blocked by both a pharmacological inhibition (using a selective PPARγ 
antagonist) and stable depletion of PPARγ. However, it was not possible to 
determine if the effect of PPARγ on aP2 expression was direct or indirect i.e. 
by binding directly to the PPREs of aP2 enhancer, as PPARγ protein levels 
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are greatly reduced upon AA treatment. This observation is in agreement with 
reports that ligands for PPARγ can decrease the amount of PPARγ protein 
(Hauser et al., 2000). However, according to the literature PPARγ requires a 
functional DBD to activate its target genes (Tontonoz et. al., 1994b), indicating 
that it must bind on the aP2 enhancer. In the presence of reduced PPARγ 
levels ChIP might not be a sensitive enough technique to detect this binding. 
 
Regulation of aP2 expression by FAs has been reported before in response to 
oleate in pre-adipocytes. However, the authors dismissed the idea of this 
event being PPARγ-mediated as none of other PPARγ gene targets were 
affected (Distel et al., 1992). Nevertheless, there are reports identifying 
PPARγ2 to be activated very early in the differentiation procedure when the 
ligands are not abundant, suggesting a key role for PPARγ2 in driving the 
initiation of adipogenesis (Saladin et al., 1999). Moreover, PPARγ has been 
shown to have a larger ligand binding cavity than observed in other nuclear 
receptors. This is likely to allow PPARγ to be more sensitive to the presence 
of a low concentration of ligands as it could be able to sense not only a single 
ligand but a pool of related ligands, making PPARγ a sensor of FAs (Itoh et 
al., 2008). Thus, as PPARγ2 is expressed early in the differentiation process 
the possibility is raised that it can be activated upon AA treatment during 
these early stages. AA could cause the generation of ligands for PPARγ which 
would activate it in order to regulate aP2, which unlike other PPARγ gene 
targets, is constitutively associated with co-activators (Guan et al., 2005).  
 
To test if AA is acting through the LBD of PPARγ, we used different mutant 
versions of PPARγ2, transfected into NIH-3T3 cells, treated with AA and 
assessed endogenous aP2 expression. These PPARγ mutants have different 
effects in the differentiation procedure. The PPARγ2-S112A mutant which 
express a PPARγ2 form that cannot be phosphorylated drives the 
differentiation program even more efficiently than the wild-type receptor (Hu et 
al., 1996). The PPARγ2-E499Q mutant has a disrupted α-helix as a result a 
perturbed ligand-dependent conformational change of the AF2 region and/or 
docking of cofactors. This mutated form can bind ligands but cannot drive the 
differentiation program as the mutated receptor is inactive (Hauser et al., 
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2000; Walkey and Spiegelman, 2008). Finally, the mutation of the PPARγ2-
Q286P occurs in the middle of α-helix 3 of the LBD, which forms the 
backbone of the ligand-binding pocket. This mutant is unable to bind or be 
activated by virtually all known agonists but can drive the differentiation 
program, indicating that a functional LBD is not necessary for adipogenesis 
(Walkey and Spiegelman, 2008). In the induction of aP2 the PPARγ2-Q286P 
mutant seems to block the action of AA, indicating that AA acts through the 
LBD. To confirm this observation, we presented evidence that the activation of 
a PPARγ LBD reporter during adipogenesis was sensitive to AA. 
 
We showed that PGF2α is the PG that mediates the effect of AA on aP2 
expression. However, PGF2α has been shown not to be a ligand for PPARγ 
(Yu et al., 1995; Forman et al., 1995), indicating that PGF2α is not the ligand 
produced by AA to mediate both effects on aP2 expression and PPARγ 
activation. PGF2α has been reported before (but also shown here) to activate 
ERK (Ueno and Fujimori, 2011). This ERK activation leads to the 
phosphorylation of PPARγ2 at the S112 residue (equivalent to S82 of 
PPARγ1). The phosphorylation of that residue has been shown to decrease 
PPARγ transcriptional activity (Camp and Tafuri, 1997; Hu et al., 1996). The 
same phosphorylation event has been shown to be caused by insulin that is 
an adipogenic agent included in the differentiation cocktail, showing that the 
ability to balance cell growth and differentiation is critical (Hu et al., 1996). 
 
There are reports of studies that elucidate the mechanism by which this 
phosphorylation event inhibits PPARγ activity. Adams et al. showed that 
phosphorylation of S112 affected both ligand-independent and ligand-
dependent transcription. The authors speculated that this phosphorylation 
event could influence transcription by altering the preinitiation complex 
formation or stability or might influence PPARγ interaction with specific 
coactivators or corepressors (Adams et al., 1997). Moreover, Shao et al. 
showed that there is an interdomain communication between the AF-1 domain 
(where the phosphorylation event occurs) with the LBD, indicating that the 
phosphorylation is affecting the ligand binding (Shao et al., 1998).  
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Taking together all our data, the PGF2α-FP receptor-calcium–PKC-ERK 
pathway seem to lead to the phosphorylation of PPARγ. However, AA 
increases also the intracellular cAMP levels which are connected with the 
production of PPARγ ligands at the early stages of differentiation (Tzameli et 
al., 2004) but also with the inhibition of ERK activity in adipocytes (Sevetson 
et a., 1993).Thus, it seems there is parallel pathway that is opposing the 
PGF2α pathway producing ligands for PPARγ. In conclusion, during the normal 
adipocyte differentiation program the endogenous PPARγ is in equilibrium 
between the phosphorylated and non-phosphorylated state. In the early 
stages of differentiation and upon AA treatment, PPARγ is activated by the 
AA-produced ligands which lead to aP2 activation whereas on the other hand, 
it gets phosphorylated and inactivated.  
 
3.3.5 The function of increased aP2 expression upon AA treatment 
 
Since aP2 up-regulation was established the next question addressed was the 
function of this increased expression. To answer that question, a PCR array 
was performed including 84 genes involved in FA metabolism. Following this 
approach we hypothesised that the pathways being affected by the increase 
of aP2 expression could be identified. For this reason pre-adipocytes were 
treated with AA and the genes Acsl4 and CPT-1a (in addition to aP2) were 
found to be up-regulated more than 2-fold. 
 
Acsl4 is a long chain acyl-CoA synthetase which preferentially uses AA as a 
substrate (Cao et al, 1998). Acsl4 converts AA into AA-CoA esters reducing 
intracellular free AA for both synthesis of cellular lipids, and degradation via β-
oxidation. Thus, it was logical for Acsl4 to be up-regulated upon AA treatment 
since AA has to be esterified in order to be used. The other gene up-regulated 
was CPT1a which is the key enzyme in FA oxidation. CPT1a is found in the 
outer membrane of mitochondria and catalyses the formation of long chain 
acyl-carnitine, which is enabled to traverse the inner mitochondrial membrane 
and thus committed to β-oxidation in the mitochondria (Gao et al., 2011). 
Overall this data suggested that the increase in the aP2 levels could mean 
that aP2 escorts the oversupply of AA to be degraded through the β-oxidation 
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process. However, preliminary data measuring β-oxidation (data not shown) 
indicated that β-oxidation was actually lower in the AA-treated cells in 
comparison with the untreated cells. Increased CPT1a mRNA along with 
increased β-oxidation has been reported before in epididymal fat of mice fed a 
rich EPA/DHA diet (Flachs et al., 2005). Moreover, increased β-oxidation but 
not increased CPT1a mRNA levels were observed in 3T3-L1 adipocytes when 
treated with EPA (Guo et al., 2005). There are currently no reports assessing 
the effect of AA treatment on β-oxidation in pre-adipocytes. In conclusion, 
more experiments are needed to define whether AA treatment promotes β-
oxidation, mitochondrial biogenesis or the effect on CPT1a mRNA levels is a 
gene-specific event. 
 
In parallel, genes that were down-regulated upon AA treatment were 
assessed. Similarly, genes that were down-regulated more than 2-fold 
considered to be significantly down-regulated. Only one gene appeared to be 
more than 2-fold down-regulated and also the vehicle control Ct value to be 
less than 30. This gene was the Acat2 or acyl CoA:cholesterol 
acyltransferase. Acat2 together with Acat1 are the enzymes that catalyse the 
cholesterol ester synthesis from cholesterol and long-chain fatty acyl-CoA 
(Tomoda and Omura, 2007). Down-regulation of this enzyme may indicate 
means that the main lipid found in LDs are TAGs and to a lesser extent 
cholesterol esters in pre-adipocytes upon AA treatment.  
 
A possible function of the increased aP2 expression could be to transfer AA 
for degradation through the macroautophagy pathway. Macroautophagy has 
been implicated in adipocyte differentiation. Knocking down Atg7 in 3T3-L1 
cells inhibited differentiation (Singh et al., 2009a). Inhibiting autophagy either 
by a pharmacological inhibitor or by a stable depletion of Atg7 further 
enhanced aP2 expression upon AA treatment. These data indicate that by 
blocking this degradative process, aP2 expression is enhanced due to 
increases in cellular lipid levels. Thus, to avoid the cellular lipotoxic effects, 
aP2 is induced to bind the excess lipid. On the other hand, when aP2 was 
depleted autophagy decreased but this time this effect was not AA-related. 
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These data show that aP2 expression is essential for the autophagy 
procedure to occur in pre-adipocytes, indicating that aP2 is mediating the 
transfer of lipids to autophagosomes or LDs which later could be sequestered 
in autophagosomes.  
 
3.3.6 The effect of AA on Fra-1 expression 
 
Fra-1 is a basic-leucine zipper (bZIP) AP-1 transcription factor that has been 
shown to be induced early in the adipocyte differentiation program (Stephens 
et al., 1992). In addition, Fra-1 expression is enhanced by PPARγ agonists 
(Albrektsen and Fleckner, 2001), FAs (Distel et al., 1992), mitogens 
(Adiseshaiah et al., 2003) and insulin (Hurd et al., 2002). We showed that Fra-
1 mRNA and protein levels were enhanced upon AA treatment at the early 
stages of differentiation. This effect was COX-mediated and PGF2α was the 
PG that could mimic the effect of AA. Furthermore, this observation was 
further confirmed by inhibiting the FP receptor either by pharmacological 
inhibition (FP antagonist) or by depleting the FP receptor. However, it should 
be noted that the effect of PGF2α on Fra-1 expression was not dose-
dependent as the higher doses of PGF2α failed to increase Fra-1 expression. 
One explanation is the homologous desensitisation i.e. a process occurring in 
response to high doses of an agonist to GPCRs which are then ‗‗turned off‘‘ or 
desensitized (Hosey, 1999). Thus, the FP receptor in response to high doses 
of PGF2α is inactivated unable to mediate the PGF2α effect on Fra-1 
expression In conclusion, the pathway AA-COX-PGF2α-FP regulates Fra-1 
expression at the early stages of adipocyte differentiation. This is the first time 
reported that Fra-1 is regulated by an AA metabolite.  
 
Since AA induces cAMP and calcium intracellular levels, PKA and PKC 
kinases could potentially be activated and regulate Fra-1 expression. Using 
selective inhibitors we found that both pathways have the potential to regulate, 
to some degree, the expression of Fra-1. However, the PKC inhibitor more 
efficiently blocked the effect of AA on Fra-1 mRNA and protein levels. This 
observation is in agreement with the FP receptor activation and its coupling 
with Gαq. Although there is no literature supporting these observations in 
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adipocytes, others have observed increased Fra-1 expression after treatment 
with isoproterenol, a cAMP-increasing and PKA-activating compound in 
chondrocytes (Mitchell et al., 2011). In astrocytes increased levels of Fra-1 
expression are reported after treatment with a phorbol-12-myristate-13-
acetate (PMA), a PKC-activating compound (Won and Suh, 2000). In 
conclusion, both PKA and PKC pathways could activate Fra-1 expression 
upon AA treatment. 
 
In addition, it was tested if the ERK activation by AA was involved in Fra-1 
induction. AA-induced Fra-1 up-regulation could be blocked by the addition of 
one of two different MEK inhibitors. This is in agreement with previous reports 
that have identified ERK as an important regulator of Fra-1 expression but not 
JNK1/2 or p38 (Adiseshaiah et al., 2008). The ERK pathway regulates Fra-1 
expression at two levels, transcriptionally but also post-translationally. It has 
been shown that ERK activates the transcription factors binding to regulatory 
elements found upstream the transcription start site of Fra-1 gene 
(Adiseshaiah et al., 2003; Adiseshaiah et al., 2005). ERK also phosphorylates 
Fra-1 protein in two serines, S252 and S265 stabilising the Fra-1 protein 
(Basbous et al., 2007). In addition, different thresholds of ERK activity control 
Fra-1 transcription and stability i.e. moderate ERK activation is enough to 
induce Fra-1 transcription whereas strong ERK activation leads to Fra-1 
phosphorylation preventing its degradation by the proteosome (Vial and 
Marshall, 2003). Finally, the ERK pathway has been shown to affect Fra-1 
function beyond regulating its transcription or protein stability but also 
regulating its transactivation activity as phospshorylation of Thr-231 by ERK is 
required for Fra-1 activation of its transactivation domain (Young et al., 2002). 
We show that AA increases cAMP intracellular levels through the EP4 
receptor that could lead to a pathway activating PKA. We also showed that 
PGE2 is activating ERK. Thus, it is possible even though the EP4 receptor 
antagonist does not have any effect on Fra-1 mRNA levels that there are two 
parallel pathways triggered by AA. One would be the AA-COX-PGF2α-FP-
PKC-ERK and the other one AA-COX-PGE2-EP4-PKA-ERK. In conclusion, it 
seems that the PGF2α pathway is the dominant pathway in Fra-1 induction as 
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the EP4 antagonist or the EP4 knockdown does not affect Fra-1 mRNA levels 
but still may play a role as its induction is PKA-dependent (Figure 3.44). 
 
Finally the role of nuclear receptor in driving Fra-1 transcription was 
investigated. Fra-1 has been shown to be transcriptionally regulated by c-Fos 
in rat fibroblasts by interacting with an AP-1 site on the first intron of Fra-1 
(Bergers et al., 1995). The same site was also shown to bind Fra-1 itself, 
revealing an autoregulatory mechanism sustaining Fra-1 expression (Casalino 
et al., 2003). In addition, three transcription factor binding elements, a 12-O-
tetradecanoylphorbol-13- acetate (TPA) response element (TRE/AP-1), an 
activating transcription factor (ATF/CREB) element and a serum response 
element (SRE) have been characterised in an enhancer element upstream 
Fra-1 transcription start site (Adiseshaiah et al., 2003; Adiseshaiah et al., 
2005). Rosiglitazone enhances Fra-1 expression in 3T3-L1 cells, indicating 
that PPARγ could play a role (Albrektsen and Fleckner, 2001). A PPARγ 
ChIP-sequencing experiment revealed that PPARγ binds to four different 
sequences upstream and downstream of the Fra-1 gene but also to a 
sequence found in the second intron, during 3T3-L1 differentiation (Nielsen R. 
personal communication). Thus, using two different approaches of depleting 
or overexpressing PPARγ, we showed that PPARγ can regulate Fra-1 
expression upon AA treatment. To further characterise this regulation, two 
sequences of the four detected from the PPARγ ChIP-sequencing experiment, 
were cloned upstream the luciferase gene. Peak 1 is the potential PPARγ 
binding element found approximately -14,000bps upstream the transcription 
start site. Based on the ChIP–sequencing analysis, PPARγ binds to that 
region as early as the first day of differentiation and the binding appears to get 
stronger during the course of the differentiation. The luciferase reporter 
construct harbouring peak 1 sequence was activated upon AA treatment and 
this activation was potentiated in the presence of PPARγ. These data indicate 
that this sequence could mediate PPARγ action on Fra-1 expression. 
However, further experiments need to be done in order to characterise this 
sequence as a novel PPARγ binding site on Fra-1 promoter.  
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Figure 3.44: Schematic representation of the proposed mechanism triggered by AA to 
regulate Fra-1 expression in the early phase of adipogenesis. AA is metabolised though 
COXs to PGs. PGF2α and PGE2 generated bind to their respective GPCRs, FP and EP4 
receptor respectively. FP is coupled to Gαq and EP4 to Gαs triggering calcium and cAMP 
generation, respectively. Both of these pathways activate ERK but the FP-mediated pathway 
is the dominant one (thick arrow). ERK induce Fra-1 transcription, stabilise and activate Fra-1 
protein. PPARγ is also regulating Fra-1 expression probably by a direct binding upstream the 
transcription start site of fosl1 gene. 
 
3.3.7 The regulation of aP2 expression by Fra-1 upon AA treatment 
 
It was investigated whether the up-regulation seen in both aP2 and Fra-1 
genes upon AA treatment was connected. There is only one report by Distel et 
al., correlating an AP-1 transcription factor with aP2. The authors identified 
binding of c-Fos on aP2 promoter characterising c-Fos binding as a negative 
regulator of aP2 gene expression (Distel et al., 1987). It is possible that Fra-1 
replaces c-Fos on the AP-1 site on aP2 promoter as Fra-1 has been shown to 
substitute for c-Fos (Fleischmann et al., 2000). Thus, Fra-1 binding on the 
aP2 promoter was investigated using primers flanking the AP1 site found at -
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120bps upstream the transcription start site of the aP2 gene (Christy et al., 
1989). Fra-1 was found to be recruited to the aP2 promoter in the vehicle-
treated cells indicating that the differentiation cocktail might drive this event 
due to Fra-1 being an early induced gene during the differentiation of 3T3-L1 
cells (Stephens et al., 1992). However, upon AA treatment a greater 
enrichment of Fra-1 on aP2 promoter was observed, indicating that AA drives 
Fra-1 recruitment to the aP2 promoter. It has been shown that AP-1 factors 
can act as either positive or negative regulators of transcription depending on 
their composition, the target gene, the cell context, or the signals received 
from the environment (Chinenov and Kerppola, 2001). To further investigate if 
Fra-1 binding has a positive or a negative impact on aP2 expression, different 
approaches were undertaken. Fra-1 overexpression and Fra-1 depletion did 
not affect on aP2 expression. However, Fra-1 depletion was around 50% 
which could mean that the remaining Fra-1 is enough to drive aP2 expression. 
Fos and Jun family proteins have both unique roles that cannot be 
compensated for by other family members but also overlapping functions. 
Thus, different Fos members could compensate for the lack of Fra-1. 
However, more experiments need to be undertaken to assess this question as 
the gene expression profile of the other Fos proteins did not indicate any up-
regulation to compensate for Fra-1 depletion. 
 
To further investigate the impact of Fra-1 on aP2 expression, Fra-1 was 
expressed in combination with different Jun proteins. AP1 factors through 
dimerization can form 18 different homo and heterodimers (Chinenov and 
Kerppola, 2001). The only combination that appeared to have a positive effect 
on aP2 expression greater than the empty vector control was the Fra-1 and 
JunD combination. The Fra-1 and JunD interaction has been shown before in 
differentiated 3T3-L1 cells upon rosiglitazone treatment (Albrektsen and 
Fleckner, 2001). However, further experiments need to be undertaken to 
characterise if this is a bona fide interaction upon AA treatment. Although, it 
should be noted that Fra-1 can interact with other bZIP transcription factors 
such as ATFs (such as ATF4) (Hai and Curran, 1991) but also with basic-
helix-loop-helix-leucine zipper (bHLHZip) transcription factors (such as USF1) 
(Pognonec et al., 1997). 
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Results: Arachidonic acid effects on the late 
stages of adipocyte differentiation 
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4.1 Introduction  
 
 
Adipocyte differentiation is a complex procedure involving the coordinated 
action of many different factors in a temporal sequence. In humans, AT 
develops in the second trimester of pregnancy and more extensively in the 
third trimester and after birth. However, adipogenesis occurs throughout the 
adult life as approximately 10% of adipocytes turn over in human AT every 
year (Spalding et al., 2008). Very little is known about the number or location 
of pre-adipocytes in vivo. Even less is known about how different stimuli at the 
early events of differentiation can affect the differentiation potential of pre-
adipocytes. Dietary fat has been correlated with hyperplasia of AT, thereby 
affecting the number of adipocytes (Faust et. al., 1978). Therefore, it was 
hypothesised that exposure of pre-adipocytes to AA can affect the early 
stages of AT development.  
 
In this chapter, experiments were designed to address if AA stimulus at the 
early stage of adipocyte differentiation can affect the differentiation potential of 
pre-adipocytes. The mechanism connecting the effect of AA at early events 
with the late events of differentiation is also addressed. 
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4.2. Results  
 
4.2.1 Inhibition of adipocyte differentiation after long exposure to AA 
 
To elucidate the effect of AA on the differentiation of 3T3-L1 cells, two days 
post-confluent cells (designated as Day 0 or D0) were treated with 1 mM, 
100μM or 10μM AA in the presence of the differentiation cocktail (MDI) for 10 
days (D10) (Figure 4.1). As a first indicator of differentiation, lipid 
accumulation was assessed by staining the cells with Oil Red O on D10 after 
the induction of differentiation. Control vehicle-treated cells became spherical 
and accumulated LDs. Treatment with 10μM AA did not have any effect on 
lipid accumulation, whereas treating with 100μM AA resulted in less lipid 
accumulation compared to the vehicle-control. Finally, in the presence of 1mM 
AA there was even less lipid accumulation (Figure 4.2).  
 
To further confirm the effect of AA on the adipocyte differentiation process, the 
expression of a number of differentiation markers was assessed. Treatment 
with 1mM AA resulted in the down-regulation of adipocyte marker genes such 
as aP2, PPARγ, C/EBPα, FAS, GLUT-4 and LPL. Down-regulation of these 
genes was also observed with 100μM but not with the lower dose 10μM 
(Figure 4.3). 
 
 
 
 
Figure 4.1: Experimental procedure for long exposure to AA. 3T3-L1 cells were induced 
to differentiate at two days post-confluence (D0) with DMEM containing 10% (v/v) FBS, 
250nM DEX, 0.5 mM IBMX and 170nM insulin. After 48 h and for the rest of the 
differentiation, the cells were replenished with DMEM containing 10% (v/v) FBS and 170nM 
insulin and the medium was changed every second day. AA conjugated with BSA was added 
when differentiation was induced on D0 and was present throughout the differentiation period. 
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Figure 4.2: AA-dependent inhibition of adipocyte differentiation after long exposure to 
AA-lipid accumulation. Two-day-post-confluent 3T3-L1 pre-adipocytes were induced to 
differentiate in the absence or presence of AA (10μM, 100μM or 1mM) with the standard 
differentiation cocktail. Cells were fixed and stained with Oil Red O on D10 of the 
differentiation program (20x magnification). 
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Figure 4.3: AA-dependent inhibition of adipocyte differentiation after long exposure to 
AA – gene expression of adipocyte markers. Cells were treated as described above. 
Briefly D0 3T3-L1 pre-adipocytes were induced to differentiate in the presence of increasing 
doses of AA throughout the differentiation program. Total RNA was harvested at the indicated 
time points and the expression of adipocyte markers A) aP2, B) PPARγ, C) C/EBPα, D) FAS, 
E) LPL and F) Glut-4 was analysed by qRT-PCR. All the time points indicate days post 
induction of differentiation. Data are presented as mean±SEM based on triplicate 
determinations from a representative experiment of two independent experiments. Student‘s 
t-test was performed for the D10 time point between the vehicle-treated and the AA-treated. 
*P<0.05, **P<0.01, ***P<0.001. 
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4.2.2 Inhibition of adipocyte differentiation after short exposure to AA 
 
The next question addressed was the effect of a short treatment with AA at 
the early stages of differentiation on the differentiation potential of the pre-
adipocytes. Thus, two days post-confluent 3T3-L1 cells were treated with 
different doses of AA for the first 24h of differentiation, then AA was withdrawn 
and the standard differentiation protocol was followed until D10 after the 
induction (Figure 4.4). The lipid accumulation was assessed by staining the 
cells with Oil Red O dye. Increasing doses of AA were inversely correlated 
with lipid accumulation (Figure 4.5 A). Furthermore, the ability of AA to inhibit 
lipid accumulation was confirmed by quantification of the intracellular TAG 
(Figure 4.5 B). To further investigate this observation the expression of some 
adipocyte differentiation markers was assessed by qRT-PCR. The expression 
of all the differentiation markers tested was much lower in the treated cells 
compared with the vehicle control-treated cells, for all the doses used (Figure 
4.6).  
 
 
 
 
 
 
 
 
Figure 4.4: Experimental procedure for short exposure to AA. D0 3T3-L1 cells were 
treated with AA for 24h in the presence of MDI. After 24h, AA was withdrawn and cells were 
kept in MDI for another 24h. The next day cells were kept in medium with insulin until the end 
of the differentiation D10. 
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Figure 4.5 Inhibition of differentiation after a short exposure to AA – lipid accumulation. 
A) Cells were treated as described in Fig 4.4. Briefly cells exposed to 100μM, 250μM, 500μM, 
750μM or 1mM AA for the first 24h of differentiation. Cells were fixed and stained with Oil Red 
O on D10 of the differentiation program (20x magnification). B) Cells were treated as 
described in A and lipids were quantified using AdipoRed stain and fluorescence measured 
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on D10 after the induction. Values shown are mean percentages of the respective vehicle 
controls (set as 100%). Data are presented as mean±SEM based on triplicate determinations 
from a representative experiment of two independent experiments. Student‘s t-test was 
conducted between the vehicle-treated and the AA-treated. * P < 0.05, ***P<0.001. 
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Figure 4.6: Inhibition of differentiation after a short exposure to AA – gene expression 
of adipocyte markers. 3T3-L1 cells were treated as described in Fig 4.4. Briefly, cells were 
treated with increasing doses of AA for 24h in the presence of MDI. After the 24h, AA was 
withdrawn and total RNA was isolated on D10 and subjected to qRT-PCR for A) aP2, B) 
PPARγ2, C) PPARγ1, D) C/EBPα, E) FAS and F) LPL. Values shown are mean percentages 
of the respective vehicle controls (set as 100%). Data are presented as mean±SEM based on 
triplicate determinations from a representative experiment of two independent experiments. 
Student‘s t-tests were conducted between the vehicle-treated and the AA-treated. * P < 0.05, 
**P<0.01, ***P<0.001. 
 
4.2.2.1 Kinetics of the inhibition of differentiation after short exposure to 
AA  
 
To investigate the kinetics of the inhibition, cells were treated for 24h with 
500μM AA in the presence of MDI, then withdrawn and harvested at different 
time points during the eight days of differentiation. On the eighth day of 
differentiation cells were stained with Oil Red O and quantified (Figure 4.7). 
LDs appeared after 24h AA of treatment in contrast to the vehicle control. 
After the withdrawal of AA and on the second day of differentiation, fewer LDs 
were present compared to the 24h time-point,, whereas there were no visible 
LDs in the vehicle–treated cells. On the fourth day of differentiation the 
vehicle-treated cells appeared to change their morphology, becoming more 
rounded and accumulating some lipid in contrast to the AA-treated which lost 
almost all their LDs. On the eighth day of differentiation the vehicle-treated 
cells had mature LDs whereas in the AA-treated cells, only few of them had 
LDs. Lipid content quantification confirmed the lipid accumulation in the AA-
treated cells for the first two days whereas the levels declined after the fourth 
day and appeared to be lower in comparison to the vehicle control on the 
eighth day (Figure 4.7 B).  
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Figure 4.7: Kinetics of the inhibition of differentiation after a short exposure to AA – 
lipid accumulation. A) Cells were treated as described in Fig 4.4. Briefly cells exposed to 
500μM AA for the first 24h of differentiation. Cells were fixed and stained with Oil Red O at 
the indicated time points (20x magnification) B) Cells were treated as described for A) and Oil 
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Red O was extracted in 100% isopropanol and quantified at the indicated time points. Values 
shown are mean percentages of the respective vehicle controls (set as 100%). Data are 
presented as mean±SEM based on triplicate determinations from a representative experiment 
of two independent experiments. Student‘s t-test was conducted between the vehicle-treated 
and the AA-treated. ***P<0.001.  
 
Total RNA and protein were isolated and the expression of some 
differentiation markers was assessed. The expression of all differentiation 
markers tested was lower in the cells exposed to AA for 24h at all points 
examined, with the exception of aP2. Its levels were much higher after 24h of 
treatment (in agreement with the previous chapter) but its levels fell below the 
vehicle-treated cells at the later time points (Figure 4.8). These observations 
were confirmed at the protein level. aP2 protein expression was increased 
after 24h of AA treatment and was above the basal levels after 48h. From the 
fourth day onwards the vehicle-treated cells appeared expressed more aP2 in 
comparison to AA-treated cells. The expression of PPARγ in AA-treated cells 
was below the basal levels in all time points tested (Figure 4.9). 
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Figure 4.8: Kinetics of the inhibition of differentiation after a short exposure to AA – 
gene expression of adipocyte markers. Cells were treated as described in Fig 4.4. Briefly, 
cells were treated with 500μM AA for 24h in the presence of MDI. After the 24h, AA was 
withdrawn and total RNA was extracted at the indicated time points. qRT-PCR was conducted 
for A) aP2, B) PPARγ2, C) PPARγ1, D) C/EBPα, E) Glut-4 and F) adiponectin. Values shown 
are mean percentages of the respective vehicle controls (set as 100%). Data are presented 
as mean±SEM based on triplicate determinations from a representative experiment of two 
independent experiments. Student‘s t-tests were conducted between the vehicle-treated and 
the AA-treated. * P < 0.05, **P<0.01, ***P<0.001.  
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Figure 4.9 AA short exposure inhibits the expression of aP2 and PPARγ. After AA 
treatment for the first 24h of differentiation whole cell lysates were harvested at the end of the 
differentiation procedure day 10-12. Western blotting was performed using antibodies against 
A) aP2 and B) PPARγ. The blots are representatives of two independent experiments. Ub: 
unspecific band. 
 
4.2.2.2 Differentiating pre-adipocytes are sensitive to the inhibitory effect 
of AA during the first 24h of differentiation.  
 
To define the time frame at which pre-adipocytes are sensitive to the inhibitory 
effect of AA, cells were treated for different time intervals during the 
differentiation procedure. The expression of adipocyte markers was assessed 
at the end of the differentiation procedure (Figure 4.10). The inhibitory effect 
of AA was maximal when present during the first 24h of differentiation. When 
AA was present between day 1 and 2 it still had an inhibitory effect on 
differentiation but was less in comparison to the 24h treatment. When AA was 
present after the second day of differentiation it did not affect the 
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differentiation. In conclusion, the presence of AA at the beginning of the 
differentiation procedure is crucial in order to exert its inhibitory effect.  
 
To further elucidate the timing of AA treatment to inhibit differentiation, cells 
were treated for shorter periods of time at the start of differentiation and the 
latter was assessed on D10 (Figure 4.10). There was no effect after treating 
the cells with AA for 2h or 4h at the beginning of the differentiation procedure. 
A small inhibitory effect was detectable after 8h of treatment. After 12h of AA 
treatment the effect was more evident but AA exert its maximum inhibitory 
effect on differentiation only after 24h. 
 
 
 
Figure 4.10: AA inhibitory effect is maximal when present during the first 24h of 
differentiation. A) Cells were treated with 1mM AA for the first 24h, between 24h and 2 days, 
between 2d and 4d, between 4d and 6d and between 6d and 8d. B) Cells were treated with 
1mM AA for the first 2, 4, 8, 12, or 24h of differentiation. Total RNA was extracted on D10 and 
qRT-PCR was performed for aP2, PPARγ and c/EBPα. Values shown are mean percentages 
of the respective vehicle controls (set as 100%). Data are presented as mean±SEM based on 
triplicate determinations from a representative experiment of two independent experiments. 
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Student‘s t-test was conducted between the vehicle-treated and the AA-treated. * P < 0.05, 
**P<0.01, ***P<0.001. 
 
4.2.2.3 A PPARγ ligand or prolonged exposure to MDI cannot rescue AA-
induced inhibition of differentiation  
 
Since PPARγ is the nuclear receptor regulating adipocyte differentiation, it 
was hypothesised that a high affinity PPARγ ligand would rescue cells from 
the inhibitory action of AA. To test this hypothesis, cells were treated with the 
PPARγ agonist, rosiglitazone in the presence or absence of AA for different 
time intervals at the beginning of differentiation and then aP2 and PPARγ 
mRNA levels were assessed on D10. As shown above, AA exerts its inhibitory 
effect after 24h of treatment. In contrast, rosiglitazone enhanced differentiation 
after 24h of treatment but lost this promoting activity when AA was present 
(Figure 4.11 A, B). 
 
In addition, it was hypothesised that AA instead of inhibiting it was rather 
causing a delay in the differentiation. To test this hypothesis, cells were 
treated with MDI for longer periods after the initial 24h AA treatment and the 
differentiation was assessed on D10. Thus, after AA withdrawal, MDI was 
added for one, two or three more days. The ability of AA to inhibit 
differentiation could not be rescued with the prolonged MDI treatment as 
shown by the expression of the differentiation markers aP2, PPARγ and 
C/EBPα, which was below the basal levels (Figure 4.11 C-E). 
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Figure 4.11: Rosiglitazone or prolonged MDI treated does not rescue the inhibition of 
differentiation by AA. A) 3T3-L1 cells were treated with 1mM AA, 10μM rosiglitazone or both 
for 2, 12 and 24h at the beginning of differentiation, after which the treatments were 
withdrawn and total RNA was isolated on D10. qRT-PCR was performed for aP2 and PPARγ. 
Graphs are representative of two independent experiments. Error bars indicate ±SD. B) Cells 
were treated with 1mM AA for the first 24h of differentiation in the presence of MDI. The next 
day AA was withdrawn and the cells kept in MDI for 1, 2 or 3 extra days (i.e. for a total of 2, 3 
or 4 days, respectively). RNA was isolated on D10 and qRT-PCR was performed for B) aP2, 
PPARγ and C/EBPα mRNA. Values shown are mean percentages of the respective vehicle 
controls (set as 100%). Data are presented as mean±SEM based on triplicate determinations 
from a representative experiment of two independent experiments. Student‘s t-test was 
conducted between the vehicle-treated and the AA-treated. * P < 0.05, **P<0.01, ***P<0.001.  
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4.2.2.4 The inhibition of differentiation after a short exposure to AA is 
not due to alternations in cell cycle, cell viability or induced cytotoxicity. 
 
To exclude any other possible causes for the inhibition of differentiation by 
AA, cell cycle, cell viability and cytotoxicity were tested after 24h of AA 
treatment.  
 
When post-confluent, growth-arrested 3T3-L1 pre-adipocytes are induced to 
differentiate with MDI the cells undergo two sequential rounds of mitosis over 
the next two days which is referred to as mitotic clonal expansion. The first 
round of mitosis is completed 24 to 36 h after induction, and the second round 
is completed 48 to 60h after induction. Therefore, since the treatment with AA 
is initiated during the period of the first mitosis, flow cytometry was employed 
to study the cell cycle by propidium iodide staining of cellular DNA. Cells were 
treated with a high dose of AA (1mM) for 24h. A total of 10,000 events were 
counted and the number of cells at each stage of the cell cycle was similar for 
control and AA-treated cells (Figure 4.12).  
 
In addition, D0 cells were treated with a high (1mM) and a low dose (100μM) 
of AA for 24h and assessed for cell viability using the MTT assay. An 
overnight treatment with 1% Triton X-100 was used as a positive control per 
supplier‘s instructions None of the doses of AA used affected cell viability 
relative to the vehicle control (Figure 4.13 A). 
 
Finally, the supernatants from cells following a 24h treatment with AA in two 
doses (100μM and 500μM) were assessed for the release of lactate 
dehydrogenase (LDH) activity. LDH is released from the cytosol of damaged 
cells into the supernatant. None of the two doses examined caused an 
increase in the LDH activity relative to the vehicle control (Figure 4.13 B).  
 
In conclusion, the inhibition of the adipocyte differentiation by a short 
exposure to AA, is not due to effects on cell cycle, cell viability or cytotoxicity 
caused by the doses of AA. 
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Figure 4.12: AA treatment does not affect the cell cycle. A) D0 3T3–L1 pre-adipocytes 
were cultured in the differentiation medium containing 1mM AA for 24 h, stained with a 
propidium iodide solution, and analysed by fluorescence-activated cell sorting. B) The 
percentage of cell population at each stage of the cell cycle was determined. The values 
represent mean percentages of three independent experiments (n=3). 
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Figure 4.13: AA treatment does not affect cell viability and does not cause cytolysis. A) 
3T3-L1 cell viability was assessed after AA treatment (1mM or 100μM) for 24h by MTT assay, 
graph of absorbance at 570 nm. 1% Triton X-100 was used as a positive control B) 3T3-L1 
supernatants were assessed after 24h of AA treatment for lactate dehydrogenase (LDH) 
activity, graph of absorbance at 490 nm. Values shown are mean percentages to vehicle-
treated (set as 100%) of three independent experiments (n=3). Error bars represent ±SEM. 
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4.2.2.5 Inhibition of adipocyte differentiation after short exposure to AA 
is mediated by PGs 
 
As it was discussed in Chapter 3 (Results 3.2.4 and 3.3.2), the effect of AA 
treatment in the first 24h of differentiation on aP2 and Fra-1 induction is 
mediated by PGs. To test if PGs also have a role in mediating the effect of AA 
on the inhibition of differentiation, cells were pre-treated with indomethacin, a 
general COX-inhibitor, prior to a 24h treatment with AA. Total RNA was 
isolated at the end of the differentiation procedure (D10) (Figure 4. 14 A, B). 
Indomethacin appeared to block the inhibition of differentiation by AA, as the 
levels of aP2 and PPARγ increased to levels comparable to the vehicle-
treated cells. Furthermore, COX-2 protein and RNA levels were assessed and 
both increased after a 24h of AA treatment in comparison with the vehicle 
control (Figure 4.14 C, D). RNA levels started declining on the second day of 
differentiation in contrast with the protein levels but both were still above the 
basal levels. At the later stages of differentiation COX-2 protein remained 
elevated in the AA-treated cells compared to the vehicle control levels, 
although RNA expression levels were similar between treated and untreated 
cells. 
 
Finally, cells were treated with individual PGs for the first 24h of differentiation, 
withdrawn and stained with Oil Red O on D10 of differentiation (Figure 4.15). 
Cells treated for the first 24h with PGF2α appeared to have reduced lipid 
accumulation in comparison with the other PGs and control. 
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Figure 4.14: Indomethacin blocked AA-induced inhibition of differentiation. Cells were 
pre-treated with indomethacin (10μM) for 30min before AA treatment (500μM) for the first 24h 
of differentiation in the presence of MDI. After 24h AA was withdrawn and the cells were 
treated according to the standard differentiation protocol until D10. Total RNA was isolated 
and qRT-PCR was performed for the differentiation markers A) aP2, B) PPARγ. The values 
represent means of three independent experiments (n=3) and they are expressed as 
percentages relative to the vehicle-control (set as 100%). Error bars indicate ±SEM. Student‘s 
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t-tests were conducted and a indicates p <0.05 between AA-treated and BSA-treated cells 
and b indicates p<0.05 between AA-treated cells in the presence or absence of indomethacin. 
C), D) Cells were treated as described above and RNA or whole cell lysates were harvested 
at the indicated time points. Western blotting was performed using antibodies against COX-2 
and GAPDH and qRT-PCR was performed for COX-2 transcripts. The blot and the graph are 
representatives of two independent experiments. Error bars represent ±SD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: PGF2α inhibits lipid accumulation. D0 cells were treated with 10μM cPGI2, 
PGE2, 15d-Δ
12,14
-PGJ2 and PGF2α for the first 24h of differentiation. After 24h PGs were 
withdrawn and stained with Oil Red O at the D10 of differentiation. Oil Red O was extracted in 
100% isopropanol and quantified. Data are presented as mean±SEM based on triplicate 
determinations from a representative experiment of two independent experiments. Student‘s 
t-test was conducted between the vehicle-treated and the PGF2α -treated. **P < 0.01. 
 
4.2.2.6 Inhibition of adipocyte differentiation after short exposure to 
PGF2α  
 
It was hypothesised that AA-dependent inhibition of differentiation was 
mediated by PGF2α given that PGF2α has been reported to inhibit adipocyte 
differentiation when present throughout the differentiation period (Liu and 
Clipstone, 2007). In addition, we had found that PGF2α mediated the effect of 
AA at the early stages of differentiation. To further investigate this hypothesis, 
cells were treated with AA for the first 24h of differentiation and the expression 
2
cP
G
I 2
P
G
E 2
-P
G
J
12
,1
4
15
-d
eo
xy
-
2
P
G
F
0
50
100
150
200
**
R
e
la
ti
v
e
 a
b
s
o
rp
ti
o
n
 A
5
1
0
n
m
(%
 v
e
h
ic
le
 c
o
n
tr
o
l)
Chapter 4  Results 
 199 
of the PGF2α synthase, AKR1B3 was examined during the whole course of 
differentiation (Figure 4.16 A). AKR1B3 mRNA expression in 3T3-L1 cells has 
been reported to be induced early in the differentiation procedure showing its 
peak at 24h and quickly decreased on the next day and maintained its low 
level during their differentiation into adipocytes (Fujimori et al., 2010). Upon 
AA treatment, AKR1B3 levels were increased after the 24h of differentiation, 
remained elevated after day two and declined to basal levels after day four of 
differentiation. The same trend was seen in the production of PGF2α but the 
levels were still above the basal levels on day eight (Figure 4.16 C). In 
addition, the expression levels of the PGF2α receptor, the FP receptor were 
increased upon AA treatment compared to the vehicle-treated cells on the 
second and fourth of differentiation (Figure 4.16 B). 
 
To test if the effect of a short treatment with PGF2α is capable of inhibiting 
differentiation in a similar manner to AA, cells were treated with serial doses of 
PGF2α for the first 24h of the differentiation, then withdrawn and either total 
RNA was isolated or the cells were stained with Oil Red O on D10 (Figure 
4.17). PGF2α at 10μM or 1 μM inhibited the expression of all the differentiation 
markers tested. An inhibitory effect was observed with 100nM PGF2α but it 
was much weaker than the higher doses and finally 10nM did not affect the 
expression of the differentiation markers tested. In accord with this 
observation, staining the cells with Oil Red O, 10μM or 1μM PGF2α strongly 
inhibited lipid accumulation whereas the lower concentration (100nM) had a 
weaker effect (Figure 4.18). In conclusion, PGF2α reproduced the inhibition of 
differentiation by AA after a short treatment of pre-adipocytes. 
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Figure 4.16: AKR1B3, FP receptor expression and PGF2α production after short 
treatment with AA. D0 cells were treated with AA (500μM) for the first 24h of differentiation. 
RNA and supernatants were isolated at the indicated time points until the eighth day of 
differentiation. qRT-PCR was performed for A) AKR1B3 and the B) FP receptor and C) PGF2α 
levels were measured using an EIA kit. Values shown as relative to the respective vehicle 
control (set as 100%). Data are presented as mean±SEM based on triplicate determinations 
from a representative experiment of two independent experiments. Student‘s t-test was 
conducted between the vehicle-treated and the AA -treated. * P < 0.05, **P<0.01, ***P<0.001. 
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Figure 4.17: Inhibition of differentiation after a short exposure to PGF2α –gene 
expression of adipocyte markers. D0 3T3-L1 cells were treated with 10nM, 100nM, 1μM or 
10μM of PGF2α for 24h in the presence of MDI. After 24h PGF2α was withdrawn and the cells 
were maintained in the differentiation cocktail. Total RNA was isolated on D10 and the qRT-
PCR was performed for A) aP2, B) PPARγ2, C) PPARγ1, D) C/EBPα, E) LPL and F) FAS 
mRNA. Relative expression was expressed as a percentage of the vehicle control (set as 
100%). Data are presented as mean±SEM based on triplicate determinations from a 
representative experiment of two independent experiments. Student‘s t-test was conducted 
between the vehicle-treated and the PGF2α-treated. *P<0.05, **P<0.01, ***P<0.001.  
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Figure 4.18: Inhibition of differentiation after a short exposure to PGF2α – lipid 
accumulation. D0 cells were treated with 10μM, 1μM or 100nM PGF2α for the first 24h of 
differentiation. Cells were fixed and stained with Oil Red O on D10 of differentiation (20x 
magnification).  
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4.2.2.7 Kinetics of the inhibition of differentiation after short exposure to 
PGF2α 
 
To determine the kinetics of the inhibition of differentiation by PGF2α, cells 
were treated with 1μM PGF2α for the first day of differentiation, then withdrawn 
and RNA isolated at different time points during the course of differentiation 
(Figure 4.19). aP2 expression was increased after 24h PGF2α  treatment in 
agreement with findings shown in Chapter 3. On the second day of 
differentiation and after PGF2α withdrawal, aP2 expression remained above 
the basal levels but from the fourth day onwards aP2 levels were lower than 
measured in the control cells. PPARγ and adiponectin expression levels were 
lower than control cells from the second day after treatment whereas C/EBPα 
expression was below the control levels after the first 24h of treatment (Figure 
4.19). 
 
To define more precisely the time at which PGF2α exerts its inhibitory effect, 
cells were treated for different time intervals during the differentiation 
procedure and the expression of aP2, PPARγ or C/EBPα was assessed at the 
end of the differentiation procedure. The inhibitory effect of PGF2α was 
dramatic when present either at the early time points between day 0 and day 
1 or between days 1 and 2 or present at the later stages of differentiation 
between day 4 and 8 (Figure 4.20 A). Finally, PGF2α had a strong inhibitory 
effect on the differentiation even when it was present only the first 2h of the 
differentiation (Figure 4.20 B). In conclusion, PGF2α strongly abrogated 
differentiation when added at the start or at the later stages of differentiation. 
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Figure 4.19: Kinetics of the inhibition of differentiation after a short exposure to PGF2α 
– gene expression of adipocyte markers. Cells were treated as described above. Briefly 
cells were treated with PGF2α (1μM) and withdrawn after the first 24h of differentiation. Total 
RNA was purified at the indicated time points. qRT-PCR was conducted for A) aP2, B) 
PPARγ2, C) C/EBPα  and D) adiponectin mRNA. Relative expression was expressed as a 
percentage of the vehicle control (set as 100%). Data are presented as mean±SEM based on 
triplicate determinations from a representative experiment of two independent experiments. 
Student‘s t-test was performed for the vehicle-treated and the PGF2α-treated cells. *P<0.05, 
**P<0.01, ***P<0.001. 
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Figure 4.20: PGF2α is a potent inhibitor of adipocyte differentation. A) D0 cells were 
treated with PGF2α 1μM for the first 24h, between 24h and 2 days, between 2d and 4d, 
between 4d and 6d and between 6d and 8d. B) Cells were treated with PGF2α 1μM for the first 
2, 4, 8, 12, or 24h of differentiation. Total RNA was isolated on D10 and qRT-PCR was 
performed for aP2, PPARγ and C/EBPα mRNA. The values are presented relative to the 
corresponding vehicle-treated control (set as 100%). Data are presented as mean±SEM 
based on triplicate determinations from a representative experiment of two independent 
experiments. Student‘s t-test was performed for the vehicle-treated and the PGF2α -treated. 
*P<0.05, **P<0.01, ***P<0.001. 
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4.2.2.8 The signalling pathway mediating AA-dependent inhibition of 
adipocyte differentiation  
 
As demonstrated in section 3.2.5, PGF2α activates ERK through its membrane 
GPCR, the FP receptor. Therefore whether the same pathway mediates the 
inhibition of differentiation by AA was examined. Cells were treated with AA 
(500μM) for the first 24h of differentiation only, and cells were harvested at 
different time points until D12 of differentiation. ERK was activated early in the 
differentiation procedure and p-ERK levels started to decline after the fourth 
day. However, in the presence of AA p-ERK levels were increased in 
comparison with the vehicle control on day 12 (Figure 4.21 A). These data 
indicated that ERK can play a role in the inhibition of differentiation by AA. 
Thus, cells were pre-treated with the MEK inhibitor PD9809 (10μM) before the 
AA 24h treatment and RNA was extracted on D10 of the differentiation (Figure 
4.21 B). The reason that this MEK inhibitor was used was that it has been 
shown not to interfere with the clonal expansion or the differentiation of pre-
adipocytes (Tang et al., 2003). PD9809 could rescue the inhibition of 
differentiation by AA, since the expression levels of aP2, PPARγ and C/EBPα 
were similar to the vehicle-control-treated cells. These data confirmed that 
ERK pathway mediates the effect of AA on the inhibition of differentiation. 
 
Finally, to determine if the inhibition of differentiation by AA is regulated by the 
FP receptor, an siRNA targeting the receptor (siFP) was used. The cells were 
maintained with the siRNA until the end of the differentiation (D10) and RNA 
or protein samples were prepared. siFP blocked the ability of AA to inhibit 
differentiation of 3T3-L1 cells, as judged by expression of aP2, PPARγ2/γ1, 
C/EBPα, LPL and FAS which were almost restored to the vehicle-treated cells 
(Figure 4.22). The protein expression of two differentiation markers aP2 and 
PPARγ was also determined. 24h of AA treatment at the beginning of 
differentiation inhibited the expression of aP2 and PPARγ protein in cells 
transfected with siControl, whereas in the presence of the siFP the levels of 
these markers were restored to levels similar to the vehicle-treated cells 
(Figure 4.23).  
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Figure 4.21: The ERK pathway mediates the inhibition of differentiation by AA. A) 3T3-
L1 cells were treated with AA (500μM) for the first 24h of differentiation and whole cell lysates 
were harvested at the indicated time points. Western blot was performed using antibodies for 
p-ERK, total-ERK and GAPDH. B) Cells were pre-treated with PD98059 (10μM) for 30min 
prior to 24h AA treatment. Total RNA was isolated at D10 and qRT-PCR was performed for B) 
aP2, C) PPARγ and D) C/EBPα. The values are presented relative to the corresponding 
vehicle-treated control (set as 100%). Data are presented as mean±SEM based on triplicate 
determinations from a representative experiment of two independent experiments. Student‘s 
t-tests were performed for AA-treated cells in the presence or absence of PD98059. *P<0.05, 
**P<0.01. Student‘s t-tests were performed for BSA and AA-treated cells in the absence of 
PD98059. a: ***P < 0.001, b: **P < 0.01, c: *P<0.05.  
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Figure 4.22: Depletion of the FP receptor prevents the inhibition of differentiation by 
AA–gene expression of adipocyte markers. 80% confluent cells were transfected with a 
non-targeting control (siControl) or an siRNA targeting the FP receptor (siFP). Three days 
after transfection the cells were treated with AA in the presence of MDI for 24h when AA was 
withdrawn and the transfection was repeated. The differentiation protocol was followed until 
D10. Total RNA was isolated and qRT-PCR was performed for A) aP2, B) PPARγ2, C) 
LPL mRNA levels
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PPARγ1, D) C/EBPα, E) LPL and F) FAS mRNA. The values are presented relative to the 
corresponding vehicle-treated control (set as 100%). Data are presented as mean±SEM 
based on triplicate determinations from a representative experiment of two independent 
experiments. Student‘s t-tests were performed for BSA and AA-treated siControl. a: ***P < 
0.001. Student‘s t-tests were performed for AA-treated siControl and siFP. b: **P < 0.01, c: 
***P<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23: Depletion of the FP receptor restores PPARγ and aP2 protein levels upon 
AA treatment. 3T3-L1 cells were transfected and treated as described in Fig 4.22. Briefly, 
cells were transfected with siControl or siFP and treated for 24h with AA (500μM). Whole 
lysates were extracted on D10 and subjected to Western blotting using antibodies for A) 
PPARγ and α–tubulin or B) aP2 and GAPDH. 
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4.2.2.9 Fra-1 mediates AA-induced inhibition of differentiation 
 
 
We found that Fra-1 expression is increased upon AA treatment at the first 
stages of differentiation (see section 3.3.1). Thus, it was hypothesised that 
Fra-1 could play a role in mediating the AA-dependent inhibition of 
differentiation. First, to test this hypothesis, Fra-1 expression levels were 
examined using the protocol of the short AA treatment for the first 24h of 
differentiation and cell lysates were harvested at different time points until the 
end of the differentiation procedure (Figure 4.24). Fra-1 protein levels 
increased after 24h AA treatment and started declining from the second day 
onwards. On the second day, the expression of Fra-1 in AA-treated cells was 
still above the basal levels. From the fourth day both vehicle-control and AA 
treated cells showed minimal levels of Fra-1, confirming that Fra-1 is 
expressed only during the early stages of differentiation (Figure 4.24).   
 
To elucidate a potential role of Fra-1 in the inhibition of differentiation by AA, 
cells were transfected with an siRNA targeting Fra-1, then treated with AA for 
the first 24h and the effect on the differentiation was evaluated on D10 either 
by an Oil Red O stain (Figure 4.25), or by qRT-PCR for the main 
differentiation markers (Figure 4.26). Depletion of Fra-1 was able to block the 
ability of AA to inhibit differentiation as the expression of all the differentiation 
markers tested in the presence of siFra-1 was similar to the vehicle-treated 
cells. This observation was further confirmed by Oil Red O staining where 
cells treated with AA and transfected with an siControl did not accumulate any 
lipid. Cells that were AA-treated and transfected with an siFra-1 they 
accumulated lipid at similar levels to the vehicle-control levels. 
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Figure 4.24: Fra-1 protein expression after a short treatment with AA at the early stages 
of differentiation. 3T3-L1 cells were treated with 500μM AA for the first 24h and whole cell 
lysates were isolated at the indicated time points during the differentiation procedure. Western 
blotting was performed using antibodies against Fra-1 and GAPDH. 
 
 
 
 
 
 
Figure 4.25 AA-induced inhibition of differentiation requires Fra-1–lipid accumulation. 
80% confluent cells were transfected with either siFra-1 or a non-targeting control (siControl). 
On the third day of transfection cells were treated with 500μM AA for 24h. The next day, AA 
was withdrawn and the differentiation protocol was carried out until D10. Cells were fixed and 
stained with Oil Red O and pictures were captured under a light microscope (20x 
magnification).  
siControl Vehicle siControl AA 500μM 
siFra-1 Vehicle siFra-1 AA 500μM 
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Figure 4.26: AA-dependent inhibition of differentiation requires the presence of Fra-1 – 
gene expression of adipocyte markers. 3T3-L1 cells were transfected with either siFra-1 or 
a non-targeting control (siControl), treated with 500μM AA for 24h and total RNA was isolated 
on D10. qRT-PCR was performed for A) aP2, B) PPARγ2, C) PPARγ1 and D) C/EBPα 
mRNA. Values shown are mean percentages of the respective vehicle control (set as 100%) 
of three independent experiments (n=3). Error bars represent ±SEM. Student‘s t-tests were 
performed for BSA and AA-treated siControl. a:***P < 0.001, d:*P<0.05. Student‘s t-tests were 
performed for AA-treated siControl and siFra-1. b: ***P < 0.001, c: *P<0.05. 
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4.2.2.10 Fra-1 regulates PPARγ phosphorylation  
 
PPARγ is the key nuclear receptor of adipogenesis. When PPARγ is not 
expressed or non-functional in pre-adipocytes then the cells lose their 
differentiation potential. Any agent that inhibits adipocyte differentiation is 
likely to affect either directly or indirectly the expression and/or function of 
PPARγ. Thus, it was hypothesised that AA treatment at the start of the 
differentiation could dysregulate PPARγ action resulting in the inhibition of 
differentiation. PGF2α has been shown before to result in increase 
phosphorylation of PPARγ at S112 leading to decreased transcriptional 
activity (Reginato et al., 1998). Thus, cells were treated for the first 24h of the 
differentiation with AA and whole cell lysates were harvested at the indicated 
time points (Figure 4.27 A). Total PPARγ levels were less in AA-treated 
compared to the vehicle-treated cells from the first 24h of treatment. The 
same trend was observed until the last of differentiation (day 8) which is 
consistent with the AA-induced inhibition of differentiation. In contrast, the 
levels of PPARγ phoshorylation at S112 appear to be elevated after AA 
treatment after the first 24h of treatment compared to the vehicle-treated cells 
and increases at the subsequent time points. In the untreated cells the 
phosphorylation status of PPARγ appears to be biphasic with an increase on 
the second day and then an increase on day 8. However, at both time points 
the phosphorylation was increased in the AA-treated cells (Figure 4.27 A). 
 
As showed in section 4.12, the depletion of Fra-1 could prevent the ability of 
AA to inhibit differentiation. Thus, it was investigated if the absence of Fra-1 
would affect the phosphorylation status of PPARγ at S112. Cells were 
transfected with the siControl and siFra-1 siRNAs, treated with AA and whole 
cell lysates were prepared at the end of the differentiation procedure. In 
siControl cells, AA treatment caused the increase in the phosphorylation 
status of PPARγ in comparison with the vehicle-treated cells. However in 
siFra-1 cells the phosphorylation status of PPARγ in AA-treated cells was 
similar with the untreated cells. In addition, the levels of total PPARγ appeared 
to be restored in the siFra-1 transfected cells treated with AA. (Figure 4.27 B). 
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In conclusion, it appears that Fra-1 is mediating the phosphorylation of PPARγ 
at S112 by an unknown mechanism.  
 
 
 
Figure 4.27: The phosphorylation of PPARγ at S112 is Fra-1-dependent. A) 3T3-L1 cells 
were treated with 500μM AA for the first 24h and whole cell lysates were isolated at the 
indicated time points during the differentiation procedure. Western blotting was performed 
using antibodies against for p-PPARγ (S112), total PPARγ and α –tubulin. B) 3T3-L1 cells 
were transfected with siControl or siFra-1 and treated for 24h with AA (500μM). Whole lysates 
were extracted on D10 and subjected to Western blotting using antibodies for p-PPARγ 
(S112), total PPARγ and α –tubulin. 
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4.2.2.11 Short exposure to AA at the start of differentiation keeps the 
cells into a pre-adipocyte state 
 
A short exposure to AA at the beginning of the differentiation procedure 
inhibits differentiation. However, the effects on cellular identity following the 
treatment could either be to promote the phenotype of non-functional 
adipocytes or cells restricted to the pre-adipocyte state. To assess this, the 
expression of Pref-1, GATA-2 and KLF-2 was examined. These genes are 
highly expressed in pre-adipocytes but decrease during differentiation and 
thus they are used as pre-adipocyte markers. Pref-1 expression increased 
dramatically after eight days of differentiation in the AA or PGF2α–treated cells 
in comparison with the vehicle-treated cells (Figure 4.28 A, B). GATA-2 
expression increased after the fourth day in the AA-treated cells whereas in 
the PGF2α-treated cells the expression was above the basal levels at all time 
points (Figure 4.28 C, D). Finally, KLF-2 expression was always above the 
basal levels at all time points in either AA- or PGF2α –treated cells (Figure 
4.28 E, F). In conclusion, short-term exposure of pre-adipocytes to AA or 
PGF2α promotes the expression phenotype of a pre-adipocyte. 
 
Since both the depletion of the FP receptor and Fra-1 rescued the inhibition of 
differentiation by AA, the expression of the pre-adipocyte markers was also 
assessed in cells under these conditions (Figure 4.29). Both siFP and siFra-1 
were able to prevent the increased levels of the pre-adipocyte markers due to 
AA treatment, indicating that both have a role in the sustained pre-adipocyte 
state caused by AA. 
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Figure 4.28: AA or PGF2α treatments at the beginning of the differentiation procedure 
retain cells in the pre-adipocyte state. 3T3-L1 cells were treated for the first 24h of 
differentiation with either AA (500μM) or PGF2α (1μM), then withdrawn and RNA was isolated 
at the indicated time points. qRT-PCR was conducted for A) and B) Pref-1, C) and D) GATA-2 
and E) and F) KLF-2 mRNA. Data are presented as mean±SEM based on triplicate 
determinations from a representative experiment of two independent experiments. Student‘s 
Pref-1 mRNA levels
1 2 4 8
0
100
200
300
400
AA 500 M
Time after treatment (d)
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
(%
 B
S
A
 c
o
n
tr
o
l)
*
Pref-1 mRNA levels
1 2 4 8
0
200
400
600
800
PGF2  1 M
Time after treatment (d)
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
(%
 e
th
a
n
o
l 
c
o
n
tr
o
l) **
A B 
GATA-2 mRNA levels
1 2 4 8
0
200
400
600
800
AA 500 M
*
Time after treatment (d)
R
e
la
ti
v
e
 e
x
p
re
s
s
s
io
n
(%
 B
S
A
 c
o
n
tr
o
l) *
GATA-2 mRNA levels
1 2 4 8
0
50
100
150
200
250
PGF2  1 M
Time after treatment (d)
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
(%
 E
th
a
n
o
l 
c
o
n
tr
o
l)
**
C D 
KLF-2 mRNA levels
1 2 4 8
0
200
400
600
800
AA 500 M
*
**
Time after treatment (d)
R
e
la
ti
v
e
 e
x
p
re
s
s
s
io
n
(%
 B
S
A
 c
o
n
tr
o
l)
**
KLF-2 mRNA levels
1 2 4 8
0
100
200
300
400
500
600
PGF2  1 M
***
Time after treatment (d)
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
(%
 E
th
a
n
o
l 
c
o
n
tr
o
l)
*
*
E F 
Chapter 4  Results 
 217 
t-test was conducted for the vehicle-treated and the AA- or PGF2α-treated cells. *P<0.05, 
**P<0.01. 
 
 
 
 
 
 
 
 
Figure 4.29: The FP receptor and Fra-1 are required for the AA-dependent up-regulation 
of pre-adipocyte marker genes. 3T3-L1 cells were transfected with siFP, siFra-1 or 
siControl, treated with 500μM AA for 24h and total RNA was isolated on D10. The expression 
of Pref-1, GATA-2 and KLF-2 was assessed after the depletion of the A) FP receptor or B) 
Fra-1. For A, data are presented mean±SEM based on triplicate determinations from a 
representative experiment of two independent experiments. Student‘s t-tests were performed 
for AA-treated siControl and siFP *P<0.05 or for BSA and AA-treated siControl. a:**P < 0.01, 
b:*P<0.05. For B, the graphs represent mean values from three independent experiments and 
error bars represent ±SEM Student‘s t-tests were performed for AA-treated siControl and 
siFra-1 *P<0.05 or for BSA and AA-treated siControl b:*P<0.05. 
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4. 3 Discussion 
 
To determine whether AA affects adipocyte differentiation, 3T3-L1 cells were 
treated with increasing doses of AA for the entire differentiation program. AA 
inhibited adipocyte differentiation in a dose-dependent manner. This 
observation is supported by previous reports showing that AA can inhibit the 
differentiation of 3T3-L1 cells (Casimir et al., 1996; Madsen et al., 2005) but 
also primary pre-adipocytes (Serrero and Lepak, 1997) and 1246 cells 
(Serrero et al., 1992). 
 
As reported in chapter 3, AA treatment for the first 24h of differentiation 
triggered a number of changes in cell signalling and gene expression. To 
investigate whether a short stimulation with AA at the beginning of the 
differentiation program modulates the differentiation potential of adipocytes, 
pre-adipocytes were treated during the first 24h and the differentiation was 
evaluated. AA abrogated the differentiation even when it was present only at 
the early stages of differentiation as the majority of the cells retained the 
morphological characteristics of fibroblasts and did not accumulate LDs. This 
was a dose-dependent effect as increasing doses of AA had an inverse effect 
on differentiation.  
 
The negative effect on the differentiation became apparent around the fourth 
day of the differentiation program when the AA-treated cells lost their initial 
LDs, whereas at the same time point the vehicle-treated cells became 
rounded and started accumulating lipid. Around the same time vehicle-treated 
cells started to express the mature differentiation markers whereas AA-treated 
cells failed to do so. In addition, AA lost its inhibitory effect when treatment 
started after the second day of differentiation or when present less than 24h. 
These data indicated that there is a window at the early stages of 
differentiation for AA to exert its inhibitory effect. This effect was not reversible 
either by the addition of a PPARγ ligand or a prolonged MDI treatment, 
showing that AA interferes with a critical early event during pre-adipocyte 
differentiation. 
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During the first 24h of differentiation, growth-arrested 3T3-L1 pre-adipocytes 
re-enter the cell cycle synchronously, undergoing mitotic clonal expansion, 
which is essential for the differentiation to occur (Tang et al, 2003). For this 
reason, cell cycle progression was tested and AA did not affect the cell 
number going through mitosis. Previous observations showed that PGF2α, a 
major AA metabolite does not interfere with the mitotic clonal expansion 
phase of adipogenesis (Liu and Clipstone, 2007). In addition, AA did not affect 
cell viability nor did it cause cytotoxicity indicating that there is another 
mechanism by which AA inhibits differentiation. 
 
PG synthesis was required for the action of AA as when cells were pre-treated 
with indomethacin, a general cyclooxygenase inhibitor, the expression of the 
differentiation markers of the AA-treated cells were at similar levels to the 
vehicle-control cells. In addition, elevated COX-2 expression was detected in 
both protein and RNA levels following AA treatment. In particular, COX-2 
protein expression was increased in the presence of AA above the basal 
levels until the end of the differentiation program. Elevated COX-2 expression 
by AA has been observed before. It has been also reported that indomethacin 
reduces COX-2 expression in AA-treated cells, indicating that PGs are 
necessary for maintaining COX-2 expression (Petersen et al., 2003). PG 
levels, in general, were shown to be lower in differentiated 3T3-L1 adipocytes 
compared to confluent or dividing pre-adipocytes (Hyman et al., 1982), 
supporting the observation that the inhibitory effect of AA on differentiation is 
likely to be an early event. 
 
The present study showed that PGF2α mimics the effect of AA on 
differentiation by inhibiting lipid accumulation when cells were treated for the 
first 24h of differentiation. PGF2α-dependent inhibition of differentiation was 
also a dose-dependent event as shown for AA. In addition, the kinetics of 
PGF2α inhibition was similar to AA as the inhibitory effect was apparent after 
the fourth day of differentiation. However, PGF2α proved to be a more potent 
inhibitory factor than AA, since PGF2α could exert its inhibitory effect during 
any time period tested and also as little as a 2h treatment was enough to 
inhibit differentiation. This finding is supported by previous reports showing 
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that fluprostenol, a selective FP receptor agonist could inhibit differentiation 
more than 60% when was present for only one hour at the beginning of the 
differentiation (Casimir et al., 1996). 
 
PGF2α has been shown to inhibit the differentiation of a number of adipocyte 
cell systems such as primary adipocytes (Serrero and Lepak, 1997), 1246 
cells (Serrero et al., 1992) and 3T3-L1 cells (Casimir et al., 1996; Miller et al., 
1996). PGF2α concentrations decreased during 3T3-L1 differentiation, an 
event that may allow cells to progress into terminal differentiation as 
maintaining preadipocyte-like levels of PGF2α prevents cells from 
differentiating (Casimir et al., 1996). This report was in agreement with our 
observations as in AA-treated cells, PGF2α levels were elevated above the 
basal levels until the end of the differentiation program, indicating the 
generation of a continuous inhibitory signal for differentiation. Furthermore, 
PGF2α synthase (AKRB13) expression had the same kinetics as COX-2 as it 
was increased after 24h of treatment and then reduced to basal levels by the 
end of differentiation. In addition, the FP receptor expression has been shown 
to be similar between pre-adipocytes and adipocytes (Miller et al., 1996) and 
the current data showed that in AA-treated cells the FP receptor expression 
was higher in comparison to the vehicle-treated cells. All these data indicate 
that the machinery for PGF2α production and function is expressed until the 
late stages of differentiation, at lower levels compared to the early stages, but 
still there to mediate the inhibitory effect of PGF2α.  
 
AA and PGF2α have been shown to enhance the activation of ERK1/2 
(Reginato et al., 1998; Petersen et al., 2003). This observation was replicated 
herein as ERK activation was sustained after 12 days of differentiation in AA-
treated cells. ERK activation has been shown to promote the clonal expansion 
at the early stages of differentiation (Prusty et al., 2002) but sustained 
expression has been linked with inhibition of differentiation (Petersen et al., 
2003). The prevention of ERK activation has little or no effect on adipogenesis 
(Petersen et al., 2003) and for this reason a MEK-inhibitor (PD98059) was 
used to assess whether the AA-induced inhibition of differentiation was ERK-
mediated. PD98059 could restore full adipogenesis in the presence of AA as 
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the expression levels of all the differentiation markers tested were similar to 
the vehicle-treated cells. Thus, ERK-activity was necessary for AA-mediated 
inhibition of adipocyte differentiation.  
 
As demonstrated in Chapter 3, ERK activation is mediated by the FP receptor, 
thus we hypothesised that PGF2α secreted after AA treatment, binds to FP 
receptor, activates ERK and inhibits differentiation. Depletion of the FP 
receptor could rescue the blockage of differentiation by AA, as cells in the 
absence of FP could express the differentiation markers at similar levels to 
vehicle-treated cells. However, further experiments need to be undertaken to 
directly link the FP receptor with ERK activation at the late stage of 
differentiation in the presence of AA. For example, assessing ERK 
phosphorylation after depletion of the FP receptor would establish that ERK 
activation is mediated by the FP receptor. However, this approach is limited 
as it is likely that ERK activation could be mediated by a variety of GPCR 
receptors expressed at the late stages of differentiation.   
 
It has been shown that the inhibitory effect of AA on differentiation is 
dependent upon the addition of cAMP elevating agents (Madsen et al., 2008) 
suggesting that the effect of AA is mediated by a PKA-sensitive pathway. 
However, although a PKA inhibitor was able to prevent the inhibition of 
differentiation by AA it could not inhibit ERK activation (Petersen et al., 2003). 
As revealed in Chapter 3, AA could enhance the generation of a calcium 
response. It has been established before that Ca2+-mobilising agents could 
inhibit adipogenesis (Ntambi and Takova, 1996). Furthermore, it has been 
suggested that the PGF2α-mediated inhibition of differentiation is through FP 
receptor-mediated increase in intracellular calcium increase (Miller et al., 
1996). However, a PKC inhibitor was not able to block the inhibition of 
differentiation by PGF2α (Miller et al., 1996). In conclusion, it is apparent that 
the regulation of adipocyte differentiation involves both PKA and PKC-
mediated signalling pathways. 
 
As described in Chapter 3, Fra-1 expression was increased by AA after a 24h 
treatment through a PKA- and a PKC-mediated pathway. Fra-1 was 
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expressed transiently, early in the differentiation procedure, but upon AA 
treatment its expression was increased above the basal levels until the 
second day of differentiation. Thus, we predicted that Fra-1 could play a role 
in the inhibitory effect of AA on adipocyte differentiation. Indeed, depleting 
Fra-1 expression could prevent the inhibitory effect of AA on the adipocyte 
differentiation. The role of Fra-1 in adipogenesis is largely unknown but it has 
been demonstrated recently that Fra-1 transgenic mice are lipodystrophic 
(Luther et al., 2011). This observation is in agreement with our data, 
implicating Fra-1 as an internal break in the differentiation procedure. It was 
suggested that Fra-1-dependent lipodystrophy was mediated by negatively 
regulating C/EBPα (Luther et al., 2011). However in our hands, although 
C/EBPα expression was reduced upon AA treatment, Fra-1 was not recruited 
on the C/EBPα promoter upon AA treatment (data not shown). 
 
As PPARγ is a crucial transcription factor regulating adipogenesis, it was 
hypothesised that, AA-induced inhibition of differentiation would have an 
impact on PPARγ expression and/or activity. Indeed, AA-treated cells showed 
lower expression of total PPARγ and more of the PPARγ phoshorylated form 
until the end of the differentiation program. It has been demonstrated that both 
ERK activation and PGF2α treatment lead to the phosphorylation of PPARγ at 
the S112 residue decreasing PPARγ transcriptional activity (Camp and Tafuri, 
1997; Reginato et al., 1998). Therefore, the AA-enhanced ERK activation in 
combination with the fact that PGF2α mediates the inhibitory effect of AA 
raises the possibility that the AA-PGF2α-FP receptor-ERK pathway leads to 
PPARγ phosphorylation and inhibition of differentiation. Furthermore, the role 
of Fra-1 on PPARγ expression was assessed as depletion of Fra-1 was 
enough to restore the normal differentiation upon AA treatment. Furthermore, 
depletion of Fra-1 was able to restore the normal levels of both total and 
phosphorylated PPARγ in AA-treated cells. In conclusion, Fra-1 appears to 
mediate PPARγ phosphorylation either directly or indirectly. Further studies 
need to be undertaken to elucidate whether Fra-1 regulates PPARγ 
expression and/or phosphorylation directly or to identify Fra-1 target genes 
that could lead to PPARγ phosphorylation. In conclusion, Fra-1 appears to be 
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a key mediator of AA-dependent inhibition of differentiation, highlighting the 
importance of early events in pre-adipocyte differentiation potential. 
 
A role for aP2 early up-regulation, upon AA treatment, in the inhibition of 
differentiation was investigated. Using aP2-depleted 3T3-L1 cells and the 
control shScramble cells, it was not possible to draw a conclusion as AA-
induced inhibition of differentiation was not observed in the shScramble cells. 
Moreover, a cell-permeable selective aP2 inhibitor targeting the fatty acid 
binding pocket did not block the inhibitory effect of AA, indicating that aP2 
early up-regulation was not related to the inhibitory effect of AA (data not 
shown).  
 
As the levels of PGs are higher in pre-adipocytes compared to differentiated 
3T3-L1 adipocytes, this indicates that the presence of PGs may maintain cells 
in the pre-adipocyte state (Hyman et al., 1982). Therefore, to determine the 
cellular identity of cells at the late stage of differentiation after the early short 
exposure to AA, the expression of Pref-1, GATA-2 and KLF-2 pre-adipocyte 
markers was assessed. The expression of all three pre-adipocyte markers 
was above the basal levels at the late stages of differentiation in AA-exposed 
cells. Pref-1 is classically used as a pre-adipocyte marker as it is specifically 
expressed in pre-adipocytes but not in mature adipocytes (Wang et al., 2006). 
GATA-2 transcription factor has been shown to inhibit adipogenesis by direct 
binding to the C/EBPβ protein and to the GATA binding site on the PPARγ2 
promoter (Tong et al., 2000; Tong et al., 2005). Constitutive expression of 
GATA-2 suppressed adipocyte differentiation and maintained cells at the pre-
adipocyte stage (Tong et al., 2000). Finally, KLF-2 is expressed in pre-
adipocytes but not in mature adipocytes and acts as a negative regulator of 
adipogenesis via direct interaction with the PPARγ promoter and inhibiting its 
expression (Banerjee et al., 2003). These data indicated that the presence of 
AA at the early stages of differentiation restricts the cells to the pre-adipocyte 
stage. Moreover, this reveal the importance of the FP receptor and Fra-1 in 
maintaining the pre-adipocyte state and their down-regulation required for 
adipogenesis to proceed. 
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In conclusion, this chapter demonstrated that AA-induced events at the 
beginning of the differentiation process affect the differentiation potential of 
pre-adipocytes. We suggest that AA after being metabolised to PGF2α, which 
binds to the FP receptor, activates ERK which regulates Fra-1 expression and 
in turn inhibits the differentiation possibly through deactivating PPARγ (Figure 
4.30).  
 
 
 
Figure 4.30: Schematic illustration of the proposed mechanism triggered by AA to 
inhibit pre-adipocyte differentiation. Upon treatment of pre-adipocytes with AA, COXs 
mediate its conversion to PGs particularly PGF2α and PGE2. These PGs bind to their 
membrane GPCRs, the FP and the EP4 receptor, respectively and trigger two different 
pathways. Both pathways lead to ERK activation but the FP mediated pathway is the 
dominant one. ERK then up-regulates Fra-1 transcription but also phosphorylates Fra-1, 
stabilising Fra-1 protein. PPARγ also up-regulates Fra-1 expression. Increased levels of Fra-1 
inhibit terminal differentiation, keeping the cells at the pre-adipocyte stage, probably by 
mediating PPARγ deactivation.  
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This thesis explored the mechanisms by which a major omega-6 PUFA, AA 
affects adipocyte differentiation. It is important to understand how 
adipogenesis is modulated as the formation of new adipocytes prevents the 
appearance of insulin resistant adipocytes, as well as the lipid deposition in 
peripheral organs such as muscle, liver, and heart. Classically, AA has been 
correlated with increased inflammation and obesity as excessive caloric intake 
(especially consumption of food rich in fat) relative to expenditure promotes 
both hyperplasia and hypertrophy of adipocytes. However, the role of AA on 
adipocyte differentiation has been controversial with some studies showing it 
is pro-adipogenic and some anti-adipogenic (Massiera et al., 2003; Madsen et 
al., 2005). Besides adipogenesis, there is increasing evidence from human 
studies correlating higher plasma levels of AA with decreased levels of serum 
proinflammatory markers and reduced risk of coronary heart disease (Harris 
et al., 2009). Thus, the role of AA in whole body metabolism appears to be 
more complex than originally thought.  
 
It is also becoming apparent that the differentiation of pre-adipocytes into 
mature adipocytes is a complex process involving both positive and negative 
signalling pathways which contribute to the adipogenic gene program. Indeed, 
our data showed that regulation of adipogenesis by AA had a dual role in 
adipogenesis with effects observed at the early and late stages of 
differentiation. In the early stages of differentiation, AA was found to positively 
regulate the expression of aP2 and Fra-1, whereas at the late stages AA 
negatively impacted adipocyte differentiation. The main focus of this thesis 
was to elucidate the signalling pathways and the molecular mechanisms 
underpinning these two events. 
 
Upon treatment of pre-adipocytes with AA, COXs convert AA to several PGs. 
We observed that this event occurred within the first few minutes after the 
addition of AA to pre-adipocyte cell monolayers. This is in agreement with 
previous reports showing that PGs are generated most effectively in 10-15 
minutes after treatment with AA in skeletal muscle (Berlin et al., 1979). 
Subsequently, PGs mediate the effect of AA to increase the levels of the two 
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key second messengers, cAMP and calcium. We showed that the AA-induced 
cAMP increase was mediated by EP4 receptor which is a PGE2 GPCR, 
whereas calcium increase was downstream of the FP receptor which is a 
PGF2α receptor. However, the EP4 antagonist did not block completely the 
cAMP production, indicating that other GPCRs could contribute to the 
increase in cAMP levels upon AA treatment. Alternatively, in addition to 
coupling to Gαq, it is conceivable that the FP receptor could be coupled to 
Gαs, mediating the cAMP increase, as it is not uncommon for GPCRs to be 
coupled with multiple α subunits. 
 
Investigating downstream effects of AA-dependent signalling we showed that 
AA, through PGs, activated ERK. ERK activation was mediated predominantly 
by the FP receptor but it cannot be excluded that other parallel pathways, 
triggered by AA, could also affect ERK activation. ERK has been shown to 
have a diverse range of substrates as it can translocate to the nucleus and 
phosphorylate transcription factors or it can regulate the activity of other 
cytoplasmic protein kinases (Davis, 1993). ERK has also been reported to 
phosphorylate cPLA2 enhancing its activity (Sa et al., 1995), a mechanism 
that could also result in sustained signal after AA treatment.  
 
We showed that AA signalling in the early stages of differentiation had two 
main downstream targets. One of them was the AA-mediated early and 
profound up-regulation of aP2. This up-regulation was mediated by the 
PGF2α-FP receptor-calcium-PKC-ERK pathway (Figure 5.1). Moreover, we 
showed that aP2 expression was enhanced by PPARγ upon AA treatment. 
aP2 is a classical gene target of PPARγ in the later stages of differentiation 
but it appears that in the early stages upon AA treatment, PPARγ ligands 
were generated to enhance its activity. However, it appears that at the same 
time AA treatment produced signals to cause the phosphorylation of PPARγ 
and its deactivation. One such metabolite has been reported to be PGF2α 
(Reginato et al., 1998). This would explain the obvious discrepancy between 
the decreased PPARγ levels and the increased levels of aP2. In conclusion, it 
appears to be a balance between positive and negative signals upon AA 
treatment that regulate PPARγ activity. 
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Furthermore, this is the first study associating a FABP with autophagy. We 
suggest that upon excess lipid treatment, aP2 mediates the transport of lipids 
to autophagosomes to avoid lipotoxic effects. On the other hand, when aP2 is 
not expressed autophagy cannot function, indicating that aP2 is critical for the 
autophagy to occur. However, other possible functions of aP2 cannot be 
excluded. For example, aP2 can translocate to the nucleus in response to 
specific ligands and interact directly with PPARγ enhancing its activity (Tan et 
al., 2002). This up-regulation of aP2 could also result in a positive feedback 
loop sustaining its expression by providing ligands to PPARγ 
 
 
 
Figure 5.1: Schematic illustration of the proposed mechanism triggered by AA to 
regulate the early and late stages of adipocyte differentiation. Upon treatment of pre-
adipocytes with AA, COXs mediate its conversion to PGs particularly PGF2α and PGE2. These 
PGs bind to their membrane GPCRs, the FP and the EP4 receptor, respectively and trigger 
two different pathways. Both pathways lead to ERK activation but the FP mediated pathway is 
the dominant one. ERK then mediates the up-regulation of aP2 and fra-1 gene transcription 
increasing the expression of aP2 and Fra-1 mRNA, respectively. ERK also phosphorylates 
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Fra-1, stabilising Fra-1 protein. PPARγ also up-regulates Fra-1 and aP2 expression. 
Increased levels of Fra-1 inhibit terminal differentiation, keeping the cells at the pre-adipocyte 
stage, probably by mediating PPARγ deactivation.  
 
From this study we showed for the first time that Fra-1 is a new factor 
regulating adipocyte differentiation upon AA treatment. We showed that the 
main receptor mediating Fra-1 up-regulation was the FP receptor which 
classically signals to PKC activation. Even though we showed that PKC was 
important for Fra-1 up-regulation, PKA signalling also appeared to be critical 
(Figure 5.1). This observation might explain the different effects of AA on 
adipogenesis in the presence of different cAMP levels. Madsen et al 
demonstrated that when cAMP levels are high AA inhibits differentiation 
whereas when cAMP levels are low, AA stimulates adipogenesis (Madsen et 
al., 2008). This could be mediated mechanistically by different levels of Fra-1 
protein. Thus, it is plausible that in the presence of high cAMP levels, Fra-1 is 
up-regulated, stabilised and able to inhibit differentiation, whereas in the 
presence of low cAMP levels, Fra-1 is expressed at levels too low to inhibit 
differentiation. However, it appears that there is a cross-talk between PKA and 
PKC pathways as it has been shown that signalling through AC/cAMP does 
not necessarily involve PKA but also PKC (Parada et al., 2005). Furthermore, 
the activation of PKC by PKA cannot be excluded (Gomes and Soares-da-
silva, 2002). In addition, calcium-activated ACs have been identified to 
mediate the activation of the cAMP/PKA pathway from calcium influx (Dunn et 
al., 2009). Finally, there is also a cross-talk between GPCRs. One such 
mechanism is the heterologous desensitisation. This involves the activation of 
one GPCR to generate a signal that causes inhibition of signalling by a 
second, heterologous GPCR mediated via phosphorylation by G protein 
coupled receptor kinases or PKA and PKC (Hosey, 1999). In conclusion, 
further studies need to be undertaken to fully elucidate the mechanism Fra-1 
is regulated by AA. 
 
Fra-1, in common with all AP-1 transcription factors, converts extracellular 
signals into changes in the expression of target genes, by binding to AP-1 
binding sites found in the promoter/enhancer regions of a large number of 
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genes. Furthermore, the activity of Fra-1 is controlled at multiple levels, at 
gene transcription, mRNA turnover, protein stability by interaction with other 
transcription factors, and by phosphorylation of its transactivation domains by 
MAPKs. Thus, the complex control of Fra-1 makes it difficult to assess its 
impact on gene expression and its relevance to human disease. 
 
Little is known about Fra-1 functions or about Fra-1 target genes. However, it 
has been reported that Fra-1 has a transactivation domain and can positively 
regulate gene expression (Young et al., 2002). In addition, Fra-1 can interact 
with HDAC1, indicating that it can negatively regulate gene expression by 
altering the chromatin landscape (Hoffmann et al., 2005). Thus, it is possible 
for Fra-1 to regulate both negatively and positively the expression of its target 
genes in order to drive the inhibition of differentiation. Further studies need to 
be performed to identify the target genes of Fra-1 after AA treatment leading 
to the inhibition of differentiation. However, one possible mechanism might be 
that Fra-1 regulates PPARγ activity. We showed that depletion of Fra-1 could 
restore normal PPARγ levels placing Fra-1 upstream PPARγ in the pathway 
regulating differentiation. Further experiments need to be performed to 
elucidate the mechanism by which PPARγ is regulated by Fra-1. In addition, 
our finding that Fra-1 is a negative regulator of adipogenesis was further 
supported by the generation of Fra-1 transgenic mice, which became 
lipodystrophic (Luther et al., 2011).  
 
In conclusion, this study established that AA can trigger different signalling 
pathways affecting the function and the differentiation potential of pre-
adipocytes. Thus, the regulation of adipogenesis by FAs appears to be more 
complicated than originally thought. It is now well-recognised that FAs can 
regulate adipogenesis in both a positive and a negative way, indicating the 
existence of a homeostatic mechanism that regulates the balance of positive 
and negative transcriptional regulators, promoting and inhibiting adipocyte 
differentiation upon high fat challenge.  
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List of qRT-PCR primers 
Gene  Sequence 5' to 3' 
Acsl4 
F GCTTCCTATCTGATTACTAGTGTTGA 
R ATCCACATAAATGATATGTTTAACACAATT 
Adiponectin 
F GAGATGCAGGTCTTCTTGGTCCTA 
R CCCCGTGGCCCTTCAG 
aP2 
F ACACCGAGATTTCCTTCAAACTG 
R CCATCTAGGGTTATGATGCTCTTCA 
AKR1B3 
F TCGTGGTGACAGCATATAGTCC 
R CCAGGAGAGACGGATCTTCA 
C/EBPα 
F TGGAGTTGACCAGTGACAATGAC 
R CAGTTCACGGCTCAGCTGTTC 
C/EBPβ 
F GAGCGACGAGTACAAGATGCGG 
R TTGTGCTGCGTCTCCAGGTTG 
C/EBPδ 
F CTGAACGACCTATACCTCAGACC 
R AGCTTCTCTCGCAGTCCAGT 
C-FOS  
F  CCTGCCCCTTCTCAACGAC 
R GCTCCACGTTGCTGATGCT 
C-Jun 
F CGGACCGTTCTATGACTGCAA 
R GGAGGAACGAGGCGTTGA 
COX-1 
F TGCCACCTTCATCCGAGAA 
R TAAGGTTGGACCGCACTGTG 
COX 2 
F TCATAAGCGAGGACCTGGGT 
R TTCACCATAAATGTGATTTAAG 
Cpt1α 
F TTAACAGCAACTACTACGCC 
R CCAGAAGACGAATAGGTTTGA 
eLOX3 
F CCGCTCTGTCATCCAGTCTACA 
R TCTTGCGATGGTGTTCACTTG 
EP1 
F GGTTCACGCACACGATGTG 
R GCTGCAGGGAGTTAGAGTTCCA 
EP2 
F CACCTCATTCTCCTGGCCATT 
R TTCATCCATGTAGGCAAAGATTGT 
EP3α 
F GCTTCCAGCTCCACCTCCTT 
R CATCATCTTTCCAGCTGGTCACT 
EP3β 
F GGAAGTTCTGCCAGATGATGAA 
R ATTCTCAGACCCAGGGAAACAG 
EP3γ 
F AGTTCTGCCAGGTAGCAAACG 
R GCCTGCCCTTTCTGTCCAT 
FAS 
F TGCGGAAACTTCAGGAAATGT 
R AGAGACGTGTCACTCCTGGACTT 
FosB 
F CAACCACCAGTGGACCTGTGT 
R CGACGGTTCCTGCACTTAGC 
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FP 
F TTCAGCTCCTGGCCATAATGT 
R AAAAAGTGTCGTTTCACAGGTCACT 
Fra-1 
F CGCAAGCTCAGGCACAGA 
R AATGAGGCTGCACCATCCA 
Fra-2 
F ATCCGGAGGGAGAGAAACAAG 
R GCCCAGACTTCTCCTCTTCCA 
GATA-2 
F GGAGACGATTGTGCTGAGTCAA 
R TTAGGGTGCTCTGCAGCAACT 
Glut-4 
F CTATTCAACCAGCATCTTCGAG 
R CTACTAAGAGCACCGAGACC 
IP 
F GTGTGCTCCCTGCCTCTCAT 
R TCCCCCATCTCTCTGCTGTCT 
Jun B 
F CTACAAACTCCTGAAACCCACCTT 
R GCCCCAGGACCCTTGAGA 
JunD 
F GGAGCTGGAGAGGCTGATCAT 
R CGGGTAGAGGAACTGCGTACTG 
KLF-2 
F ACCAAGAGCTCGCACCTAAA 
R TCCTTCCCAGTTGCAATGAT 
LPL 
F CCAGGATGCAACATTGGAGA 
R CAACTCAGGCAGAGCCCTTT 
L19 
F GGAAAAAGAAGGTCTGGTTGGA 
R TGATCTGCTGACGGGAGTTG 
PPARγ 
F CGAGTCTGTGGGGATAAAGC 
R GGATCCGGCAGTTAAGATCA 
PPARγ1 
F AGAAGCGGTGAACCACTGATATTC 
R AGAGGTCCACAGAGCTGATTCC 
PPARγ2 
F TGGGTGAAACTCTGGGAGATTC 
R AGAGGTCCACAGAGCTGATTCC 
PREF-1 
F CTCTTGCTCCTGCTGGCTTT 
R ATTGCTAGCCTCGCAGAATC 
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ChIP primers 
Promoter  Sequence 5' to 3' 
aP2-AP1 
F CCAGGGAGAACCAAAGTTGAG 
R CCTTCATGACCAGACCCTGT 
 
Cloning primers 
Construct  Sequence 5' to 3' 
aP2-PGL3 
F GAATTCCCAGCAGGAATCA 
R GGCTGCAGCACAGGAGGGT 
c-Jun-pcDNA 
F ATGACTGCAAAGATGGAAA 
R AAACGTTTGCAACTGCTGCGTT 
JunB-pcDNA 
F ATGTGCACGAAAATGGAACA 
R GAAGGCGTGTCCCTTGA 
Fra-1 peak1-PGL3 
F AAGTCTGATTGGTTTCTACCATTG 
R GGTGCCAACTCCTGCTCTG 
Fra-1 peak2-PGL3 
F ACCAATCCAGGCACTTATGG 
R GCCTCTCGGAGTCTGGTCTT 
Fra-1-pcDNA 
F ATGTACCGAGACTACGGGGAAC 
R CAAAGCCAGGAGTGTAGGA 
 
 
 
 
 
 
 
 
 
